Development of Modified Vaccinia Virus Ankara-based Influenza Vaccines by Altenburg, A.F. (Arwen)
Development of Modified
Vaccinia Virus Ankara-based
Influenza Vaccines
Arwen F. Altenburg
Developm
ent of M
odified Vaccinia Virus Ankara-based Influenza Vaccines
2018
Arw
en F. Altenburg
Development of Modified 
Vaccinia Virus Ankara-based 
Influenza Vaccines
Arwen F. Altenburg
Colofon
The studies presented in this thesis were financially supported by the European Commission FP7 project 
FLUNIVAC (602604) and the ERC grant FLUPLAN (250136). The studies were performed within the 
framework of the Erasmus Molecular Medicine Post Graduate School.
Printing of this thesis was financially supported by Novavax, Aerogen, Cirion Foundation, Eurogentec & 
Greiner Bio-One.
Cover design: Arwen F. Altenburg & Nynke J. Altenburg
Photograph p187:  Nynke J. Altenburg
Print: ProefschriftMaken || www.proefschriftmaken.nl  
ISBN: 978-94-6295-796-1
This thesis was printed on FCS paper.
© Arwen F. Altenburg, 2017. All rights reserved.
	
	
Development of Modified Vaccinia Virus
Ankara-based Influenza Vaccines
Ontwikkeling van op Modified Vaccinia virus
Ankara-gebaseerde influenzavaccines
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de
rector magnificus
Prof.dr. H.A.P. Pols 
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op 
woensdag 31 januari 2018 om 11:30 uur
Arwen Fieke Altenburg
geboren te Buren
Promotiecommissie
Promotor: Prof.dr. G.F. Rimmelzwaan
Overige leden: Prof.dr. R.A.M. Fouchier
  Prof.dr. R.W. Hendriks
  Prof.dr. G. Sutter
Co-promotor: Dr. R.D. de Vries
‘There is a theory which states that if ever anyone discovers 
exactly what the Universe is for and why it is here, it will 
instantly disappear and be replaced by something even 
more bizarre and inexplicable. There is another theory 
mentioned, which states that this has already happened.’
Douglas Adams
The Hitchhiker’s Guide to the Galaxy

Table of contents
Chapter 1 | General introduction  9
1.1 Influenza virus
1.2 Immune response against influenza viruses
1.3 Influenza vaccines
1.4 Novel (universal) influenza vaccines
1.5 Modified Vaccinia virus Ankara-based influenza vaccines
1.6 Outline of the thesis 
Chapter 2 | Validation of MVA as vaccine vector 39
2.1 Modified Vaccinia virus Ankara preferentially targets antigen presenting cells 
in vitro, ex vivo and in vivo. Scientific Reports, 2017.
2.2 Effects of pre-existing orthopoxvirus-specific immunity on the performance of 
Modified Vaccinia virus Ankara-based influenza vaccines. Submitted.
Chapter 3 | Pre-clinical assessment of MVA-based influenza vaccines 85
3.1 Increased protein degradation improves influenza virus nucleoprotein-
specific CD8+ T cell activation in vitro but not in C57BL/6 mice. Journal of 
Virology, 2016.
3.2 Protein- and Modified Vaccinia virus Ankara-based influenza virus 
nucleoprotein vaccines are differentially immunogenic in BALB/c mice. 
Clinical & Experimental Immunology, 2017.
3.3 Matrix-M™ adjuvant enhances immunogenicity of both protein- and Modified 
Vaccinia virus Ankara-based influenza vaccines. Submitted.
Chapter 4 | Clinical assessment of an MVA-based H5N1 influenza vaccine  125
4.1 Induction of cross-clade antibody and T cell responses by an MVA-based 
influenza H5N1 vaccine in a randomized phase I/IIa clinical trial. Manuscript 
in preparation. 
Chapter 5 | Summarizing discussion 143
Chapter 6 | References 155
Chapter 7 | Nederlandse samenvatting 177
Chapter 8 | About the author 185
8.1 Curriculum Vitae
8.2 PhD portfolio
8.3 List of publications
Dankwoord  193

Chapter 1
General introduction
9
Partially based on:
1. RD de Vries, AF Altenburg & GF Rimmelzwaan. Universal influenza vaccines: a realistic 
option? Clinical Microbiology and Infection, 2016; 22: S120-S124.
2. RD de Vries, AF Altenburg & GF Rimmelzwaan. Universal influenza vaccines, science 
fiction or soon reality? Expert Review Vaccines, 2015; 14(10): 1299-1301.
3. AF Altenburg, GF Rimmelzwaan & RD de Vries. Virus-specific T cells as correlate of (cross-) 
protective immunity against influenza. Vaccine, 2015; 33(4): 500-506.
4. AF Altenburg et al. Modified Vaccinia virus Ankara (MVA) as production platform for vaccines 
against influenza and other viral respiratory diseases. Viruses, 2014; 6(7): 2735-2761.
C
ha
pt
er
 1
.1
10
Chapter 1 | General introduction
1.1 Influenza virus
Influenza viruses are infectious pathogens (~100nm) that belong to the family of 
orthomyxoviridae. This family consists of seven genera, including influenza A and 
B viruses1,2. Influenza viruses are distinguished based on genome size and surface 
(glyco)proteins3. The nomenclature of influenza viruses is based on serotype/host 
species (if not human)/geographical location of isolation/strain number/year of 
isolation, e.g. A/Mallard/Netherlands/12/00 or A/Netherlands/602/09. Influenza A 
viruses are further classified based on the two major surface proteins hemagglutinin 
(HA) and neuraminidase (NA). Thus far, 18 types of HA (H1-18) and 11 types of NA 
(N1-11) have been described4-6. The subtypes of influenza A virus are based on the 
types of their HA and NA, for example H1N1 or H3N2. Influenza B viruses are not 
divided into subtypes but are discriminated into two lineages: B/Yamagata/16/88-like 
and B/Victoria/2/87-like4.
Influenza A, endemic in aquatic birds and swine, and B viruses cause seasonal 
epidemics in the human population4. In humans, most infections are self-limiting 
and restricted to the upper respiratory tract. Complications leading to morbidity and 
mortality following infection are predominantly observed in high risk groups, such 
as immunocompromised individuals and the elderly. Therefore, annual vaccination 
of these risk groups is recommended. It is estimated that influenza virus epidemics 
annually cause 3-5 million cases of severe respiratory illness worldwide, resulting 
in 250.000-500.000 fatal cases7. Furthermore, if an antigenically distinct influenza 
virus, often of a novel subtype originating from animal reservoirs, is introduced into 
the human population, the population at large is at risk due to the lack of strain-
specific neutralizing antibodies4.
Structure of influenza A viruses
An influenza virus particle possesses an envelope derived from the plasma 
membrane of the infected host cell from which the particle has budded. There 
are three different virus proteins present on the surface of the virus particle: two 
major membrane glycoproteins HA and NA, and the Matrix protein 2 ion channel 
(M2). The envelop encapsulates a layer of Matrix protein 1 (M1) that contains the 
viral ribonucleoproteins (vRNPs) comprised of eight negative-sense RNA strands1 
(Fig. 1). These RNA strands are each folded into a helical hairpin coated with 
nucleoprotein (NP) and have a polymerase complex comprised of PA, PB1 and 
PB2 subunits attached to the terminus8. In addition to the proteins that are essential 
for the structure of the virus particle, the viral RNA genome encodes non-structural 
proteins such as nuclear export protein (NEP) and non-structural protein 2 (NS2)1.
Influenza A viruses increase the coding capacity of the eight RNA segments by 
the use of alternative open reading frames and splicing. For example, M1 and M2 
proteins are derived from the same RNA segment and the PB1 gene segment is 
known to encode several non-structural proteins in addition to the PB1 polymerase 
subunit. These PB1-F2 and PB1-N40 proteins are involved in immune evasion and 
induction of apoptosis in the infected cell, thereby allowing for more efficient virus 
replication1,9,10.
11
General introduction | Chapter 1
C
hapter 1.1
Hemagglutinin (HA)
Neuraminidase (NA)
Matrix protein (M)2
Matrix protein (M)1
Polymerase complex
(PA, PB1, PB2)
Nucleoprotein (NP)
RNA
Envelope
PB2
PB1
PA
HA
NP
NA
M
NS (NS1 & NEP)
Figure 1. Schematic overview of the structure and gene segments of an influenza A virus. There 
are two surface glycoproteins present in the lipid bilayer of a virion: HA and NA. The third surface protein 
is M2. Below the lipid bilayer resides a capsid of M1, which contains eight negative-sense RNA strands 
encoding the indicated influenza virus proteins. The RNA is coated by NP with the polymerase complex 
consisting of PA, PB1 and PB2 subunits at the terminus.
Replication cycle
Influenza viruses infect cells through attachment of the receptor binding site in the 
head-domain of the viral HA protein to sialic acids on the host’s cell surface. HA from 
human influenza viruses preferentially binds to sialic acid attached to galactose by 
an α2,6 linkage, which is predominantly present on cells in the upper respiratory 
tract. In contrast, avian influenza viruses mostly bind α2,3 sialic acids that are 
mainly present in the human lower respiratory tract. The receptor binding preference 
partially explains why some avian influenza viruses can cause severe lung disease 
in humans but are not efficiently transmitted between individuals without adaptive 
mutations11,12.
After attachment, the influenza virus particle is internalized through receptor-
mediated endocytosis. The low pH in the endosome induces conformational 
changes in HA, thereby exposing the fusion peptide required for interaction with the 
endosomal membrane. The M2 ion channel allows for influx of H+ molecules into 
the virus particle, leading to disruption of protein interactions between M1 and the 
vRNP1,13. Combined, these mechanisms result in the release of the viral genome 
into the cytoplasm of the cell. The nuclear localization signal (NLS) in NP leads to 
translocation of the vRNP from the cytoplasm to the nucleus where the polymerase 
complex attached to each RNA strand starts transcription of the negative-sense RNA 
genome into positive-sense RNA1. New genomic RNA is synthesised in the nucleus 
using positive-sense complementary (c)RNA as a template. Furthermore, positive-
sense messenger (m)RNA is transported to the cytoplasm for translation of new viral 
proteins (Fig. 2). 
Before the viral mRNA can be exported from the nucleus, the RNA needs to be 
stabilized by addition of a 5’ cap and a 3’ poly-A-tail to the transcripts. The 5’ cap on 
viral transcripts is obtained from host RNA transcripts through ‘cap-snatching’ by the 
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Chapter 1 | General introduction
polymerase subunits14,15, thereby efficiently inhibiting translation of host transcripts. 
The 3’ poly-A-tail is automatically included in the transcript through a conserved 
U-stretch in the viral template RNA15,16. With these modifications, viral mRNA can be 
transported to the cytoplasm where the 5’ cap allows for recognition of viral mRNA 
by the host’s translational machinery.
After translation, the transmembrane proteins HA, NA and M2 are transported 
through the Golgi system to the plasma membrane. Newly synthesised NP, PA, 
PB1 and PB2 molecules return to the nucleus where new vRNP complexes are 
assembled. Nuclear export of vRNP is mediated by M1, most likely in combination 
with NEP/NS2, after which the vRNP complex translocates to the plasma membrane 
for assembly into new virus particles. The plasma membrane forms an outward 
curvature until the virus core is completely enveloped by the lipid bilayer. Membrane 
fusion is initiated and the progeny virus particle is formed. Newly formed virus 
particles remain attached to the infected cell surface through the interaction of sialic 
acid with HA. Enzymatic activity of NA is required for the destruction of sialic acid 
and the release of progeny virions from the cell, allowing further spread of the virus 
infection1 (Fig. 2).
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Figure 2. Influenza virus replication cycle. HA binds to sialic acid on the host’s cell surface, thereby 
initializing internalization of the virus particle. Due to the low pH in the endosome, conformational changes 
in HA are induced leading to the fusion of the viral and endosomal membranes. vRNP is released into the 
cytoplasm and translocated to the nucleus. Genomic, negative-sense RNA is translated into mRNA – for 
the synthesis of virus proteins – and cRNA, which serves as a template for the production of new genomic 
RNA. Viral proteins and vRNP assemble at the plasma membrane where a new virion buds from the cell. 
NA releases progeny virus particles from the cell through cleavage of sialic acids on the host cell surface.
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Seasonal and pandemic influenza
Influenza viruses are able to perpetuate in the human population through evasion 
of recognition by virus neutralizing antibodies due to the continuous accumulation 
of mutations in the surface glycoproteins HA and NA, i.e. antigenic drift4,17,18. This 
results in seasonal influenza epidemics that are caused by influenza A(H1N1), 
A(H3N2) or B viruses.
In addition to infections caused by antigenic drift variants, antigenically distinct 
influenza viruses originating from animal reservoirs are occasionally introduced into 
the human population. This antigenic shift can occur in animal reservoirs through re-
assortment of gene segments derived from two or more different influenza viruses, 
often resulting in a virus with new subtypes of HA and NA proteins. These novel 
influenza viruses have the potential to cause serious pandemics when they acquire 
the ability to be transmitted efficiently from human-to-human because antibodies 
against these viruses are virtually absent in the population at large. The last four 
pandemics have been caused by influenza A viruses of the H1N1 (1918 and 2009), 
H2N2 (1957) and H3N2 (1968) subtypes.
During the last decades, zoonotic transmission of highly pathogenic avian influenza 
A viruses, in particular those of the A(H5N1) subtype, has been reported regularly. In 
order to monitor viral adaptations to acquire the ability to efficiently spread between 
individuals, transmission experiments have been performed in ferrets. Since 
distribution of sialic acids with an α2,6 and α2,3 linkage in the ferret respiratory 
tract is similar to the human respiratory tract, influenza virus pathogenesis and 
transmission is expected to be similar in ferrets and humans. Therefore, this animal 
model is the best proxy to gain insight in viral adaptations required for human-
to-human transmission. Interestingly, it has been demonstrated that only a few 
mutations in HA and proteins of the polymerase complex were sufficient for A(H5N1) 
viruses to become airborne transmissible between ferrets19-21, and some of these 
mutations have already been detected in naturally circulating A(H5N1) viruses22. 
Human infections with avian viruses from other subtypes have been reported as well, 
including infections with viruses of the A(H5N6)23, A(H6N1)24, A(H7N3)25, A(H7N7)26, 
A(H7N9)27, A(H9N2)28 and A(H10N8)29 subtypes. With the correct adaptations, 
any one of these viruses could potentially become transmissible from human-to-
human and cause a widespread outbreak and eventual pandemic with considerable 
morbidity and mortality.
C
ha
pt
er
 1
.2
14
Chapter 1 | General introduction
1.2 Immune response against influenza viruses
To study the immune response against influenza viruses different animal models 
are used, including mice, ferrets and non-human primates. The mouse model is 
the most attractive, because specific-pathogen free mice are readily available, mice 
are easily housed in groups at relatively low cost and genetically modified mouse 
models are available. Furthermore, the immune response can be studied in detail 
due to a complete understanding of the mouse immune system in combination 
with an extensive, well characterized set of mouse-specific reagents. However, 
influenza viruses sometimes require adaptation to cause substantial disease in 
mice. Furthermore, the pathogenesis in and transmission between mice is different 
compared to humans. Therefore, the ferret model is favoured for these studies 
as they accurately reflect human disease and are usually susceptible to human 
influenza viruses. Disadvantages of the ferret model include the costs, the size of 
the animal, which requires larger housing, and the lack of available species-specific 
reagents. The latter particularly complicates assessment of the immune response 
against influenza viruses. Non-human primates are also susceptible to most human 
influenza viruses and in contrast to ferrets, there is an extensive toolset available for 
studies on the immune system in this species. However, this animal model is more 
expensive than the ferret model and ethical issues complicate the use of non-human 
primates30. Taken together, the mouse model is considered an appropriate model for 
preliminary assessment of intervention strategies and fundamental research of the 
immune response against influenza viruses.
Innate immune response
The innate immune system is hallmarked by a rapid response (within hours) upon an 
infection. This response is aspecific, i.e. responds similar to a primary or re-infection 
with the same pathogen, and involves chemical as well as cellular components.
An influenza virus infection is first detected by pattern recognition receptors (PRRs). 
These molecules are expressed on most cells, including non-hematopoietic cells, 
and are sensors activated by evolutionary conserved pathogen associated molecular 
patterns (PAMPs). There are different families of PRRs capable of specifically 
detecting an intracellular or extracellular pathogen. First, extracellular virions can 
be detected by Toll-like receptors (TLRs) and C-type lectin receptors (CLRs), which 
recognize viral nucleic acids and leucine-rich repeats on transmembrane proteins. In 
addition, TLRs present in the endolysosome can be activated by single- or double-
stranded RNA present in cell debris from influenza virus-infected cells or single-
stranded genomic viral RNA in phagocytosed and degraded virions. Second, once an 
infection has been established, intrinsic cellular PRRs such as retinoic acid-inducible 
gene I (RIG-I)-like receptors and nucleotide oligomerization domain (NOD)-like 
receptors detect nucleic acid structures in the cytosol of infected cells. Furthermore, 
specific intracellular viral protein structures and stress signals, including signals from 
neighbouring dying cells, can activate intrinsic PRRs. Recognition of an influenza 
virus infection by PRRs induces a series of events generally starting with the 
production of type I interferons (IFN) and other anti-viral cytokines and chemokines. 
These signalling molecules are involved in the induction of an antiviral state in cells 
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in the vicinity of the infection, activation of the complement system, recruitment 
and/or activation of innate immune cells and regulation of induction of the adaptive 
immune response31-33. 
The innate immune response is multifaceted and comprises many components that 
are often interlaced. The complement system consists of soluble proteins that are 
activated in a cascade-like manner. Studies in mice have shown that complement 
factors may play an important role in early control of an influenza virus infection 
before the adaptive immune system has responded34,35. Complement factors can 
directly bind to virions thereby inducing phagocytosis (opsonisation) or virolysis. 
Furthermore, complement factors can initiate lysis of influenza virus-infected cells 
and act as signalling molecules by binding to specific complement receptors on 
leukocytes31,36. Natural killer (NK) cells are another important first line of defence 
against influenza virus infections. Activation of NK cells requires signalling from the 
activation receptors after they have bound their ligand on virally infected cells, in 
combination with downregulation of inhibitory receptor ligands. Many viruses have 
developed mechanisms interfering with the major histocompatibility complex (MHC) 
class I pathway, leading to reduced inhibitory signalling in NK cells. Activated NK 
cells have cytolytic capacities and produce cytokines to induce other anti-viral 
immune responses31,32,37. 
Other innate immune cells involved in the influenza virus-specific innate immune 
response include monocytes, present in the blood stream and peripheral tissues, 
which are the precursor of macrophages and dendritic cells (DCs). Macrophages are 
professional phagocytes that can engulf and degrade influenza virions, and patrol 
most organs and barriers, including mucosal tissues. Specialized macrophages 
present in the alveoli of the lung (alveolar macrophages) can become infected with 
influenza viruses and subsequently produce high levels of type I IFNs to prevent 
infection of other, perhaps more vulnerable, cells32. In addition, immature DCs are 
also present in all barriers throughout the body. DCs are characterized as professional 
antigen presenting cells (APC) that orchestrate both innate and adaptive immune 
responses. Immature DCs possess a specific set of PRRs to recognize an incoming 
pathogen and can be can be activated by direct influenza virus infection, uptake of 
a virus or soluble antigen (most likely to be remnants of apoptotic infected cells) or 
by signalling molecules. Mature DCs can travel to secondary lymphoid tissues, such 
as lymph nodes (LN), for activation of adaptive immune cells. DCs are key players 
in deciding between an anti-bacterial (extracellular) and anti-viral (intracellular) 
immune response through the secretion of a variety of inflammatory cytokines31,32,38. 
Influenza viruses have developed the capacity to evade different components of the 
innate immune system. For example, M1 was shown to interact with complement 
protein C1qA, thereby inhibiting virus neutralization39. Furthermore, influenza virus 
non-structural proteins can act as IFN antagonist and the PB1-F2 protein has pro-
apoptotic properties and is thought to induce apoptosis of immune cells specifically1,9. 
These properties contribute to suppression of the innate response and are critical for 
influenza virus while establishing a productive infection.
C
ha
pt
er
 1
.2
16
Chapter 1 | General introduction
Adaptive immune response
Hallmarks of the adaptive immune response are its specificity and formation of 
immunological memory. This response is slow compared to the innate immune 
response and may take days to develop upon the first encounter with a pathogen. 
After the first exposure, immunological memory is formed which allows a rapid and 
pathogen-specific response upon the second encounter. The adaptive immune 
response can be divided into two main components: humoral and cellular immunity. 
Humoral immunity
Naïve B cells circulate in the blood and reside in secondary lymphoid organs, such 
as the LN and the spleen. Given the short half-life, between 3 days and 8 weeks, 
only a small number of B cells produced in the bone marrow transitions to a mature 
state. B cell maturation takes place in the LN and requires specific recognition of an 
antigen – a virion or viral antigen carried by APCs – by the B cell receptor (BCR). The 
BCR-antigen complex is internalized into endosomes where the antigen is degraded 
for presentation on MHC class II molecules to CD4+ T cells. Co-stimulation by CD4+ 
T cells is required for subsequent B cell proliferation and differentiation. During the 
maturation process, binding to the antigen is optimized (affinity maturation) and 
immunoglobulin (Ig) isotype class switching takes place from IgM to predominantly 
IgG or IgA. Subsequently, mature B cells proliferate and differentiate into plasma 
cells, which produce soluble Ig (i.e. antibodies), or memory B cells40. 
Antibodies are capable of recognizing structures on the surface of a virus particle or 
transmembrane proteins on a virus-infected cell and have several effector functions, 
partially dependent on epitope specificity. First, antibodies can have influenza virus 
neutralizing capacities, achieved by blocking the receptor-binding pocket on HA or 
by preventing conformational changes necessary for endosomal membrane fusion 
and uncoating38. Second, the fragment crystallisable (Fc) tail of antibodies bound 
to influenza virus particles or influenza virus-infected cells can induce complement 
activation leading to direct virolysis, inhibition of virus attachment to the host cell, 
induction of phagocytosis (antibody-dependent phagocytosis, ADP)41, complement-
dependent cytotoxicity (CDC)42 or antibody-dependent cellular cytotoxicity (ADCC)43-
45. Finally, antibodies can prevent the release of progeny virions from an infected cell 
by inhibition of NA activity46. Since neutralizing antibodies can directly interfere with 
the initial infection of a host, whereas non-neutralizing antibodies mainly interfere 
after establishment of infection, neutralizing antibodies are considered to be more 
effective38.
Influenza virus-specific serum antibodies can initially be detected 7-12 days after a 
primary infection, but memory B cells remain and can be maintained for decades. 
These cells reside in the spleen and other secondary lymphoid tissues in a resting 
state, not secreting antibodies. Re-exposure to viral antigens induces rapid 
proliferation and differentiation of the memory B cells into plasma cells. This leads 
to production of higher antibody concentrations compared to the primary infection to 
rapidly clear the infection38,40.
17
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The influenza virus-specific antibody response is mainly directed against the two 
surface glycoproteins HA and NA, which corresponds well with protection from 
infection with homologous influenza virus strains47. Influenza viruses are capable 
of efficiently evading the humoral response by accumulating antigenic changes in 
the surface proteins, leading to evasion of HA- and NA-specific antibodies17,18,48. 
Furthermore, glycosylation of HA is thought to modulate the immunogenicity of 
certain epitopes49-51. It has even been suggested that the stalk-domain of HA from 
an A(H7N9) influenza virus can inhibit formation of antibodies against the HA head-
domain52. Thus, virus-specific antibodies have the capacity to efficiently neutralize 
an influenza virus infection, but in general do not provide protection against the wide 
range of influenza virus subtypes.
Cellular immunity
In addition to humoral immunity, infection with (seasonal) influenza virus also induces 
T cell responses53-57. T cells are activated during an infection by recognition of MHC – 
human leukocyte antigens (HLA) in humans – class I or II molecules presenting virus 
peptides generally obtained from different origins. Viral peptides presented on MHC 
class I molecules are released from proteins though proteasomal degradation in 
the cytosol of infected cells. These peptides are transported into the endoplasmatic 
reticulum (ER) by the protein ‘transporter associated with antigen processing’ (TAP) 
where the peptides are loaded onto MHC class I molecules. Subsequently, the MHC-
peptide complex is transported to the cell surface for presentation to CD8+ T cells58. 
MHC class I molecules are present on virtually all nucleated cells. In contrast, MHC 
class II is only present on professional APC such as DCs. APCs engulf antigens, such 
as influenza virus-infected apoptotic cells, from their environment into endosomes 
that subsequently fuse with lysosomes where the contents are degraded. MHC class 
II molecules are transported to the endolysosomes, allowing peptides to be loaded 
on the MHC class II molecules. Subsequently, these complexes are transported 
to the cell surface for presentation to CD4+ T cells59 (Fig. 3). Of note, antigens of 
extracellular origin can also be presented on MHC class I molecules by DCs, a 
process defined as cross-presentation60,61.
Since influenza viruses infect epithelial cells of the respiratory tract, sentinel lung-
resident CD103+ DC present in the immediate proximity of respiratory epithelial 
cells are in a unique position to capture antigens from virus-infected cells, mature 
and migrate to LN, and exert their function as professional APC by activating naïve 
T cells62-64. After the T cell receptor (TCR) recognizes a MHC-peptide complex, 
there is clonal expansion of virus-specific naïve T cells into effector cells. Co-
stimulatory signals are required to prevent abortive clonal expansion and stimulate 
differentiation65. In the course of an influenza virus infection, primed T cells migrate 
from LN to the lungs where they exert their antiviral effects by eliminating influenza 
virus-infected epithelial cells.
After clearance of infection, immunological memory is established. There are 
various memory T cell subsets, however, the role of each subset during a secondary 
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infection is incompletely understood. In general, the memory T cells can be divided 
into long-lived central memory T cells (TCM) and effector memory T cells (TEM)
66. 
Because there is less variability in the internal influenza virus proteins it has been 
hypothesized that heterosubtypic immunity, i.e. virus-specific T cells that respond 
to a secondary infection with an antigenically different virus, is mainly conferred by 
immune responses against these conserved internal epitopes. Similar to HA and NA, 
the internal epitopes that are mainly recognized by T cells are subject to selective 
pressure. It has been shown that small sequence variations in an epitope can 
significantly impact the immune response against a virus67-70. However, mutations in 
conserved regions of the internal influenza virus proteins, such as NP, M1 and the 
polymerase subunits, seem to be hampered by functional constraints71. Therefore, 
influenza virus-specific T cells are mainly targeted against the more conserved 
internal proteins and, because of their cross-reactive nature, contribute significantly 
to heterosubtypic immunity72-75.
viral proteins
proteasome
peptides
TAP
endolysosome
Golgi
ERMHC class I
CD8+ T cell
MHC class II
CD4+ T cell
endosome
infected cell professional APC
apoptotic cell
endosome
Figure 3. MHC class I and II antigen presentation pathways. Viral proteins are degraded by the 
proteasome in the cytosol of an influenza virus-infected cell. The peptides released from the proteins are 
transported to the ER by TAP. Subsequently, peptides are loaded onto MHC class I molecules, followed 
by transportation to the cell surface. CD8+ T cells with a T cell receptor (TCR) specific for the peptide-
MHC class I complex will recognize the complex and become activated to subsequently exert effector 
functions. Virtually all nucleated cells are capable of antigen presentation via the MHC class I pathway. In 
contrast, only professional APC can obtain antigens from exogenous origin, e.g. cell debris from influenza 
virus-infected cells. Antigens are degraded in the endolysosome and loaded onto MHC class II molecules, 
which are derived from the ER. The peptide-MHC class II complex is transported to the cell surface for 
presentation to CD4+ T cells.
CD8+ T cells
Decades ago it was already recognized that influenza virus infections in mice 
lacking MHC class I-restricted CD8+ T cells resulted in delayed virus clearance 
and more severe diseases upon re-infection76. However, depletion of CD8+ T cells 
from influenza virus-infected mice still led to viral clearance76-79, indicating that other
19
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branches of the immune system were also involved. In experimentally infected 
humans an inverse correlation between CD8+ cytotoxic T lymphocytes (CTL) present 
in peripheral blood and virus shedding has been observed72. Over the years, the role 
of CD8+ T cells in clearing influenza virus infections has been confirmed in various 
animal models73,76,80,81. More recently, it was demonstrated that pre-existing virus-
specific CD8+ T cells in humans correlated with protection against disease severity 
caused by infection with 2009 pandemic A(H1N1) influenza viruses82.
CTL responses are often directed at only a fraction of all potential antigenic epitopes, 
which are defined as immunodominant epitopes83. Several factors have been 
implicated to influence immunodominance, for example in mice the prevalence of 
high avidity T cells in a starting population predominantly determines the hierarchy 
in the T cell response84. After primary activation by APC, T cells migrate to the 
lung to exert their effector functions. Classically, CD8+ T cells exert their effects via 
cytolytic contact-dependent pathways85, however, CTL have also been shown to 
have suppressor functions in mice and humans by the secretion of cytokines or 
chemokines86,87. Furthermore, in the mouse model CD8+ T cells have been shown 
to produce chemokines upon antigen-specific interaction with epithelial cells88 and 
promote chemokine production by epithelial cells themselves89 (Fig. 4).
CD8+ T cells can be divided in Tc1, Tc2 and Tc17 subgroups depending on the 
cytokine production profile. Tc1 and Tc2 have direct cytolytic capacity in mice, 
whereas this is not the case for the Tc17 subset90,91. Direct cytolytic capacity is 
exerted via either release of perforin and granzymes, or via apoptosis triggered by 
Fas/FasLigand (FasL) or tumor necrosis factor (TNF) receptor 1 interaction85,92. Tc17 
can efficiently recruit B cells, neutrophils, NK cells, macrophages and T cells by 
the production of cytokines and chemokines81. By themselves, each of the Tc1, Tc2 
and Tc17 subgroups was able to confer protection from infection with a lethal dose 
of influenza virus in mice90,91, suggesting that there is a redundancy in the effector 
mechanisms of CD8+ T cells81. Although the secretion of chemokines and cytokines 
is important to establish solid anti-viral immunity, the contact-dependent pathway is 
still considered to be the major effector mechanism by which CD8+ T cells exert their 
protective effects92. 
Immunological memory is established after resolution of an influenza virus 
infection. It has been hypothesized that antigen presentation by distinct DC subsets 
orchestrates the CD8+ T cell memory response by determining whether responding 
CD8+ T cells differentiate into cells with either an effector or a memory phenotype. 
CD103+CD11b+/− migratory respiratory DC support the generation of CD8+ effector 
cells that migrate to the infected mouse lungs. In contrast, CD103−CD11bhigh DC 
support the generation of CD8+ TCM that remain within the draining LN
64. Furthermore, 
the infectious dose during initial infection might have an effect on the phenotype 
distribution of the developing CD8+ memory response93. 
As with other respiratory virus infections, influenza virus-specific effector and memory 
CD8+ T cells following infection are not only found in the secondary lymphoid organs 
of mice and humans, but a relatively large pool also persists locally94-98. This lung 
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resident memory population in mice is comprised of circulating memory T cells, 
which are continuously recruited to the lung through CXCR3, and tissue resident 
memory T (TRM) cells that are retained in the lung by the collagen-binding integrin 
VLA-199,100. Furthermore, the maintenance of CD8+ memory T cells in the lungs of 
mice has been attributed to persistent antigen presentation in the draining LN of the 
lung96. Although in mice the number of antigen-specific CD8+ T cells in the draining 
LN remains stable101, over time the functionality of the CD8+ T cell recall response 
wanes102. This waning correlated with the loss of high avidity memory CD8+ T cells103.
CD4+ T cells
Compared to CD8+ T cells, the importance of CD4+ T cells during the immune 
response against an influenza virus infection was only recognized more recently. 
Although CD4+ T cells by themselves are unable to efficiently clear an influenza 
virus infection in mice, their helper effects to CD8+ T cells and B cells indicate an 
important role in the defence against influenza virus infections104,105. Furthermore, 
the transfer of influenza virus-specific CD4+ T cells into naïve mice protected them 
from challenge, even in the absence of CD8+ T cells or B cells106. It was shown 
that CD4+ T cell memory is generated after a primary infection105 and responses to 
immunodominant epitopes in Matrix protein and NP are predominantly mediated by 
CD4+ T cells107,108. Furthermore, pre-existing CD4+ T cells specific for influenza virus 
internal proteins were associated with lower virus shedding and less severe illness in 
experimentally infected humans108. However, in these experiments individuals were 
intranasally inoculated with a high dose (106 TCID50) of virus, which does not mimic 
a natural human infection. As a limitation to this study, peripheral blood is not the 
optimal site to assess cellular immunity and recall responses, since virus-specific 
memory lymphocytes may not circulate to a high extent but rather reside in mucosal 
or peripheral tissues109.
Similar to CD8+ T cells, CD4+ T cells can be divided into several subgroups depending 
on the cytokine secretion profiles during infection110. These subgroups of CD4+ T 
cells have distinct functions and, as with CD8+ T cells, several redundant CD4+ T 
cell mechanisms to protect against influenza virus infections have been described 
for mice106. The main functions of CD4+ T cells include activation of APC and, most 
importantly, providing help in the activation of CD8+ T cells and B cells77,110-113 (Fig. 
4). Mouse studies suggest that optimal CD4+ T cell help to B cells is induced when 
the respective epitopes that activate the CD4+ T cell or B cell lies physically within 
same viral protein114,115. Crucially, CD4+ T cell help to B cells was the limiting factor 
for the kinetics and the magnitude of the virus-specific antibody response115, which 
emphasises the importance of the induction of efficient CD4+ T cell help during an 
influenza virus infection as well as for vaccination strategies. Additional functions 
of CD4+ T cells include direct lysis of virus-infected cells in a perforin-dependent 
manner116. It was recently shown, in both explanted lung tissue and in human cell 
cultures, that primary bronchial epithelial cells can be MHC class II positive, allowing 
a direct role for cytotoxic CD4+ T cells within the infected lung108. Furthermore, 
memory CD4+ T cells play a role in the induction of an antiviral state of cells in the 
vicinity of virus-infected cells110 and rapid initiation of the innate antiviral response in 
the lung111 (Fig. 4).
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Following influenza virus infection, virus-specific CD4+ memory T cells with the 
ability to rapidly expand upon re-infection with influenza virus are generated111,117. 
Using a mouse model, it was shown that CD4+ T cells induced during primary 
infection indirectly contribute to viral clearance by providing help to CTL. However, 
upon secondary infection, influenza virus-specific memory CD4+ T cells can also 
induce direct protective responses through helper-independent mechanisms via the 
production of INF-ɣ in the lungs118. Repeated re-infection of the host can lead to the 
exhaustion of the memory CD4+ T cell pool, resulting in reduced cytokine production 
and help to antibody producing B cells119.
DC
CD8+
T cell
1
2
3
CD4+
T cell
B cell
9
8
7
6
5
4
Figure 4. T cell immunity against influenza virus. CD4+ and CD8+ T cells contribute to immunity against 
influenza virus through several mechanisms. After activation of T cells via MHC-restricted influenza virus 
antigen presentation, the main function of virus-specific CD8+ T cells is direct lysis of influenza virus-
infected cells (1). In addition, virus-specific CD8+ T cells produce (antiviral) chemokines and cytokines 
(2) and stimulate epithelial cells to produce these molecules (3). Influenza virus-specific CD4+ T cells aid 
in the activation of APC (4), CD8+ T cells (5) and B cells (6). Furthermore, CD4+ T cells can have direct 
cytotoxic effects (7), induce an antiviral state in cells in the vicinity (8) and activate the innate immune 
system through production of chemokines and cytokines (9).
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1.3 Influenza vaccines
Antigenic drift of influenza viruses, requires almost annual updates of the seasonal 
influenza vaccine composition. The World Health Organization (WHO) makes a 
recommendation for vaccine strains twice a year based on the strains that are most 
likely to circulate next season120. Complications leading to morbidity and mortality 
following seasonal influenza virus infections are predominantly observed in high-risk 
groups, such as the elderly and immunocompromised. Therefore, annual vaccination 
of these high-risk groups against seasonal influenza viruses is recommended121. 
Furthermore, in case of an influenza virus pandemic a tailor-made vaccine needs to 
be developed momentarily. This is an unwanted and time-consuming process in the 
face of a pandemic. Currently, inactivated whole virus, split virion, subunit and live 
attenuated influenza vaccines are available.
Inactivated/recombinant influenza vaccines
Inactivated and recombinant protein influenza vaccines are used to prevent both 
seasonal and pandemic influenza virus infections, and to reduce influenza-related 
morbidity and mortality. Trivalent inactivated vaccines (TIV) are most commonly 
used, particularly in high-risk groups such as the elderly, against seasonal influenza 
virus infections. These vaccines contain components of three influenza viruses 
responsible for epidemic outbreaks: A(H1N1) and A(H3N2) influenza viruses and an 
influenza B virus. More recently, quadrivalent vaccines have become available that 
contain an additional, antigenically different influenza B virus120. Using the annual 
WHO prediction of influenza viruses that are likely to circulate in the next season 
whole-inactivated, split virion (virus particles disrupted by a detergent) or subunit 
(purified protein) vaccines are prepared121. All these vaccines aim at the induction of 
virus-neutralizing antibodies against HA, and to a lesser extent NA.
In case of a pandemic outbreak, procedures are in place to rapidly develop an 
inactivated vaccine that antigenically matches the pandemic influenza virus. For 
the highly pathogenic avian influenza viruses of the A(H5N1) subtype pre-pandemic 
inactivated influenza vaccines have been stockpiled in some countries122. Similar to 
TIV, the pre-pandemic A(H5N1) vaccine also induces neutralizing antibody responses 
predominantly against HA and poorly induce a heterosubtypic immune response. 
Thus, due to the continuous antigenic changes in HA of H5 influenza viruses, the 
stockpiled vaccine may be a poor antigenic match with eventual pandemic influenza 
viruses. 
Traditionally inactivated influenza vaccine components are grown on embryonated 
chicken eggs121. Reassortant viruses with the HA and NA gene segment from the 
influenza A virus of interest in the A/Puerto Rico/8/34 backbone are generated 
to produce vaccine components, because these reassortant viruses generally 
replicate better in eggs than the wild-type virus. In contrast, reassortant influenza 
B viruses generally do not replicate better than the wild-type virus on chicken 
cells and therefore have to be adapted to replicate in eggs, which could lead to 
unwanted antigenic changes in HA. In general, growing influenza viruses for 
vaccine production in chicken eggs is a slow and labour-intensive process123. In 
order to expand production capacities, influenza vaccines produced in mammalian 
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cell lines have been approved in the United States and Europe123-125. Furthermore, 
recombinant influenza vaccines are now commercially available that are prepared 
using a baculovirus expression system. This system uses recombinant baculoviruses 
containing the HA gene segment of the influenza virus of interest and are grown on 
insect cells. Since the HA protein is not significant for the baculovirus replication 
cycle, adaptation of these proteins to the cell line does not occur frequently. Thus, 
potential antigenic changes in the HA protein during the manufacturing process are 
limited. The HA protein produced using the baculovirus expression system is purified 
and can be used as influenza vaccine preparation126. 
In general, inactivated vaccines are poorly immunogenic, but immunogenicity can 
be improved by the addition of an adjuvant to the vaccine preparation. Currently, 
MF59 and adjuvant system (AS)03 adjuvants (both oil-in-water emulsions) have 
been approved for the use in conjunction with human influenza vaccines. These 
adjuvants recruit and activate innate immune cells, and increase antigen uptake 
and subsequent transport to the draining LN. The use of MF59 or AS03 adjuvants 
in influenza vaccine preparations results in antigen dose sparing and/or induction of 
broader immune responses127-130.
For decades, the use of inactivated influenza vaccines has helped to reduce 
influenza-related morbidity and mortality131. However, the preparation and use of 
current inactivated influenza vaccines has limitations. First, if the vaccine strains 
do not match the epidemic influenza strains antigenically, vaccine effectiveness 
will be reduced. In addition, the seasonal influenza vaccine will offer little or no 
protection against influenza viruses of a novel subtype with pandemic potential. 
Second, the vaccine production capacity, even of all manufacturers combined, is 
limited. This is especially problematic in the case of a pandemic outbreak, which 
was illustrated during the 2009 pandemic caused by swine-origin influenza virus 
of the A(H1N1) subtype. In some countries, tailor-made vaccines, in which the HA 
matched the pandemic strain antigenically, only became available after the peak of 
the pandemic132-135. Third, subjects in the high-risk groups may not respond optimally 
to vaccination and therefore the vaccine is least effective in the people who need it 
most. Finally, inactivated influenza vaccines inefficiently induce virus-specific CD8+ T 
cells, which substantially contribute to enhanced viral clearance and have the ability 
to provide cross-protective immunity136,137. Moreover, these vaccines may even 
hamper the induction of CD8+ T cell responses otherwise induced by for example 
natural infections138-141.
Live attenuated influenza vaccines
In addition to inactivated influenza vaccines, live-attenuated influenza vaccines (LAIV) 
are available in some countries and are especially used to vaccinate children121. 
Attenuated viruses are prepared by reverse genetics, thereby introducing HA (and 
NA) RNA segments into the backbone of an influenza virus adapted to replicate 
at 25oC. The attenuated vaccine viruses containing HA and NA gene segments of 
influenza viruses recommended by the WHO are grown on embryonated chicken 
eggs142,143. The vaccine is administered as a spray intranasally and has been shown 
capable to induce antibodies, including mucosal IgA, CD4+ and CD8+ T cells143.
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Vaccination with LAIV has been proven safe without any serious adverse events, 
although with the use of attenuated viruses potentially similar symptoms as observed 
with a natural infection can arise. Furthermore, when using live-attenuated vaccines 
there is always a risk of reversion of the attenuated virus to the virulent form. Virus 
shedding has been observed for several days after vaccination in children, but 
transmission of the attenuated virus seems to be rare121. 
Recently, there has been debate about the effectiveness of LAIV following reports 
of studies unable to show significant LAIV effectiveness. Other studies showed 
significant LAIV effectiveness, however, the vaccine did not perform better than 
the inactivated influenza vaccines144,145. Thus far, the WHO has not changed the 
influenza vaccine recommendations, but further investigation into LAIV effectiveness 
is warranted144.
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1.4 Novel (universal) influenza vaccines
In order to develop vaccines that induce immunity against different influenza viruses 
within the same subtype (intrasubtypic immunity) or against influenza viruses of 
different subtypes (intersubtypic immunity), different viral components are currently 
evaluated as novel vaccine targets (Fig. 5). These targets should be immunogenic, 
accessible during infection and conserved across several subtypes of influenza 
virus. In addition, novel delivery strategies and vaccine production platforms are 
evaluated to develop long-lasting and broadly reactive influenza virus-specific 
immune responses.
Novel vaccine targets
HA stalk-specific antibodies
Broadly neutralizing antibodies specific for the head-domain of HA have been 
described146-151. However, considering the high mutation rate of the head-domain, 
eliciting an antibody response specific for the relatively conserved stalk-domain 
is believed to have more potential to induce heterosubtypic immunity. It has been 
shown that passive immunization with stalk-specific antibodies affords protection 
against infection with a heterologous influenza virus in mice and ferrets146,150,152-158. 
Human stalk-specific antibodies induced by influenza virus infection or vaccination 
have been identified and are specific for epitopes shared by either group I subtypes 
of HA (including H1, H2, H5, H6 and H9), group II HA subtypes (H3, H4, H7, H10, 
H14 and H15) or even both146,152,159-161. However, upon natural infection the HA 
stalk-specific antibody response is subdominant compared with the response to 
the globular head region and the magnitude of the stalk-specific antibody response 
varies considerably between individuals. Given the low frequency of stalk-specific B 
cells it is unlikely that the antibody levels induced upon influenza virus infection can 
afford protection146,161.
In the context of the development of a universal influenza vaccine, various designs 
of stalk-based immunogens have been proposed. First, the globular head of HA 
has been removed to avoid the immunodominant antibody response to this variable 
region162-165. However, to retain the correct conformation of the stalk-domain without 
the head has been a challenge. Therefore, extra stabilizing mutations have been 
introduced and synthetic HA stalk molecules have been constructed164,165. Second, 
modifications have been made to the head-domain by the introduction of extra 
glycosylation sites. Glycosylation shields the head-domain from recognition by 
virus-specific B cells in favour of an antibody response to the stalk-domain166. A 
third approach to induce stalk-specific antibodies is to sequentially immunize with 
chimeric HA molecules carrying a (irrelevant) head-domain of different HA subtypes 
but the same stalk-domain in order to boost the stalk- and not the head-specific 
immune response. This approach has resulted in substantial antibody responses to 
the stalk, which afforded protection against challenge infection with heterosubtypic 
viruses158,167-171 (Fig. 5).
In contrast to virus-neutralizing antibodies specific for the head-domain, stalk-specific 
antibodies do not inhibit agglutination of erythrocytes in a hemagglutination inhibition 
(HI) assay. Therefore, alternative mechanisms than interference with receptor 
C
ha
pt
er
 1
.4
26
Chapter 1 | General introduction
binding have been proposed for their protective effect. These include prevention of 
conformational changes of HA in the endosomes and subsequent fusion of the virus 
membrane with the endosomal membrane159, effects on virus egress from the infected 
cells150 and interference with maturation of HA by preventing cleavage of HA by host 
proteases168. Furthermore, recently it was shown that interactions between the Fc 
region of broadly neutralizing HA stalk-specific antibodies and Fc-ɣ receptors were 
essential in protecting mice from lethal influenza virus challenge. This suggests that 
ADCC or ADP mediated by HA stalk-specific antibodies contributed to protection45.
Antibodies against NA 
Upon an influenza virus infection NA-specific antibodies are induced, which can be 
boosted by vaccination with TIV172. Because antibodies to NA have been shown to 
cross-react with different NAs of the same subtype, these antibodies may afford a 
degree of cross-protection in the absence of a matching HA, e.g. A(H1N1) versus 
A(H5N1)173-175. In contrast to HA head-domain antibodies, NA-specific antibodies do 
not prevent virus infection but rather prevent release of newly formed virus particles46 
(Fig. 5).
Not only NA-specific antibodies elicited through natural infection, but also NA 
antibodies induced by vaccination have been shown to provide intrasubtypic 
protection. Vaccination of mice with a DNA plasmid expressing NA provided 
protection against infection with a influenza virus containing a structurally similar 
NA protein173,176. Given the narrow range of protection of this NA-specific antibody 
response, a stand-alone NA-based vaccine is not the most attractive candidate for 
universal influenza vaccine development. However, the addition of NA to an HA 
component can improve the virus-specific antibody response177.
Antibodies against M2
The ectodomain of M2 (M2e) is considered a good candidate for universal influenza 
vaccine development because it is relatively conserved among influenza A 
viruses178. The protective effect of M2-specific antibodies has been demonstrated 
after hyperimmunization and passive administration179. Antibodies specific for M2 
are unable to neutralize influenza virus due to their inability to bind the protein on 
the virion surface, however, antibodies can bind to M2e when it is exposed on the 
surface of infected host cells. These antibodies mediate killing of the infected cells by 
ADCC, most likely by NK cells180 (Fig. 5). Furthermore, M2-specific antibodies may 
also opsonize infected cells for phagocytosis by macrophages43,181.
Due to its poor immunogenicity, vaccine development based on M2 protein is 
challenging. However, if the M2-based peptide vaccine is adjuvanted, a robust 
antibody response can be induced182. Several M2-based influenza vaccine 
candidates have been described and validated in various animal models, including 
DNA constructs183, virus-like particles (VLPs)43,180,181,184 and viral vectors185. It has 
been shown in mice that M2-based vaccines can provide protection against infection 
with a heterologous virus181,185,186. Moreover, even six months after vaccination 
mice were protected from a homologous challenge infection181, indicating that an 
M2-based vaccine can provide long-term protection. Currently, M2-based vaccines 
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are evaluated in clinical trials187. M2-specific antibodies alone cannot provide sterile 
immunity178, therefore, combining M2 with another influenza antigen might induce a 
better protective immune response179.
Antibodies against NP
Protective effects of NP-specific antibodies have been demonstrated in mouse 
models188,189 and was shown to be dependent on Fc receptors and CD8+ T cells. 
Therefore, it has been suggested that formation of NP immune complexes and 
opsonisation plays a role in conferring protection188,189, although this could not be 
confirmed in vitro190. More recently, it has been shown that NP-specific antibodies 
inducing ADCC could be detected in children and adults. These antibody responses 
cross-reacted with NP from seasonal A(H1N1) and A(H3N2) influenza viruses, 
A(H1N1)pandemic(pdm)09 and A(H7N9) influenza viruses191. Thus, although NP-
specific antibodies may not induce virus neutralization, they could be an important 
component to establish heterosubtypic immunity. 
Broadly reactive T cell responses
It was already recognized over 30 years ago that conserved internal influenza 
virus proteins, such as NP and M1, are targets for CTL that consequently cross-
react with influenza viruses of different subtypes72-75,107. Indeed, CTL induced after 
infection with seasonal A(H1N1) and A(H3N2) influenza viruses cross-react with 
A(H5N1)53,55,107, A(H1N1)pdm0956,192,193, variant A(H3N2)56 and A(H7N9)57 influenza 
viruses. During the pandemic of 2009, it was demonstrated that the frequency of pre-
existing cross-reactive CD8+ T cells was inversely associated with disease severity 
in individuals infected with the A(H1N1)pdm09 virus82,194. In acutely infected patients 
a rapid anamnestic cross-reactive virus-specific CD8+ CTL response was observed, 
which may have contributed to accelerated clearance of the virus195. Furthermore, 
in patients infected with the avian A(H7N9) virus that emerged in China, disease 
outcome correlated with the virus-specific CD8+ T cell response196. This indicates 
that vaccines capable of inducing influenza virus-specific CD8+ T cell responses may 
afford broadly protective immunity (Fig. 5).
It is now generally accepted that virus-specific CD8+ T cells play an important role 
in cross-protective immunity197. More recently, it has been demonstrated both in 
animal models and humans that CD4+ T helper cells contribute to cross-protective 
immunity as well105,106,108,116,118. Upon infection with heterologous influenza viruses, 
cross-reactive anamnestic T cell responses contribute to accelerated clearance of 
infection and reduction of clinical symptoms82,195.
Various studies attempted to define the relative contribution of CD4+ and/or CD8+ T 
cells to heterosubtypic immunity, and it has been suggested that CD8+ T cells are 
the major mediators82,197. It has been shown in mice that CD8+ T cells in combination 
with non-neutralizing antibodies directed against internal influenza virus proteins 
were capable of providing complete protection against a lethal influenza virus 
challenge. This process was, at least in part, dependent on alveolar macrophages198. 
In contrast, there are also mouse studies showing that CD4+ T cells199,200 and/or B 
cells201,202 contribute to heterosubtypic immunity. Clearly, the immune response to 
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influenza virus is multifactorial203 and therefore it is difficult to attribute heterosubtypic 
immunity to a single effector mechanism. Although T cell mediated immunity induced 
by either vaccination or natural infection may not induce sterile immunity, it could 
afford a significant degree of clinical protection against both seasonal and pandemic 
influenza viruses.
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Figure 5. Design approaches for novel universal influenza vaccines. Different approaches are 
currently investigated for the design of novel universal influenza vaccines. Vaccines can be designed 
to induce HA stalk-specific antibody responses (1-3), non-neutralizing antibody responses (4-5) or CD8+ 
T cell responses (6). In order to redirect antibody responses towards the conserved HA stalk-domain, 
several modifications have been made to HA. These include headless HA molecules (1), ‘shielded’ head 
HA molecules through introduction of glycosylation sites (2) and chimeric HA molecules (3). The latter 
boost the stalk-specific antibody response through repeated vaccinations with molecules expressing 
similar a stalk-domain but different head-domains. Furthermore, non-neutralizing antibodies (antibodies-
specific for NP, M2, NA and HA stalk) can be important in protection from influenza virus, in particular 
antibodies that prevent virus egress from cells (4) or are capable of inducing ADCC/ADP (5). Finally, 
conserved internal proteins such as NP or polymerase complex can be used as antigens to induce virus-
specific CTL response (6).
Respiratory vaccine administration
In addition to the identification of novel vaccine target proteins, alternative vaccination 
strategies are currently under investigation. Most vaccines, including TIV, are 
administered intramuscularly and therefore induce a systemic immune response. 
However, influenza virus mainly causes infection of the respiratory tract and induction 
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of local immunity by respiratory vaccination may be more effective. An added benefit 
of respiratory vaccine administration is that no needles are required. This would 
facilitate large-scale vaccination campaigns without the need for professional health 
care workers and destruction of potentially contaminated needles.
Currently, LAIV is already administered as a nasal spray to children and has been 
shown to induce local mucosal IgA antibody responses204,205. In addition, LAIV 
vaccination has also been shown capable of inducing a mucosal immune response 
in adults, however, the number of individuals that seroconverted was low. Of note, 
the majority of the volunteers in this study previously received TIV, which induced 
antibodies that can neutralize the attenuated vaccine virus resulting in reduced LAIV 
effeciveness206. Furthermore, intranasal instillation of a vaccine candidate comprised 
of a cocktail of VLPs displaying four subtypes of HA protected mice from infection 
with influenza viruses of eight different HA subtypes. Since sterile immunity against 
heterosubtypic viruses was not achieved, factors other than neutralizing antibodies 
were considered to mediate the observed protection207.
Vaccine vectors
For the efficient induction of virus-specific CD8+ T cells, vaccine delivery systems 
are required that allow de novo synthesis of viral proteins. In this respect, the use 
of viral vectors for the delivery of viral proteins holds promise, because it allows for 
synthesis of viral proteins in the cytosol of infected cells and thus facilitates antigen 
processing and presentation to virus-specific CD8+ T cells. Furthermore, the antigens 
of interest are (over-)expressed in their native conformation, thus are also able to 
induce antibodies of the proper specificity. 
Viral vector-based influenza vaccine candidates that are currently under 
development include baculovirus, parainfluenza virus 5, alphavirus and Newcastle 
disease virus vaccine vectors208,209. However, efficacy/safety in humans has not been 
extensively tested for these vectors. In addition, recombinant adenoviruses (rAd) 
are investigated, forming a stable vector system that allows for easy insertion of 
an antigen of interest. There are many serotypes of adenoviruses of which several 
have been tested as a vaccine vector, either as a replication competent vector or 
modified to become replication-deficient209. These vectors readily express the 
antigen of interest and are capable of inducing innate, cellular and humoral immune 
responses. Drawbacks of the use of rAd vaccine vectors include two clinical trial 
failures with rAd5210,211 and potential interference of pre-existing adenovirus-specific 
immunity in humans212,213. The use of a non-human, low-prevalent and/or genetically 
altered rAd vectors is investigated as an alternative214-218. In addition to adenovirus 
vectors, several poxvirus-based vaccine vectors have been investigated for the 
development of vaccines. First, the replication competent vaccinia virus (VACV), 
used in vaccination campaigns to eradicate smallpox, was used as a recombinant 
vaccine vector expressing various influenza virus antigens. However, substantial 
reactogenicity against the VACV vector was observed in various animal models, 
which propelled development of attenuated VACV-derived virus vectors. This 
includes NYVACV, created by the deletion of 18 open reading frames from the VACV 
genome, and Modified Vaccinia virus Ankara (MVA)209. 
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Modified Vaccinia virus Ankara
MVA is derived from Chorioallantois Vaccinia virus Ankara through serial passaging 
in chicken embryo fibroblasts (CEF)219,220, which resulted in major deletions in the 
viral genome and many mutations that affected most known VACV virulence and 
immune evasion factors221-223. Consequently, efficient MVA replication is restricted 
to avian cells and the virus is unable to produce infectious progeny in most cells 
of mammalian origin224-226. The host cell restriction of MVA is associated with a late 
block in the assembly of viral particles in non-permissive cells. This phenotype is 
rather exceptional among poxviruses with host range deficiencies, which are usually 
blocked prior to this stage during the abortive infection in mammalian cells227-229. 
Non-replicating MVA allows for unimpaired synthesis of viral early, intermediate and 
abundant late gene products, which supported its development as safe and particularly 
efficient viral vector226. Moreover, the biological safety and replication deficiency of 
MVA has been confirmed in various in vivo models, including avian species and 
animal models with severe immunodeficiencies230-233, and immunocompromised 
humans234. Therefore, recombinant (r)MVA viruses as genetically modified organisms 
can be used under conditions of biosafety level (BSL-)1 in most countries, provided 
that innocuous heterologous gene sequences are expressed. The latter attribute is 
an important advantage compared to replication competent poxvirus vectors (BSL-2 
organisms) and other viral vectors, and has certainly contributed to the increasing 
use of rMVA in clinical testing.
Antigens encoded by target gene sequences inserted into the MVA genome are 
transcribed under the highly specific control of poxviral promoters that are only 
recognized and activated by virus encoded enzymes and transcription factors. Since 
there is no survival of MVA infected host cells it can be assumed that full clearance 
of recombinant virus and DNA occurs within days after vaccine administration, 
ensuring only transient expression of proteins. Despite this transient production, 
MVA vector vaccines are able to elicit high levels of antigen-specific humoral and 
cellular immune responses, as was demonstrated with the first MVA candidate 
vaccine delivering influenza antigens235,236. 
Another characteristic of MVA vaccines is their level of immunogenicity and 
protective capacity when compared to replicating VACV vaccines, expressing an 
identical transgene235,237,238. Replication competent vectors are expected produce 
more antigen per vaccination than non-replicating vectors because of their capacity 
to amplify and spread to new cells in vivo. Nevertheless, the efficacy of MVA-based 
vaccines was as good as or even better than the vaccinations with replication 
competent VACV vectors in mice and non-human primates. These observations 
are explained by the capacity of MVA to activate various components of the host 
innate immune system, probably because of the lack of immune evasion factors 
encoded by wild-type VACV239-246. Unlike other VACV strains, MVA does not 
produce the soluble viral proteins that function as receptor-like inhibitors of type I 
and type II IFN, TNF and chemokines241. Moreover, MVA infection can be sensed 
by multiple intracellular host detection mechanisms resulting in the production of 
IFN, inflammatory cytokines and chemokines243. In addition, MVA has lost several 
of the VACV inhibitors targeting intracellular signalling pathways, e.g. host NF-κB 
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activation. As a consequence, in vivo administration of MVA, but not other VACV 
strains, can trigger the rapid immigration of monocytes, neutrophils and CD4+ T cells 
to the site of inoculation245. These intrinsic immunostimulatory activities suggest that 
the use of additional adjuvant systems together with MVA might be dispensable for 
most vaccine applications. 
MVA has potential as a rapid response vaccine platform for newly emerging and 
potentially pandemic viruses. Established standard protocols allow rapid generation 
of rMVAs that are suitable for clinical evaluation247. This is done by simultaneous 
infection of CEF with fully characterized non-recombinant MVA seed virus and 
subsequent transfection of vector plasmid DNA containing the target gene of interest. 
Through homologous recombination, the heterologous gene sequences are inserted 
in the viral genome. The rMVA is clonally selected and amplified by serial passaging 
on CEF derived from certified embryonated eggs of specific pathogen free (SPF) 
chickens. The ideal process from a human case of infection with a novel respiratory 
virus to the construction and isolation of a candidate rMVA would takes 6-12 weeks 
(Fig. 6).
Figure 6. Ideal timeline for construction of an MVA-based vaccine after a human case of infection 
with a novel respiratory virus. Influenza virus is used as an example. After the emergence of a novel 
respiratory virus with the ability of infecting humans (1), the virus is isolated (2) and the sequence of a 
target gene of interest can be obtained within a week (3). Subsequently, the gene of interest is cloned or 
synthesized and subcloned into an MVA shuttle vector plasmid (4). This plasmid is then transfected in 
cells infected with wild-type (wt)MVA. Through homologous recombination the gene of interest is inserted 
into the MVA genome (5). By serial plaque passaging on CEF a good laboratory practice (GLP) compliant 
rMVA is clonally isolated (6). The process from cloning to obtaining the rMVA takes about 6-12 weeks.
1. Human case of 
infection with novel
influenza virus
2. Virus isolation 3. Nucleotide
sequencing and 
cloning of viral genes
4. Clone viral gene
into MVA shuttle
vector
5. Generation of recombinant 
MVA by homologous
recombination 
6. Recombinant MVA
1 week 6-12 weeks
ATG...
shuttle vector
Transfection with
shuttle vector
Infection with MVA
In order to produce enough vaccine doses for a large-scale vaccination campaign, 
bulks of tissue culture are required. Primary CEFs are readily prepared from 
embryonated eggs without need for further amplification and, as known from the 
production of seasonal influenza vaccines, millions of eggs can be obtained and 
handled within days. CEF can be produced at a large scale and cryopreserved for a 
later time point, however, this negatively impacts the quality of the cells. Therefore, 
especially in the context of pandemic preparedness, continuous cell lines that allow 
for efficient MVA propagation, such as the duck cell lines AGE1.CR and AGE1.
CR.pIX248, would be more beneficial.
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After generation of rMVA, the vector vaccine needs to be validated in vitro to verify 
genetic stability, antigen expression and unimpaired growth capacity. Subsequently, 
in vivo experiments in pre-clinical models (e.g. mice, ferrets and/or macaques) are 
performed to determine vaccine immunogenicity and efficacy, usually testing various 
dosages and routes of administration. If successful in the pre-clinical phase, the 
vaccine can be tested in humans. Thus far, no MVA-based vaccine is registered 
and marketed for human use, but numerous vaccines have been tested in clinical 
trials249,250. If the vaccine is successful during the incrementing phases of the clinical 
trials, it can be registered for common use. Currently, this process is too long for 
rapid rMVA validation in the face of a pandemic (Fig. 7).
1. Recombinant MVA 2. In vitro
characterization 
3. Preclinical evaluation 
of immunogenicity
4. Clinical trials 5. Registration
phase I phase II phase III
6-12 weeks 12-24 weeks 1 year 1 year 1-2 years 1-2 years
Figure 7. Timeline for evaluation of a novel MVA-based vaccine. A newly developed rMVA vaccine 
(1) is tested in vitro to assess correct gene insertion and protein expression in rMVA infected cells, e.g. 
by western blot or flow cytometry (2). Subsequently, vaccine immunogenicity and efficacy is tested in an 
appropriate animal model (3). If the MVA-based vaccine is successful in the pre-clinical tests, the vaccine 
is tested in phase I, II and III clinical trials (4). Finally, when the vaccine has proven safe and effective, it 
can be filed for market authorization (5).
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1.5 Modified Vaccinia virus Ankara-based influenza vaccines
Antigen expression from MVA allows for efficient induction of immune responses 
involving both the humoral and cellular component of the immune system. Therefore, 
the MVA virus vector is of considerable interest for the development of novel 
influenza vaccines. Many MVA-based influenza vaccines have been generated and 
are currently at different stages of development.
rMVA-H1
In order to evaluate an MVA-based vaccine against A(H1N1)pdm09 influenza virus, 
the HA gene of the prototypic A/California/7/09 influenza virus was cloned into rMVA 
(rMVA-H1). Mice vaccinated with rMVA-H1 were protected from a challenge infection 
with A(H1N1)pdm09 influenza virus. Protection correlated with the induction of 
virus-specific neutralizing antibodies and T cells251. Furthermore, vaccination with 
rMVA-H1 induced cross-protective immunity against some but not all swine A(H1N1) 
influenza viruses252. 
The rMVA-H1 vaccine candidate was also evaluated in ferrets and non-human 
primates. One vaccination afforded only modest protection in ferrets, but a second 
vaccination induced robust antibody titres that reduced virus replication after 
challenge infection with A(H1N1)pdm09 influenza virus. However, full sterile immunity 
was not achieved in this study, possibly related to the route of administration and/or 
dose of challenge virus253. Furthermore, rMVA expressing HA from A/California/04/07 
was assessed in macaques and provided full protection against an antigenically 
similar A(H1N1)pdm09 virus254. Taken together, these data indicate that an rMVA-H1 
vaccine would have been able to induce protective immunity against the influenza 
virus responsible for the 2009 pandemic, although the extent of cross-protection 
against unrelated A(H1N1) influenza viruses may have been limited.
rMVA-H5
The development of efficacious A(H5N1) vaccines is complicated by the co-circulation 
of different H5 influenza viruses that belong to antigenically distinct clades. Ideally, 
a novel vaccine induces antibodies that cross-react with A(H5N1) influenza viruses 
from multiple clades. Several rMVA vaccines expressing the HA gene of different 
A(H5N1) influenza viruses have been constructed and tested in animal models255. 
rMVA expressing the HA gene of influenza virus A/Vietnam/1194/04 (rMVA-H5) 
induced strong antibody responses that cross-reacted with other viruses to some 
extent and protected mice from infection with homologous and heterologous A(H5N1) 
viruses256,257. rMVA-H5 induced superior protective immunity against homologous 
and heterologous A(H5N1) viruses in mice compared to rMVA expressing HA 
genes of A/Hong Kong/156/97, A/Indonesia/5/05, A/turkey/Turkey/1/05, A/Chicken/
Egypt/3/06 or A/Anhui/1/05 H5N1 influenza viruses257. Furthermore, this rMVA-H5 
vaccine candidate has been evaluated in non-human primates. Two vaccinations 
with rMVA-H5 protected cynomolgus macaques against infection with influenza 
viruses A/Vietnam/1194/04 or A/Indonesia/5/05258,259. rMVA-H5 also proved to be 
immunogenic in chickens and afforded protection against infection with A(H5N1)233. 
The favourable outcome of pre-clinical testing of rMVA-H5 prompted the further 
clinical testing of this vaccine candidate in a phase I/IIa trial. The vaccine was shown 
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to be immunogenic in humans and induced cross-reactive antibody responses 
against antigenically diverse H5 influenza viruses260,261.
The minimal dose of rMVA-H5 required to induce protection from a lethal infection 
A(H5N1) influenza virus has been investigated in mice. Interestingly, a single dose 
of 105 plaque-forming units (PFU) was sufficient for the induction of sterile immunity 
against a challenge infection with the homologous influenza virus. However, two 
vaccinations with ≥104 PFU rMVA-H5 were required for induction of protective 
immunity against challenge infections with either the homologous or a heterologous 
influenza virus262. These data indicate that in case of a pandemic, when large 
numbers of vaccine doses need to be produced in a short period of time, protective 
immunity against A(H5N1) viruses can be induced with one or two relatively low 
doses of MVA. 
In addition to MVA-based H5 influenza vaccines expressing a wild-type HA gene, 
rational design approaches have been taken to induce broadly reactive immune 
responses. To that end, potential B and T cell epitopes in HA derived from A(H5N1) 
viruses were selected and recombined into a mosaic proteins using an in silico 
approach. This mosaic H5 (H5M) was expressed by MVA (rMVA-H5M) and was 
shown to induce broader T cell responses than MVA expressing wild-type HA. 
Vaccine-induced antibody responses were long lived and vaccination provided 
protection against both A(H5N1) and A(H1N1) influenza viruses263. 
Other rMVA-HA vaccines
rMVA expressing HA from H3N8 A/Equine/Kentucky/1/81 (rMVA-H3) has been 
evaluated in ponies as standalone vaccine or in combination with a DNA HA 
vaccine. Vaccination with rMVA-H3 was shown to induce antigen-specific antibody 
and T cell responses, and protected from disease caused by a challenge infection 
with the homologous influenza virus264. Furthermore, rMVA expressing HA from 
A/Shanghai/2/13 (rMVA-H7) has been constructed and tested in ferrets. The vaccine 
significantly reduced viral loads in the trachea and lungs after a challenge with 
A(H7N9) influenza virus265.
rMVA-NP
In order to induce virus-specific T cell responses with an MVA-based vaccine, MVA 
expressing NP derived from H3N8 A/Equine/Kentucky/1/81 was assessed in ponies 
in combination with a DNA NP vaccine. This vaccine regimen was shown to induce 
both humoral and cellular immunity against influenza virus. However, full protection 
from a challenge infection with the homologous virus was not observed although 
disease severity was reduced264. In addition, rMVA expressing NP from influenza 
virus A(H5N1) was constructed. Vaccination with this rMVA-NP vaccine induced 
humoral and cellular NP-specific immune responses in mice and provided partial 
protection from a lethal challenge with the homologous A(H5N1) influenza virus. In 
contrast, mice primed with a sub-lethal A(H1N1)pdm09 infection followed by rMVA-
NP vaccination were fully protected from the challenge. Sub-lethal infection with 
A(H1N1)pdm09 was not enough to achieve this level of protection, indicating that 
vaccination with rMVA-NP can boost cross-reactive immune responses. Cross-
reactive immune responses induced by vaccination with rMVA-NP were shown 
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to (partially) protect from a lethal A(H9N2) or A(H7N1) influenza virus infection in 
mice266. In contrast, in macaques vaccination with a similar rMVA-NP vaccine did not 
afford cross-reactive protection against a challenge with the heterologous A(H1N1)
pdm09 influenza virus254. 
rMVA-HA+NP
In order to elicit both virus-specific antibodies and T cell responses with a single 
vaccine, multivalent rMVA vaccines expressing both the HA and NP genes have 
been constructed and tested in mice. rMVA expressing HA and NP genes derived 
from influenza virus A/Puerto Rico/8/34 (H1N1) induced protective antibody and CTL 
responses against a homologous or heterologous infection in mice235,267.
Other rMVA-HA+NP vaccines expressing NP derived from A/Vietnam/1203/04 
(H5N1) and HA from either the same A(H5N1) influenza virus (rMVA-H5+NP) or 
H1N1pdm09 (rMVA-H1+NP) have been constructed. Vaccination with rMVA-H1+NP 
induced cross-protective immunity against infection with the homologous A(H1N1)
pdm09 influenza virus, an unrelated A(H1N1) influenza virus and an A(H5N1) 
influenza virus in mice. Furthermore, this vaccine afforded partial protection against 
a challenge with A(H3N2) influenza viruses. In contrast, rMVA-H5+NP only induced 
only protection against A(H5N1) and A(H1N1)pdm09 influenza viruses in mice268. 
In concordance with these results, vaccination of macaques with rMVA-H1+NP 
provided protection from an A(H1N1)pdm09 influenza virus challenge, whereas 
rMVA-H5+NP induced only partial protection254.
rMVA-NP+M1
Multivalent rMVAs expressing genes encoding the relatively conserved internal 
structural proteins NP and M1, aiming exclusively at the induction of virus-specific 
T cell responses, have been constructed. The rMVA-NP+M1 vaccine was tested 
in phase I and phase IIa clinical trials and mainly induced virus-specific CD8+ T 
cells, which were detected one week after intramuscular (IM) injection and 
induced protective immunity against an experimental infection one month after 
vaccination269,270. Furthermore, the vaccine was assessed in people over 60 years of 
age and shown to be safe and immunogenic271.
Different vaccination strategies have been investigated for the rMVA-NP+M1 
vaccine272-274. Priming with an adenovirus vector expressing NP and M1 and a 
subsequent boost with MVA expressing the same antigens induced higher levels 
of protective T cells than vaccination with either of the vectors alone in mice. The 
strongest T cell responses were obtained after IM injection (adenovirus vector) 
and intranasal (IN) instillation or IM injection (MVA) compared to intradermal (ID) 
injection273. In addition, rMVA-NP+M1 vaccination has been tested in combination 
with TIV as a cocktail, heterologous prime-boost regimen or as simultaneous adjacent 
vaccinations in mice and humans. Priming with rMVA-NP+M1 and subsequent 
boosting with TIV resulted in higher levels of total IgG but did not affect the number 
of IFN-ɣ-producing T cells when compared to vaccination with rMVA alone275,276. The 
heterologous prime-boost strategy protected mice from a heterologous challenge 
infection six months after vaccination275.
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MVA expressing other (combinations of) influenza virus proteins
To develop a universal influenza vaccine, different rMVAs expressing a variety of 
conserved antigens derived from A(H5N1) influenza virus were constructed. These 
antigens included PB1, M1, M2, the HA stalk-domain, HA-stalk combined with NP, 
HA-stalk in combination with four repeats of M2e – derived from A(H5N1), A(H9N2), 
A(H7N2) and A(H1N1) viruses – and HA-stalk+4xM2e+NP. Mice were immunized 
twice with the respective rMVA vaccines and subsequently challenged with A(H5N1), 
A(H7N1) or mouse adapted A(H9N2) influenza virus. Both rMVA expressing HA-
stalk+NP and HA-stalk+4xM2e+NP induced heterosubtypic immunity. Co-expression 
of NP seemed essential since expression of NP induced virus-specific CD4+ and 
CD8+ T cells266. All the other rMVA vaccines tested (rMVA-HA-stalk, rMVA-HA-
stalk+M2e, rMVA-M1, rMVA-M2, rMVA-PB1) failed to induce protective immunity. 
Interestingly, vaccination with rMVA-M1 predisposed for more severe disease upon 
challenge infection of the mice, although the difference in survival rates with the 
naïve control group was not statistically significant266. Furthermore, rMVA expressing 
NA derived from A(H1N1)pdm09 was constructed. After two vaccinations with either 
106 or 107 PFU, partial protection against a A/California/7/2009 H1N1 influenza virus 
challenge was observed251. Taken together, rMVA is widely used for the development 
of influenza vaccines and encouraging results have been obtained.
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1.6 Outline of the thesis
This thesis discusses the development and evaluation of novel MVA-based 
influenza vaccine candidates that aim at the induction of broadly protective immune 
responses. Chapter 2 describes studies performed to validate MVA as a vaccine 
vector. In chapter 2.1 the in vivo tropism of rMVA in mice, ferrets and macaques is 
described and delivery of rMVA by IM injection is compared to administration via the 
respiratory tract. The results of this study advance our understanding of the tropism 
and immunogenicity of MVA-based vaccines, and aid in the development of novel 
vaccines and delivery systems. Chapter 2.2 discusses the effect of pre-existing MVA-
specific immunity, induced by either smallpox vaccination or repeated rMVA-based 
vaccination, on the performance of rMVA-based vaccines. Since pre-existing vector-
specific immunity is known to have a detrimental effect on for example adenovirus 
vector-based vaccines, it is essential to understand the implications of pre-existing 
immunity to MVA on vaccine immunogenicity and efficacy.
In chapter 3, novel MVA-based influenza vaccine candidates were tested in pre-clinical 
studies. Chapter 3.1 and 3.2 describe rMVA-based influenza vaccine candidates 
designed to optimize influenza virus-specific T cell responses. Modifications to 
NP aiming at enhanced proteasomal protein degradation to increase subsequent 
release of peptides for presentation on MHC class I molecules were investigated. 
The immunogenicity and protective capacity of rMVA vaccines expressing (modified) 
NP was addressed in C57BL/6 mice (chapter 3.1) and BALB/c mice (chapter 
3.2). Furthermore, the immunogenicity of rMVA-based vaccines expressing the 
NP (chapter 3.2) or HA (chapter 3.3) gene was compared to vaccination with 
corresponding protein-based vaccines with and without Matrix-M™ adjuvant. These 
studies provide insight in optimization of induction of influenza virus-specific immune 
responses using MVA-based vaccines and the added value of using MVA-based 
vaccines over protein-based vaccines. In addition, chapter 3.3 addresses the effect 
of supplementing either protein- or MVA-based vaccines with Matrix-M™ adjuvant. 
Recruitment, proliferation and activation of different immune cell populations in the 
draining LN shortly after vaccination was described. The results of this study highlight 
the immune potentiating effects of Matrix-M™ adjuvant with both protein- and MVA-
based HA vaccines.
Finally, in chapter 4 the immunogenicity of an rMVA-based vaccine candidate 
expressing the HA gene from avian influenza A(H5N1) virus was assessed in a phase 
1/2a clinical trial. The breadth and functionality of the vaccine-induced antibody and 
T cell response was analysed. This study further validates the rMVA-H5 vaccine 
candidate for human use in the event of a pandemic outbreak with influenza viruses 
of the H5 subtype.
Collectively, the studies described in chapters 2-4 fill gaps in the current understanding 
of the MVA vaccine vector in general and as an influenza vaccine in particular, and 
provide essential information for licencing of MVA as a vaccine vector. Furthermore, 
novel MVA-based influenza vaccine candidates have been constructed and tested. 
The implications of the results obtained in these studies are discussed in chapter 5.

Chapter 2
Validation of MVA as vaccine vector
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CHAPTER 2.1
Modified Vaccinia virus Ankara preferentially targets antigen
presenting cells in vitro, ex vivo and in vivo
AF Altenburg*, CE van de Sandt*, BWS Li, RJ MacLoughlin, RAM Fouchier, G van Amerongen,
A Volz, RW Hendriks, RL de Swart, G Sutter, GF Rimmelzwaan & RD de Vries
*Authors contributed equally
Scientific Reports, 2017; 7(1)8580: 1-14
Modified Vaccinia virus Ankara (MVA) is a promising vaccine vector with an 
excellent safety profile. However, despite extensive pre-clinical and clinical 
testing, surprisingly little is known about the cellular tropism of MVA, especially 
in relevant animal species. Here, we performed in vitro, ex vivo and in vivo 
experiments with recombinant MVA expressing green fluorescent protein 
(rMVA-GFP). In both human peripheral blood mononuclear cells and mouse 
lung explants, rMVA-GFP predominantly infected antigen presenting cells. 
Subsequent in vivo experiments performed in mice, ferrets and non-human 
primates indicated that preferential targeting of dendritic cells and alveolar 
macrophages was observed after respiratory administration, although subtle 
differences were observed between the respective animal species. Following 
intramuscular injection, rMVA-GFP was detected in interdigitating cells 
between myocytes, but also in myocytes themselves. These data are important 
in advancing our understanding of the basis for the immunogenicity of MVA-
based vaccines and aid rational vaccine design and delivery strategies.
Introduction
Modified Vaccinia virus Ankara (MVA) is an attenuated poxvirus that is frequently 
used as viral vector. MVA is derived from the chorioallantois vaccinia virus strain 
Ankara by serial passaging in chicken embryo fibroblasts (CEF) over 500 times. 
This resulted in major deletions in the viral genome and rendered MVA replication-
deficient in mammalian cells223. MVA was used in smallpox vaccination regimens 
and has been tested in numerous clinical trials, resulting in the immunization of 
>100.000 study subjects without serious adverse events277,278. Moreover, MVA-
based vaccines also proved safe in immunocompromised non-human primates279. 
Given this impressive safety record, combined with the capacity to encode genes of 
interest of up to 10 kb in size, MVA holds promise as a vaccine vector. Vaccination 
with recombinant (r)MVA leads to efficient induction of both humoral and cellular 
immune responses targeting proteins encoded by the inserted transgene (reviewed 
by de Vries et al.209 & Altenburg et al.280). Because of these favourable properties, 
there has been considerable interest in developing rMVA-based vaccines against 
various infectious diseases and cancer, reflected by the steady increase in the 
number of clinical trials that have been performed with rMVA in recent years250.
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Despite frequent testing in clinical trials, the cellular tropism of MVA, particularly in 
relevant animal models, has been studied only to a limited extent. Even though the 
poxvirus lifecycle is complicated, in general poxviruses enter target cells via direct 
fusion with the cell membrane or endocytosis281, but the cellular receptor enabling 
either process has not been identified. Because MVA promiscuously infects almost 
any cell type, a putative cellular receptor is expected to be a ubiquitously expressed 
protein shared by different cell types282. Extensive research has been performed 
with vaccinia virus (VACV), the parental pathogenic and replication-competent 
poxvirus closely related to MVA, which implicated an important role for cell surface 
proteoglycans in VACV attachment283,284. Identical or similar proteins could be 
involved in attachment and entry of MVA into target cells.
Recombinant viruses expressing fluorescent reporter proteins that can be sensitively 
traced in vitro and in vivo have been instrumental in improving our understanding of 
the tropism of different viruses285-288. Previous in vitro studies with human peripheral 
blood mononuclear cells (PBMC), performed to determine the cellular tropism of 
VACV, showed that recombinant VACV expressing green fluorescent protein 
(GFP) preferentially infected professional antigen-presenting cells (APC)282,289,290. In 
accordance with these results, similar in vitro infection studies with rMVA expressing 
GFP (rMVA-GFP) also demonstrated that APC were preferentially infected, directly 
followed by apoptosis of these target cells245,291,292. Furthermore, to determine the 
tissue tropism of MVA in vivo, mice were previously inoculated via the intranasal (IN), 
intraperitoneal (IP) or subcutaneous (SC) route with rMVA expressing luciferase231,293. 
In these studies, it was shown that following IN instillation rMVA-infected cells could 
be detected in nasal-associated lymphoid tissue (NALT), lungs and draining lymph 
nodes (LN) of the lungs. Following IP and SC injection, rMVA-encoded luciferase 
was detected in all lymphoid organs, lungs, liver and ovaries. A mouse study with 
rMVA-GFP demonstrated predominant infection of CD11c+ dendritic cells (DC) in 
the spleen at 9 hour post-administration (HPA), however, in this study rMVA-GFP 
was administered intravenously292, which is not a standard immunization route. 
These studies focused on tissue tropism in mice, but the nature and phenotype of 
cells targeted by MVA in vivo in this and other, more relevant, animal models after 
administration via routes commonly used for vaccination, remain largely unknown.
In order to extensively elucidate the tissue and cell tropism of MVA, we performed in 
vitro, ex vivo and in vivo infection studies with rMVA-GFP. In addition, we compared 
the in vivo cell tropism of MVA after IM injection with tropism after direct delivery to 
the respiratory tract. We demonstrated predominant infection of CD11c+ MHC class 
II+ DC by rMVA-GFP in vitro in human PBMC and ex vivo in mouse lung explants. 
In vivo, rMVA-GFP was detected in both interdigitating cells in between myocytes 
and myocytes themselves after IM injection, whereas direct administration of rMVA-
GFP to the respiratory tract led to preferential targeting of alveolar macrophages 
(AM) in mice and DC in non-human primates, respectively. Since GFP+ cells were 
subsequently detected in the LN draining the site of administration, we concluded 
that rMVA-GFP-infected cells migrated to secondary lymphoid tissues and that direct 
targeting of professional APC is involved in the shaping of the immune response.
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Results
rMVA-GFP predominantly infects professional APC in vitro and ex vivo
To determine the cellular tropism of MVA in vitro, human PBMC were inoculated with 
rMVA-GFP at incrementing multiplicity of infection (MOI), ranging from 0.01 to 100. 
The percentage GFP+ cells within different cell populations was determined by flow 
cytometry 24h post-inoculation. CD11c+ HLA-DRhigh DC and CD14+ monocytes were 
readily infected by rMVA-GFP, even at low MOI. CD20+ HLA-DR+ B-lymphocytes 
were also easily infected by rMVA-GFP, followed by CD56+ NK cells. In contrast, 
CD3+ T-lymphocytes were refractory to infection with rMVA-GFP (Fig. 1A).
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Figure 1. Populations infected by rMVA-GFP in vitro in human PBMC and ex vivo in mouse lung 
slices. (A) Human PBMC were inoculated with rMVA-GFP at various MOI. Percentage of GFP+ live 
cells within DC, B-lymphocyte, monocyte, NK cell and T-lymphocyte populations were determined 
by flow cytometry at 24h post-infection. Mean of duplicates and standard deviation are indicated. (B) 
Lung slices were inoculated with rMVA-GFP and analysed by flow cytometry after 24h. GFP+ cells in 
single cell suspensions of lung tissue and culture supernatant were detected. (C) GFP+ cells in single 
cell suspensions of lung slices were phenotyped by flow cytometry. Populations were defined as CD3+, 
CD19+, CD11b− CD11chigh, CD11bdim CD11c−, CD11b+ CD11cdim or CD11b+ CD11c+. Mean percentage of 
infection per population of four lung slice cultures is indicated.
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To determine MVA tropism in the respiratory tract, mouse lung slices were prepared 
and inoculated ex vivo with rMVA-GFP. At 24h post-inoculation, both the emigrant 
cells in the lung slice culture supernatant and single cells suspensions of the 
lung tissue were analysed for the presence of GFP+ cells using flow cytometry. 
Interestingly, GFP+ cells were mainly present in the supernatant of inoculated lung 
slice cultures, however, could also be detected in the single cell suspensions (Fig. 
1B). Phenotyping of GFP+ tissue-resident lung cells showed predominant rMVA-GFP 
infection of CD11b− CD11chigh myeloid cells, commonly identified as AM or CD103+ 
DC294. However, CD11c+ and CD11cdim myeloid cells double positive for CD11b+ 
were also infected (Fig. 1C). CD19+ B-lymphocytes were infected to a limited extent, 
whereas CD11bdim CD11c− single positive cells and CD3+ T-lymphocytes were found 
refractory to infection (Fig. 1C).
rMVA-GFP-infected tissues and cells after IM or respiratory administration in vivo
In order to determine the tissue and cell tropism of MVA in vivo, rMVA-GFP was 
administered IM and to the respiratory tract of three different animal species 
(mice, ferrets and non-human primates, Fig. 2). Respiratory tract administration 
was performed by IN instillation, intra-tracheal (IT) inoculation or aerosol (AER) 
inhalation, depending on the animal model. Importantly, all routes in the respective 
animal models allowed for rMVA-GFP deposition in the lower respiratory tract. First, 
107, 108 or 109 plaque-forming units (PFU) rMVA-GFP was administered to C57BL/6 
mice via the IM or IN route. 6, 24 or 48 HPA mice were sacrificed to determine the 
optimal dose and time-point for follow-up experiments in ferrets and non-human 
primates.
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Figure 2. Experimental setup of rMVA-GFP in vivo studies. Three different doses (107-109 PFU) of 
rMVA-GFP were administered to mice via IM injection or IN instillation. At 6, 24 or 48 HPA, mice were 
euthanized. Ferrets and macaques received 109 rMVA-GFP via IM injection or direct respiratory tract 
administration (IT inoculation for ferrets, AER inhalation for macaques) and were euthanized 6 HPA.
rMVA-GFP targets myocytes and interdigitating cells after IM injection of mice
After IM injection of rMVA-GFP in mice, GFP+ cells were consistently detected in the 
hind leg muscle in which rMVA-GFP was injected. Direct confocal laser scanning 
microscopy (CLSM) of muscle slices resulted in detection of GFP fluorescence in 
the muscle fibers (Fig. 3A & Fig. S1). Phenotypic characterization by dual staining 
and subsequent CLSM and immunohistochemistry (IHC) proved difficult for mouse 
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tissues, however, myocytes were clearly infected (Fig. 3B). GFP was never found 
in the isotype control staining of hind leg muscle (Fig. 3B). Furthermore, GFP+ 
interdigitating cells were detected in the muscles and were identified as either having 
macrophage-/DC-like morphology or as part of the endomysium, the connective 
tissue that separates muscle fibers (Fig. 3C). Using IHC, GFP+ cells were never 
found in the front leg muscle, which was used as a negative control (Fig. 3C).
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◄ Figure 3. GFP+ cells in muscle or respiratory tract after IM injection or IN instillation of rMVA-
GFP to mice. (A) Maximum intensity projection of a Z-stack of the hind leg muscle 24h after IM injection of 
rMVA-GFP. Green = GFP. Red = nucleus (stained by TO-PRO3). (B) Detection of GFP+ myocytes in hind 
leg muscle tissue after IM rMVA-GFP injection by staining with rabbit anti-GFP or rabbit Ig isotype (green) 
in combination with DAPI (blue). (C) Morphological characterization of GFP+ cells in hind leg muscle tissue 
after IM rMVA-GFP injection by CLSM (left two panels) or IHC (right two panels) showing hind leg muscle 
(24 HPA) or negative control front leg muscle (6 HPA). GFP+ interdigitating cells are indicated by arrows. 
CLSM: GFP = green, nucleus = blue (DAPI). IHC: GFP = red and counterstaining with haematoxylin. 
(D) Detection of GFP+ cells in the nasal turbinates and lungs 6 or 24h after IN instillation of rMVA-GFP. 
GFP+ cells are shown in red (indicated by arrows). Tissues were counterstained with haematoxylin. (E) 
Morphological characterization of GFP+ cells in lungs after IN instillation of rMVA-GFP by staining with 
rabbit anti-GFP or rabbit Ig isotype (green) in combination with DAPI (blue). GFP+ cell with macrophage-/
DC-like morphology is indicated by arrow. (F) Percentage of GFP+ cells within different cell populations 
6h after IN instillation of 107, 108 or 109 PFU rMVA-GFP determined by flow cytometry. Results are shown 
as mean of two mice. (G) Relative contribution of the different cellular subsets to the GFP+ population by 
reversed gating. The average percentages of all mice that received rMVA-GFP by IN instillation and were 
euthanized 6 HPA are shown. IMφ = interstitial macrophages. Contrast of some CLSM images has been 
linearly enhanced using Adobe Photoshop CC. Scale bars are indicated in each figure.
rMVA-GFP targets predominantly AM in mice after IN instillation
At 6 or 24h after IN instillation of rMVA-GFP in mice, GFP+ cells were detected 
in both the nasal turbinates and the lungs. Mice were inoculated with a relatively 
large volume, directly exposing both the nasal cavity and the lungs. In the nasal 
turbinates, GFP+ cells were exclusively observed in the epithelial layer and had the 
morphology of epithelial cells. In the lungs, GFP+ cells were also detected in the 
epithelium of bronchioles, however, single GFP+ cells with an AM-like morphology 
were also observed in the lumen of the alveoli by IHC and CLSM (Fig. 3D-E). These 
data show that rMVA-GFP+ cells can consistently be detected at the anatomical site 
of administration and the infected cells morphologically resemble epithelial cells or 
AM.
Lungs of mice inoculated via the IN route were obtained during necropsy and 
single cell suspensions were prepared to determine the phenotype of GFP+ cells by 
multicolour flow cytometry (Fig. S2). GFP+ cells in the lungs were predominantly AM 
(defined as CD3−, CD19−, NK1.1−, Siglec-F+, CD11c+, F4/80+ and CD11b+), however, 
GFP+ DC (defined as CD3−, CD19−, NK1.1−, MHC class II+ and CD11c+) were also 
detected albeit to a lesser extent (Fig. 3E). Similar results were observed 24 HPA, 
whereas no GFP+ cells could be detected in the lungs 48 HPA (data not shown). 
Notably, when all GFP+ cells were selected at 6 HPA and subsequently characterized 
on basis of expression of various surface markers by reverse gating, it was found 
that AM constituted the largest proportion of GFP+ cells (48%, Fig. 3F).
rMVA-GFP-infected cells migrate to the draining LN and spread systemically in mice
To determine whether rMVA-GFP-infected cells migrated to the draining LN, the 
inguinal LN (ING-LN, draining the hind leg muscle) or mediastinal LN (MED-LN, 
draining the chest) was examined for presence of GFP+ cells after IM injection or IN 
instillation, respectively. As internal negative controls the axillary (AX-LN) draining 
the front leg muscle (after IM injection) or ING-LN (after IN instillation) were used. 
To determine whether rMVA-GFP could be detected systemically, blood and spleen 
samples were analysed for the presence of GFP+ cells.
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After IM injection, GFP+ cells were detected in single cell suspensions of the draining 
ING-LN as early as 6 HPA, mainly in mice that received the highest dose (109 PFU) 
rMVA-GFP. GFP+ cells were hardly detected at later time-points and were never 
observed in the control AX-LN (Fig. 4A, left panel). Notably, GFP+ cells were also 
detected systemically; in white blood cells (WBC) and single cell suspensions of the 
spleen at 6 and 24 HPA (Fig. 4A). After IN instillation of rMVA-GFP, low numbers of 
GFP+ cells were detected in the MED-LN at all time-points, but not in the control ING-
LN (Fig. 4B, left panel). Similar to IM rMVA-GFP injection, GFP+ cells were detected 
systemically in WBC and spleen after IN instillation (Fig. 4B). Collectively, these data 
illustrate that both after IM injection and IN instillation, GFP+ cells can be detected in 
the LN draining the site of inoculation and systemically.
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Figure 4. Dissemination of GFP+ cells after IM injection or IN instillation of rMVA-GFP to mice. At 
6, 24 or 48 HPA of 107, 108 or 109 PFU rMVA-GFP administration by IM injection (A) or IN instillation (B), 
GFP+ cells were detected in LN, WBC and spleens using flow cytometry. Number of GFP+ cells per 106 
total cells is shown, mean of four mice is indicated.
rMVA-GFP-infected cells in ferrets are of DC- or macrophage-like morphology
After determination of the optimal dose and kinetics of GFP expression in mice, 
ferrets received a high dose (109 PFU) of rMVA-GFP via either IM injection or IT 
inoculation and were sacrificed at 6 HPA. GFP+ cells were detected in hind leg 
muscle slices after IM injection and lung slices and broncho-alveolar lavage (BAL) 
cells after IT inoculation, respectively (Fig. 5A). Although direct CLSM could not be
used to determine the phenotype of GFP+ cells, it demonstrated that rMVA-GFP 
infected cells were present at the site of administration at 6 HPA. BAL cells, WBC 
and single cells suspensions of lymphoid tissues obtained from ferrets were directly 
analysed for GFP expression by flow cytometry. By performing positive/negative 
scorings based on flow cytometry data (Fig. 5B), BAL cells were consistently positive 
after IT inoculation and GFP+ cells disseminated from the site of administration and 
could be detected in the ING-LN draining the hind leg muscle and trachea-bronchial 
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Figure 5. Detection of GFP+ cells in ferrets after IM injection and IT inoculation of rMVA-GFP. (A) 
Direct detection of GFP+ cells using CLSM after IM injection (left panel) or IT inoculation (middle and right 
panel) of 109 PFU rMVA-GFP, 6 HPA. Middle panel shows direct CLSM of a lung slice, whereas the right 
panel shows cells recovered from the lungs by BAL. Contrast of certain images was linearly enhanced 
using Adobe Photoshop CC. (B) Overview of detection of GFP+ cells in BAL (left [L] or right [R] lung lobes), 
TB-LN, ING-LN, WBC or spleen in each individual ferret (n=2 per group) after IM injection or IT inoculation 
of rMVA-GFP. Green = GFP+. Red = GFP-negative. (C) Frequency of GFP+ cells in the respective tissues 
after IM injection or IT inoculation of rMVA-GFP. Number of GFP+ cells per 106 total cells is shown, mean 
of two ferrets is indicated. (D) GFP+ cells were phenotypically characterized as DC-like, monocyte-like or 
lymphocyte-like cells based on scatter properties of the different cell types.
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(TB-)LN draining the lungs after IM injection or IT inoculation, respectively (Fig. 5B-
C). Systemic rMVA-GFP+ cells were detected in both the spleen and WBC of multiple 
animals, however, the detection was not consistent. Low frequencies of GFP+ cells 
were found in BAL after IM injection, potentially due to the circulation of GFP+ cells 
in these animals (reflected by GFP+ cells in PBMC). Of note, some tissues that 
scored positive in flow cytometry (Fig. 5B) appear negative in Fig. 5C, due to the 
low frequency of GFP+ events. Fig. S3 illustrates when tissues were scored positive 
using flow cytometry.
Phenotyping of GFP+ cells in ferrets was experimentally challenging due to lack 
of the required ferret-specific antibodies directed against discriminative surface 
antigens. Therefore, we reversely gated the GFP+ events observed in flow cytometry 
and discriminated between three different populations based on known scatter 
properties of different cell types: lymphocyte-like, monocyte-like and DC-like cells 
(Fig. S3). Notably, GFP+ cells were equally distributed over the different populations 
for BAL, WBC and splenocytes, but there was a clear preference for DC-like cells 
in the draining LN of the hind leg muscle or lung after IM injection or IT inoculation, 
respectively. This suggests migration of rMVA-GFP-infected DC from the site of 
administration to the draining LN (Fig. 5D).
Validation of rMVA-GFP aerosol for administration to non-human primates
During aerosolization, an aerosol plume consisting of a droplet size distribution 
was generated. From within this plume, smaller droplets have a tendency towards 
deposition in the lower airways, whereas larger droplets most likely deposit in the 
nasal cavity and conducting airways. In order to fully characterize the aerosol and 
predict where in the respiratory tract rMVA-GFP may deposit, cascade impaction was 
performed during which the aerosol is fractioned into discrete droplet size ranges 
between 0.98 and 14.1μm. Each fraction was titrated in order to determine in what 
size aerosol droplets viable rMVA-GFP is present (Fig. S4). The Fine Particle Fraction 
(FPF) – the percentage of the rMVA particles contained in droplets under 5μm – 
was calculated as 96.75% with a mass median aerodynamic diameter (MMAD) of 
1.70μm, predicting targeting of the lower airways of non-human primates. However, 
through the use of a facemask interface it was ensured that the nasal cavity/upper 
airways were exposed to aerosol as well. Collectively, these results confirm that 
rMVA-GFP can be delivered to the upper and lower respiratory tract of non-human 
primates via aerosol inhalation.
rMVA-GFP predominantly infects myocytes, DC and AM in non-human primates
After completion of ferret experiments, cynomolgus macaques were inoculated with 
109 PFU rMVA-GFP by IM injection or aerosol (AER) inhalation295-297. Slices from 
either the hind leg muscle or lungs obtained from non-human primates at necropsy 
6 HPA were analysed by direct CLSM, which revealed presence of GFP+ cells after 
IM injection or AER inhalation, respectively (Fig. 6A). 3D reconstruction of a Z-stack 
obtained by CLSM of a non-human primate lung slice revealed that GFP+ cells were 
predominantly detected in the lumen of the alveoli, and to a lesser extent directly in 
or connected to the epithelium lining the alveoli (Fig. 6A right panel, Fig. S5).
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Figure 6. Identification of rMVA-GFP+ cells in macaque muscle or lung after IM injection or AER 
inhalation, respectively. (A) Detection of GFP+ cells at site of rMVA-GFP administration. Left panel: hind 
leg muscle after IM injection stained with rabbit anti-GFP (green, indicated by arrows) and DAPI (blue). 
Right panel: direct detection of GFP fluorescence in lung slices after AER inhalation counterstained with 
TO-PRO3 (red). Maximum intensity projection of a Z-stack is shown. (B) Dual immunofluorescent staining 
of muscle slices after IM injection of rMVA-GFP with rabbit anti-GFP (green) in combination with DAPI 
(blue) and mouse anti-Mac387, anti-MHC class II or anti-desmin (red). Co-localization of GFP and desmin 
is indicated by an arrow. (C) Dual immunofluorescent staining of lung slices after AER inhalation of rMVA-
GFP with rabbit anti-GFP (green) in combination with DAPI (blue) and mouse anti-cytokeratin, anti-CD20, 
anti-Mac387, anti-MHC class II or anti-CD11c (red). Co-localization of GFP and MHC class II or CD11c 
is indicated by arrows. (D) Lung slices stained with isotype control antibodies (rabbit Ig as control for 
anti-GFP, mouse IgG1 and 2a as control for cytokeratin, CD20, Mac387, MHC class II, CD11c, CD3 and 
desmin). (E) Percentage of GFP+ BAL cells within different cell populations after IM injection or AER 
inhalation of rMVA-GFP determined by flow cytometry. Mean of two macaques is indicated. (F) Relative 
contribution of the different subsets to the GFP+ population determined by reversed gating. The averages 
of the two animals that received rMVA-GFP by AER are shown. Contrast of some CLSM images has been 
enhanced linearly using Adobe Photoshop CC. Scale bars are indicated in images.
Direct imaging of muscle and lung slices by CLSM did not allow identification of the 
phenotype of GFP+ cells, but guided collection of GFP+ tissues that could be used 
for subsequent dual immunofluorescent staining. Mac387+ interstitial macrophages 
(IMφ) and MHC class II+ antigen presenting cells were only detected infrequently 
in the muscles and co-localization with GFP could not be observed in non-human 
primates that received rMVA-GFP by IM injection. However, GFP mainly co-localized
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with desmin, a specific marker for myocytes (Fig. 6B). Dual immunofluorescent 
staining of GFP+ lung slices of non-human primates that were inoculated by AER 
inhalation revealed co-localization with MHC class II+ and CD11c+ APC (Fig. 6C). 
Morphologically, these cells resembled DC and AM. Co-localization of GFP with 
specific markers for T-lymphocytes (CD3, not shown), epithelial cells (cytokeratin), 
B-lymphocytes (CD20) or IMφ (Mac387) was not observed after AER inhalation (Fig. 
6C). Isotype control stainings of lung slices were negative (Fig. 6D).
Subsequently, BAL samples from non-human primates inoculated by AER were 
analysed by multicolour flow cytometry. DC (CD45+ HLA-DR+ Siglec-8− CD16− 
CD11b+ CD11c+), eosinophils (CD45+ HLA-DR+ Siglec-8+ CD16+), AM (CD45+ 
HLA-DR+ Siglec-8− CD16− CD11b+ CD11c−), neutrophils (CD45+ HLA-DR+ Siglec-8− 
CD16+), B-lymphocytes (CD45+ CD3− HLA-DR+), CD4+/CD8+ T-lymphocytes (CD45+ 
CD3+) and non-leukocytes (CD45−) were analysed for GFP expression (Fig. S6). 
Respiratory samples collected after IM injection were used as negative control and 
indeed GFP+ cells were not detected (Fig. 6E). The relative percentage of GFP+ 
cells within subsets was highest in B-lymphocytes and DCs (Fig. 6E). In addition, 
GFP+ eosinophils, AM, neutrophils and non-leukocytes, probably representing 
epithelial cells, were detected (Fig. 6E). Reverse gating of GFP+ cells showed that 
DCs constituted 55.1% of the GFP+ cells and were the largest GFP+ cell population. 
Interestingly, although B-lymphocytes showed the highest rMVA-GFP infection rate, 
the number of B-lymphocytes recovered from non-human primate lungs was low, 
which explains the low contribution of B-lymphocytes to the total GFP+ cell population 
(Fig. 6E-F).
rMVA-GFP-infected cells migrate to the draining LN in non-human primates
To determine whether rMVA-GFP+ cells in non-human primates migrated to draining 
LN and spread systemically, WBC and single cell suspensions of the LN and spleen 
were analysed by flow cytometry. By performing positive/negative scorings based on 
flow cytometry data of the different tissues, we found that the BAL of AER inoculated 
macaques was consistently positive, and showed that GFP+ cells had migrated to 
the draining ING-LN after IM injection (2/2 non-human primates, Fig. 7A). However, 
the TB-LN was not consistently GFP+ after AER inhalation (1/2 non-human primates, 
Fig. 7A). GFP+ cells were never detected in the spleen, and GFP+ WBC were only 
observed after IM injection in 1/2 animals (Fig. 7A). Thus, apart from migration of 
MVA-infected cells to the draining LN, systemic spread of GFP+ cells was detected to 
a limited extent (Fig. 7). Of note, some tissues that scored positive in flow cytometry 
(Fig. 7A) appear negative in Fig. 7B, due to the low frequency of GFP+ events. Fig. 
S6 illustrates when tissues were scored positive using flow cytometry.
Discussion
In this study, we systematically assessed tissue and cell tropism of the vaccine 
vector MVA in vitro, ex vivo and in vivo using an rMVA expressing a fluorescent 
reporter protein. Even though different animal species and administration routes 
were used, we demonstrated consistent predominant infection of MHC class II+ 
APCs. In addition, in the different species local myocytes and local epithelial cells 
were infected after either IM injection or respiratory administration, respectively.
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Figure 7. Dissemination of rMVA-GFP+ cells in macaques. (A) Overview of GFP+ cells detected in 
BAL, TB-LN, ING-LN, WBC or spleen in each individual macaque (n=2 per group) after IM injection or 
AER inhalation of rMVA-GFP. Green = GFP+. Red = GFP-negative. (B) Frequency of GFP+ cells in the 
respective tissues after IM injection or AER inhalation of rMVA-GFP. Number of GFP+ cells per 106 total 
cells is shown, mean of two macaques is indicated.
Vaccination is the cornerstone control measure to reduce morbidity and mortality 
caused by infectious diseases. However, vaccination against hypervariable and 
emerging pathogens can be challenging. For example, seasonal influenza vaccines 
need to be updated almost annually to antigenically match emerging drift variant 
viruses and to maintain vaccine efficacy. Furthermore, in case of an emerging 
pandemic strain of influenza virus, timely production of a pandemic influenza 
vaccine has proven to be challenging132,133. The rapid construction of recombinant 
viral vaccine vectors, such as MVA, which allows easy insertion of any or multiple 
antigens of choice and rapid production of a large number of vaccine doses, is an 
attractive alternative to conventional vaccine production technology266,274. In addition, 
MVA has been considered as vaccine delivery system for many other infectious 
diseases and cancers298,299. Despite the increasing number of successful clinical 
trials performed with rMVA-based vaccines in recent years250, surprisingly little is 
known about their mode of action and the in vivo tissue and cell tropism of MVA, 
particularly in the ferret model, the golden standard for influenza virus pathogenesis 
studies, and animal models more closely related to humans, such as non-human 
primates. This gap of knowledge could potentially hamper future registration of MVA-
based vaccines for use in humans.
In this study, we describe the use of rMVA-GFP, allowing detection of single rMVA-
GFP infected cells with high sensitivity, to elucidate the tropism of the viral vector 
MVA. In vitro tropism was investigated by inoculating human PBMC with rMVA-
GFP, ex vivo tropism by inoculation of mouse lung explants and in vivo tropism by 
inoculating three different animal species via two different administration routes. In 
general, myeloid cells (mainly DC and macrophages) were preferentially infected 
by rMVA-GFP, independent of the experimental set-up, animal species or route of 
administration. Direct targeting of APC in mice, ferrets and non-human primates 
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confirms the suitability of MVA as vaccine vector, since they are involved in shaping 
the immune response. Of note, the relation between vector tropism and vaccine 
immunogenicity is not always straightforward, for example optimizing DC infection 
by an adenovirus vector did not result in increased immunogenicity in non-human 
primates300.
Upon in vitro inoculation of human PBMC with rMVA-GFP, DCs, monocytes and 
B-lymphocytes – all expressing MHC class II – were predominantly infected. NK 
cells were also targeted by rMVA-GFP (Fig. 1A) but T-lymphocytes were refractory 
to MVA infection, which was in accordance with previously published data obtained 
with both VACV and MVA290-292. In addition, the tropism of rMVA-GFP was assessed 
ex vivo in the respiratory tract in mouse lung slices. Due to limited use of surface 
markers, discrimination of distinct DC and monocyte populations was not possible. 
However, GFP+ cells were mainly identified in CD11chigh cells, most likely AM or 
CD103+ DC294 (Fig. 1C). Although these in vitro and ex vivo studies to elucidate the 
cellular tropism of MVA are of interest, they may not accurately reflect the in vivo 
situation and the cells infected with MVA at the site of administration.
Previous in vivo studies mainly focused on the tissue tropism of MVA231,293,301, 
whereas this study focused on the cellular tropism. In vivo administration of rMVA-
GFP to mice, ferrets and non-human primates – via the IM or respiratory route – 
consistently resulted in the detection of GFP+ cells at the site of administration. In 
pre-clinical and clinical studies MVA is most commonly administered by IM injection, 
however, the local cell types that are initially infected by MVA have thus far not 
been identified. Here we showed that directly after IM injection, rMVA-GFP infected 
both myocytes and interdigitating cells, potentially macrophages, DC or part of the 
endomysium (Fig. 3, 5, 6). Unfortunately, we were unable to determine the exact 
phenotype the rMVA-GFP-infected interdigitating cells in non-human primates due 
to the low frequency of GFP+ cells in the muscle tissue.
Due to sensitive detection of GFP+ cells in single cell suspensions of lungs or BAL 
cells, identification of rMVA-GFP+ cells after respiratory administration of rMVA-GFP 
was feasible. IN instillation of mice with a relative large volume rMVA-GFP delivered 
the vector both to nasal turbinates and lungs. Consequently, MVA-infected epithelial 
cells were detected in the nasal turbinates and lungs, however, AM in the lungs were 
also frequently infected (Fig. 3). This is in concordance with results obtained in other 
studies, which showed that IN instillation of mice with rMVA-GFP resulted in the 
infection of CD11c+ MHC class II− AM detected in BAL244. Targeting of myeloid cells 
was also observed after IT inoculation of ferrets with rMVA-GFP (Fig. 5), however, 
lack of ferret-specific antibodies required to distinguish between cell populations 
hampered the possibility to determine the exact phenotype of these rMVA-GFP-
infected cells.
In contrast to mice, the predominant target cells for rMVA-GFP in the lungs of non-
human primates were not characterized as CD11c+ MHC class II− AM, but as CD11c+ 
MHC class II+ DC. This was shown by both flow cytometry of BAL cells and in situ by 
CLSM after dual immunofluorescence staining of lung tissue (Fig. 6). In addition to 
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preferential targeting of DC, rMVA-GFP was also detected in AM, CD45− epithelial 
cells, eosinophils and neutrophils by flow cytometry of BAL cells. The highest infection 
rate was observed in B-lymphocytes, but the numbers of B-lymphocytes present in 
BAL obtained from non-human primates were low (Fig. 6). DC largely contributed 
to the total number of rMVA-GFP+ cells, but neutrophils also formed a substantial 
component. Interestingly, it has been shown that after intradermal injection of MVA 
in mice, neutrophils become infected by MVA and subsequently migrate to the 
draining LN and bone marrow where they can prime phenotypically different CD8+ 
T-lymphocyte populations302.
In addition to detection at the site of administration, GFP+ cells were also detected in 
the respective draining LN after either IM injection or administration into the airways 
as early as 6 HPA. As the only exception, IN instillation of mice led to detection 
of GFP+ cells in the draining LN at later time-points (24-48 HPA, Fig. 4), possibly 
because the MED-LN were tested in this species instead of the TB-LN, which could 
not be harvested during necropsy of mice. Taken together, these data suggest 
that after administration, MVA locally infects APC that subsequently migrate to the 
draining LN. In addition, GFP+ cells were detected systemically in both blood and 
spleen in mice, particularly at 24 HPA (Fig. 4). Ferrets and non-human primates 
were euthanized 6 HPA, which could explain why systemic spread of MVA-GFP+ 
cells was observed only to a limited extent (Fig. 5, 7).
The standard route for administration of MVA-based vaccines is intramuscular 
(IM) injection. However, for the induction of protective mucosal immunity against 
respiratory pathogens, delivery of MVA to the respiratory tract has been considered 
(reviewed by Tonnis et al.303)206,295,304. In this study, rMVA-GFP was administered to 
the respiratory tract of non-human primates as an aerosol, as best possible proxy for 
future studies with MVA-based respiratory vaccines. Importantly, the aerosol droplet 
size and nebulizer delivery system chosen in this study allowed exposure of the entire 
upper and lower respiratory tract to infectious virus, allowing accurate definition of 
target cells (Fig. S4). Furthermore, aerosol delivery is under extensive investigation 
as an alternative for vaccine delivery by injection, as it abolishes the necessity for 
hypodermic needles. This facilitates safety of large-scale vaccination campaigns 
in developing countries with high prevalence of blood-borne infections, as there 
is no need for a complicated infrastructure to dispose of potentially contaminated 
needles. Finally, direct administration of vaccines to the respiratory tract could lead 
to efficient induction of local immune responses leading to increased protection from 
respiratory pathogens. This has been evaluated extensively with a live-attenuated 
influenza vaccine administered IN to children (FluMist®), showing that nasal spray 
administration led to efficient induction of local mucosal IgA antibody responses204-206. 
Similar advantages potentially exist when rMVA is used as live vaccine against 
respiratory pathogens and could lead to the induction of local humoral and cellular 
immune responses (tissue-resident T-lymphocytes)304,305.
In summary, we are the first to comprehensively examine the tropism of MVA in 
vitro, ex vivo and in vivo in different species. Preferential targeting of APCs by rMVA-
GFP was demonstrated in vivo in each animal model, regardless of the route of 
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administration. Furthermore, delivery of rMVA-GFP to the respiratory tract of non-
human primates as an aerosol also resulted in infection of local epithelial cells 
and IM injection resulted in infection of myocytes. In mice, AM were preferentially 
infected over DC which was opposite in the case of non-human primates. Of interest, 
preferential targeting of DC over AM would be an advantage for a vector-based 
vaccine, as AM are notoriously inefficient APC in comparison to DC306-309. As a proxy 
for the sequence of events after vaccination of humans with MVA, the non-human 
primate data show that directly after administration, MVA infects local APC, which in 
the case of aerosol delivery were CD11c+ MHC class II+ DC in the lung. These rMVA-
GFP+ DC subsequently migrate to the draining LN, where they can present antigens 
via both MHC class I and II to responder cells, leading to an efficient shaping of the 
immune response (reviewed by Braciale et al.310)311. Previously, it was shown that 
infection of DC with MVA induced their maturation, potentially forming the basis of 
direct and cross-presentation of MVA-encoded antigens by HLA class I and II291. 
Whether rMVA-GFP-infected APC present antigens to responder cells directly, or 
via uptake of antigen by other DC for MHC class II- and cross-presentation, was 
not examined in this study. Data obtained in this study show that direct targeting 
of professional APC could explain the excellent immunogenicity of MVA-based 
vaccines. Knowledge on targeting of specific cell types by MVA could guide future 
vaccine design and delivery strategies.
Materials and Methods
Ethics statement
The use of human PMBC for scientific research was approved by the Medical Ethics Committee (METC) 
of the Erasmus MC (permit number MEC-2015-095). All participants gave informed consent and 
permission for use of materials to study infectious diseases, no identifying information was published. 
All work described has been carried out in accordance with the code of ethics of the world medical 
association (declaration of Helsinki). Animal experiments were conducted in strict compliance with 
European guidelines (EU directive on animal testing 2010/63/EU) and the animal protocol was approved 
by an independent animal experimentation ethical review committee (Erasmus MC permit number 
EUR3293). Animal welfare was observed on a daily basis and to minimize animal suffering all animal 
handling was performed under light anaesthesia using 4% isoflurane in oxygen (mice) or a mixture of 
10.mg/kg ketamine and 0.05mg/kg medetomidine (ferrets and non-human primates). To antagonize the 
effect of medetomidine, atipamezole was administered after handling.
Generation of rMVA-GFP
rMVA-GFP was generated by homologous recombination as described previously247. Briefly, MVA clonal 
isolate F6223 served as the parental virus for generating rMVA-GFP. Vector plasmid pG06-P11-GFP was 
used to direct insertion of GFP coding sequences under the transcriptional control of the natural VACV 
late promotor P11 into the deletion III site in the MVA genome. Virus stocks were generated in CEF, 
purified by ultracentrifugation through 36% sucrose and reconstituted in a 120mM NaCl 10mM Tris-HCl 
buffer (pH 7.4). Titre of the rMVA-GFP stock was determined by plaque assay on CEF and the construct 
was validated by PCR, nucleotide sequencing and transgene expression in various cell types.
In vitro infections of human PBMC
PBMC were isolated from blood obtained from healthy humans and seeded into 96-wells low-adherent 
V-bottom plates at 50.000 cells/well. Subsequently, cells were inoculated with rMVA-GFP at incrementing 
MOI (range MOI 0.01–100, 3-fold titration), for 1h, washed and incubated for 24h in Roswell Park Memorial 
Institute (RPMI) 1640 medium (Lonza) supplemented with 10% heat-inactivated foetal bovine serum (HI-
FBS, Greiner Bio-One), 100μg/ml penicillin, 100U/ml streptomycin (Lonza) and 2mM L-Glutamine (Lonza) 
(P/S/G) at 37°C. After 24h, cells were harvested and stained with CD3APC/Cy7 (BD Pharmingen), CD11cAPC 
(BD Pharmingen), CD14PerCP/Cy5.5 (BD Pharmingen), CD56PE (BD Pharmingen), CD20PE/Cy7 (Becton 
Dickinson) and HLA-DRPB (Biolegend), in combination with LIVE/DEAD aqua fixable stain (Invitrogen). 
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Cells were analysed on a flow cytometer (FACS Canto II) and the percentage of infected cells (GFP+) 
within the respective subsets was determined using FACS Diva software (BD Biosciences).
Ex vivo infection of mouse lung explants
Lungs from mice that received IM injection with rMVA-GFP (no GFP+ events were detected in the lungs) 
were inflated with 4% low-melting 2-hydroxyethylagarose in PBS mixed with an equal part of Dulbeccos’ 
Modified Eagle’s Medium (DMEM, Lonza Bio-Whittaker)/Ham’s F12 medium (Gibco) supplemented with 
10% HI-FBS, P/S/G and amphotericin B (1μg/ml, institutional pharmacy). Lung slices of approximately 
1mm thick were cut and used for ex vivo infections with rMVA-GFP as described previously312. In short, 24h 
post-inoculation single cell suspensions were obtained by digestion (described below), and subsequently 
stained with CD3PerCP (BD Pharmingen), CD19PE-Cy7 (BD Pharmingen), CD11cAPC (BD Pharmingen) 
and CD11bAPC-Cy7 (BD Pharmingen), in combination with LIVE/DEAD aqua fixable stain. Samples were 
acquired on a flow cytometer (FACS Canto II) and analysed using FACS Diva software (BD Biosciences). 
One mock-infected lung slice was excluded from the FACS analysis due to high aspecific background.
In vivo inoculation of mice with rMVA-GFP
Specified pathogen free, 6-8-week-old, female C57BL/6 mice (n=72) were purchased from Charles River 
and housed in individual ventilated cage (IVC) units with access to food and water ad libitum. Mice were 
inoculated with 107, 108 or 109 PFU rMVA-GFP in PBS administered either by IM injection in both hind 
legs (50μl/leg) or IN instillation (50μl). Mice were euthanized by cervical dislocation under isoflurane 
anaesthesia at 6, 24 and 48 HPA. After euthanasia, blood, ING-LN, spleen, head, lungs and trachea were 
obtained from all animals for analysis. In addition, the AX-LN and leg muscles were collected from IM 
injected animals and the MED-LN was collected from IN instilled mice.
In vivo inoculation of ferrets with rMVA-GFP
Four 6-12 months old female ferrets (Mustela Putorius furo) were housed in negatively pressurized, 
HEPA-filtered BSL-3 isolator cages and provided with commercial food pellets and water ad libitum. 
Ferrets were inoculated with 109 PFU rMVA-GFP in PBS via either IM injection, in both hind legs (200μl/
leg), or IT inoculation (1ml). Ferrets were euthanized by exsanguination at 6 HPA under deep ketamine 
sedation (20mg/kg body weight, Fig. 2). Blood, ING-LN, spleen, nose, trachea, primary bronchus, lungs, 
BAL and TB-LN were obtained from all animals. Leg muscles were exclusively obtained from the IM 
injected ferrets.
Droplet size characterization of rMVA-GFP aerosol
To characterize the aerosol droplet diameter following nebulization of rMVA-GFP, 109 PFU rMVA-GFP 
diluted in 0.5ml PBS was nebulized using a vibrating mesh nebulizer (Aeroneb Lab nebulizer, Aerogen 
Limited) as previously described313. The MMAD of the resulting aerosol was determined using a Cascade 
Impactor at 15 litres per minute vacuum flow rate (NGI, Copley Scientific).
In vivo aerosol inoculation of non-human primates with rMVA-GFP
Four male, healthy cynomolgus macaques (6-8-years-old, Macaca fascicularis) were obtained and reused 
one year after a non-lethal measles vaccination and challenge experiment. All animals were housed in 
negatively pressurized, HEPA-filtered BSL-3 isolator cages and were inoculated with 109 PFU rMVA-GFP 
in PBS via either IM injection in both hind legs (200μl/leg), or by aerosol inhalation. Briefly, rMVA-GFP 
was administered using a nebulizer (Aeroneb Lab nebulizer, Aerogen Limited) connected to a 22mm 
T-piece and using a silicone pediatric resuscitation mask (ComfortSeal silicone mask assembly, small, 
Monaghan Medical Corp.) as the interface with the non-human primates297. Using this method, 109 PFU 
rMVA-GFP (0.5ml) was nebulized and administered to the non-human primates. Animals were euthanized 
by exsanguination at 6 HPA under deep ketamine sedation (20mg/kg body weight, Fig. 2). Blood, inguinal 
LN, spleen, nasal septum, nasal concha, trachea, primary bronchus, lungs, BAL and TB-LN were collected 
from all animals. Leg muscles were exclusively obtained from IM injected non-human primates.
Processing of blood, BAL and lymphoid samples
Blood samples from mice, ferrets and non-human primates were collected in Vacuette tubes containing 
K3EDTA as an anticoagulant. Pure WBC were obtained by treatment of EDTA blood with red blood cell 
(RBC) lysis buffer (Roche diagnostics). A BAL was performed post-mortem in ferrets and non-human 
primates by direct infusion of 10ml PBS into the lungs, followed by immediate recovery of the fluid. 
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Lymphoid organs were collected from animals during necropsy in Iscove’s Modified Dulbecco’s Medium 
(IMDM, Lonza Bio-Whittaker) supplemented with 5% HI-FBS and P/S/G. Single cell suspensions were 
generated by using 100μm cell strainers (Falcon). Spleen single cell suspensions were subsequently 
treated with RBC lysis buffer in order to remove erythrocytes. Collectively, WBC, BAL cells and single cell 
suspensions from lymphoid organs were directly analysed for presence of GFP by flow cytometry on a 
FACS Canto II (BD Biosciences). GFP+ samples were subsequently stained in order to phenotype GFP+ 
events (see below). Mouse ING-LN and WBC samples after IM injection (n=1), spleen after IN instillation 
(n=1) were excluded from FACS analysis due to high background signal.
Preparation and processing of lungs
Mouse lungs were either fixed by inflation with 10% formalin or complete single cell suspensions were 
prepared by digestion. Formalin-fixed tissues were subsequently analysed by immunohistochemistry and/
or dual immunofluorescent staining. Single cell suspensions were prepared by treatment with 300U/ml 
collagenase type I (Invitrogen) and 0.15mg/ml DNase (Roche diagnostics) diluted in Hank’s Balanced 
Salt Solution (HBSS, Gibco) for 1h at 37°C, followed by filtration over 100μm cell strainers. Excess 
erythrocytes were removed by treatment with RBC lysis buffer if necessary. Single cell suspensions were 
used directly for detection of GFP by flow cytometry. GFP+ samples were subsequently stained in order 
to phenotype GFP+ events (see below).
Ferret and non-human primate lungs were inflated with 4% low-melting 2-hydroxyethylagarose in PBS 
mixed with an equal part of DMEM/Ham’s F12 medium (Gibco) supplemented with 10% HI-FBS, P/S/G 
and amphotericin B. Lung slices of approximately 1mm thick were cut and used for direct analysis of 
GFP fluorescence using CLSM. After direct detection of GFP, lung slices were fixed in 10% formalin, 
paraffin embedded and subsequently analysed by immunohistochemistry and/or dual immunofluorescent 
staining.
Phenotyping by flow cytometry
Freshly isolated WBC, BAL cells and single cell suspensions prepared from lymphoid organs or the 
lungs were analysed directly for GFP expression using a FACS Canto II flow cytometer and FACS Diva 
software (BD Bioscience). Approximately 1 × 106 events were obtained per sample to allow detection of 
low frequent GFP+ populations. Samples positive for GFP were subsequently stained to phenotype the 
GFP+ cells. Cells obtained from mouse lungs were subdivided into DC, eosinophils, AM, neutrophils, 
IMφ, CD4+ and CD8+ T-lymphocytes, B-lymphocytes and NK cells by blocking Fc receptors with 2.4G2 
and staining with Siglec-FPE (BD), CD3PE/CF594 (BD), CD19PerCP/Cy5.5 (eBioscience), CD8PE/Cy7 (eBioscience), 
CD11cEF450 (eBioscience), CD4BV605 (BD), MHCIIBV650 (BD), CD45BV711 (BD), F4/80Biotin (eBioscience) followed 
by StreptavidineBV786 (BD), NK1.1APC (BD), CD11bAF700 (eBioscience) and Gr-1APC/EF780 (eBioscience). 
BAL cells obtained from non-human primates were subdivided into DC, eosinophils, AM, neutrophils, 
monocytes, epithelial cells, CD4+ and CD8+ T-lymphocytes and B-lymphocytes by blocking Fc receptors 
with human serum and staining with CD33PE (eBioscience), CD19PE/TXR (Beckman Coulter), CD16PerCP/
Cy5.5 (BD), CD11bPE/Cy7 (BD), CD8aEF450 (eBioscience), CD68Biotin (Biolegend) followed by StreptavidineBV650 
(BD), MHCIIBV711 (BD), CD45BV786 (BD), Siglec-8APC (Biolegend), CD11cAF700 (BD) and CD3APC/Cy7 (BD). 
For both mice and non-human primates, dead cells were disregarded in the analysis by excluding cells 
stained with LIVE/DEAD aqua fixable stain and the percentage GFP+ cells within each cell population was 
determined using a FACS LSR II (BD Biosciences).
Tissue preparation for immunohistochemistry
To determine the tropism of rMVA-GFP in the upper respiratory tract, complete mouse heads were fixed 
in 10% formalin. Heads were subsequently decalcified for eight days using a 10% EDTA buffer, split in 
two halves, and decalcification was continued for another two days, followed by embedding in paraffin. 
To determine cellular tropism in the upper respiratory tract from ferrets and non-human primates, nasal 
tissue from ferrets was harvested and formalin fixed, and the nasal septa and concha from non-human 
primates were harvested and fixed. Tissues were decalcified before embedding into paraffin if required. 
Furthermore, in addition to analysis of the nasal cavities and lungs, the trachea and primary bronchi 
from all animals were collected in 10% formalin. To determine the tropism of rMVA-GFP in the muscles, 
hind and front leg muscles were harvested in PBS. If possible, the exact site of the rMVA-GFP injection 
was harvested. Subsequently, slices were cut for direct examination of GFP fluorescence using CLSM. 
Positive slices were formalin-fixed and paraffin-embedded, followed by immunohistochemistry and/or 
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dual immunofluorescence staining. In all animal models, the front leg muscles formed the appropriate 
negative control for the inoculated hind leg muscle tissues.
Direct confocal laser scanning microscopy (CLSM)
Slices obtained from muscle tissues or agarose-inflated lungs were directly analysed for GFP 
fluorescence using CLSM with a LSM700 system fitted on an Axio Observer Z1 inverted microscope 
(Zeiss). Images and videos were generated using Zen software. GFP+ muscle from mice and lungs slices 
from cynomolgus macaques were transferred to 4% (w/v) paraformaldehyde in PBS, permeabilized with 
0.1% (v/v) Triton-X100 for 30min and subsequently counterstained for nuclei with TO-PRO-3 (Invitrogen).
Immunohistochemistry and dual immunofluorescence analysis of formalin-fixed tissues
Sections from formalin-fixed paraffin-embedded tissues were cut (3μm) and deparaffinised. In order 
to detect GFP, antigen retrieval was performed in 10mM citrate buffer. For histological evaluation, 
samples were subsequently incubated overnight with anti-GFP polyclonal rabbit antibody (Invitrogen) at 
4°C, followed by incubation with a secondary goat-anti-rabbit-biotin antibody (DAKO) and streptavidin-
HRP (DAKO). GFP was detected using 3-amino-9-ethylcarbazole (AEC) as substrate. The slides were 
counterstained with haematoxylin313.
On mouse and non-human primate hind leg muscle and lung tissues dual immunofluorescence stainings 
were performed. After antigen retrieval in citrate buffer, tissues were incubated with 10% normal goat 
serum (Bio-Connect) in PBS. Mouse tissues were stained with rabbit anti-GFP (Invitrogen) or rabbit IgG 
isotype (R&D Systems) followed by goat-anti-rabbit Alexa Fluor (AF)488 (Life Technologies). Non-human 
primate tissues were stained with rabbit anti-GFP in combination with mouse-derived antibodies: anti-
desmin (Abcam), anti-cytokeratin (DAKO), anti-Mac387 (AbD Serotec), anti-MHC class II (HLA-DP/DQ/
DR, DAKO), anti-CD11c (Novocastra Biosystems Newcastle Ltd) or anti-CD20 (DAKO). As a negative 
control, lung slices were stained with rabbit IgG isotype in combination with either mouse IgG1 or IgG2a 
isotype (R&D Systems). Subsequently, tissues were stained with goat-anti-rabbit AF488 and goat-anti-
mouse AF549 (Invitrogen). All samples were treated with ProLong Gold antifade reagent with DAPI (Life 
Technologies) before analysis using CLSM with a LSM700 system fitted on an Axio Observer Z1 inverted 
microscope (Zeiss). Images were analysed using Zen software.
Data availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information files).
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Supplementary Material
[Online movie]
Figure S1. CLSM 3D render of mouse hind leg muscle. Z-stack of a hind leg muscle slice from a IM 
rMVA-GFP injected mouse was obtained by CLSM. A 3D render of the maximum intensity projection was 
generated using the Zen software. GPF = green. Nucleus = red.
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Figure S2. Gating strategy to define populations for phenotypic analysis of GFP+ cells in the lungs 
of mice. Live cells were gated followed by selection of non-lymphocytes and lymphocytes based on the 
forward / sideward scatter. Subsequently, CD3− CD19− NK1.1
− cells were selected in the non-lymphocyte 
population. MHC class II+ CD11c+ cells were defined as DC and Siglec-8+ CD11c− were classified as 
eosinophils. Siglec-8+ CD11c+ F4-80+ CD11b+ cells were identified as alveolar macrophages (AM). 
Siglec-8- cells were further subdivided into a Ly6-G+ CD11b+ neutrophil population and Ly6-G− CD11b+ F4-
80+ interstitial macrophages (IM). Following selection of lymphocytes in the forward / sideward scatterplot, 
CD3+ CD19− NK1.1− cells were selected and divided into CD4+ and CD8+ T-lymphocytes. Furthermore, 
CD3− CD19− NK1.1+ cells were defined as NK cells and CD3− CD19+ NK1.1− cells were defined as 
B-lymphocytes.
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Figure S3. Gating strategy to detect GFP+ cells in ferret tissues. (A) Example of detection of GFP+ 
cells in unstained single cell suspensions from different ferret tissues. Detection of GFP+ cells in a sample 
containing abundant GFP+ cells (panel 1, BAL left side after IT inoculation), background level GFP+ cells 
(panel 2, ING-LN after IM injection) or no GFP+ cells (panel 3, ING-LN after IT inoculation) is shown. (B-
C) Gating strategy to define GFP+ DC-like, monocyte-like and lymphocyte-like cell populations in ferret 
tissues. As an example, the gating strategy of BAL is shown after IM injection (B, negative control) or IT 
inoculation (C) with rMVA-GFP. First, viable cells were gated followed by selection of single cells. Next, 
all GFP+ cells were selected after which lymphocyte-like, monocyte-like or DC-like cell populations were 
reversely gated in the scatter plot. Gate name and percentage of events are indicated in each gate.
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Figure S4. Droplet size characterization of rMVA-GFP aerosol. rMVA-GFP was nebulized and several 
droplet fractions of increasing size between 0.98 and 14.1μm in diameter were collected using a cascade 
impactor. Cumulative distribution of rMVA-GFP particles across the range of droplet diameters is shown.
[Online movie]
Figure S5. CLSM 3D render of macaque lung. Z-stack was obtained of a lung slice from a macaque that 
received rMVA-GFP via AER inhalation. A 3D render of the maximum intensity projection was generated 
using Zen software. GPF = green. Nucleus = red.
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CHAPTER 2.2
Effects of pre-existing orthopoxvirus-specific immunity on the 
performance of Modified Vaccinia virus Ankara-based 
influenza vaccines
AF Altenburg, SE van Trierum, E de Bruin, D de Meulder, CE van de Sandt, FRM van der Klis, 
RAM Fouchier, MPG Koopmans, GF Rimmelzwaan & RD de Vries
Submitted
The replication-deficient orthopoxvirus Modified Vaccinia virus Ankara (MVA) is 
a promising vaccine vector against various pathogens with an excellent safety 
record. However, pre-existing vector-specific immunity is frequently referred to 
as drawback for the use of MVA-based vaccines. To address if this is an issue, 
mice were vaccinated with MVA-based influenza vaccines in the presence or 
absence of orthopoxvirus-specific immunity. Importantly, protective efficacy 
of an MVA-based influenza vaccine against homologous challenge was not 
impaired in the presence of orthopoxvirus-specific pre-existing immunity. 
However, orthopoxvirus-specific pre-existing immunity reduced the induction 
of antigen-specific antibodies under suboptimal conditions and completely 
prevented induction of antigen-specific T cell responses by rMVA-based 
vaccination. Notably, antibodies induced by vaccinia virus vaccination, both 
in mice and humans, were not capable of neutralizing MVA. Thus, when 
using rMVA-based vaccines it is important to consider the main correlate of 
protection induced by the vaccine, the vaccine dose and the orthopoxvirus 
immune status of vaccine recipients.
Introduction
Recombinant viral vectors are under development as novel vaccine candidates 
that induce immunity to antigens of interest expressed from transgenes. Numerous 
vector-based vaccine candidates have been tested over the last decades, targeting 
a wide range of cancers or infectious diseases209,250,280,314,315. Modified Vaccinia virus 
Ankara (MVA), a member of the Orthopoxvirus genus, is a promising vaccine vector 
derived from the vaccinia virus (VACV) strain chorioallantois vaccinia virus Ankara 
through extensive serial passaging in chicken embryo fibroblasts (CEF). This serial 
passaging resulted in the loss of approximately 15% of the parental genome at so-
called ‘deletion sites’223,225, allowing for easy generation of recombinant (r)MVA by 
insertion of one or multiple genes encoding antigens of interest into the MVA genome. 
Furthermore, MVA has lost the ability to replicate in most mammalian cell types, 
leading to an excellent safety record in humans and even safe administration to 
immunocompromised subjects234,277-279. Since MVA is a live, but replication-deficient, 
vector infects cells and drives endogenous expression of antigens under the control 
of a VACV promotor, resulting in efficient antigen presentation and subsequent 
induction of antigen-specific B and T cell responses209,280,316.
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There is considerable interest in the development of novel influenza vaccines 
that induce broadly protective or ‘universal’ immunity against different subtypes of 
influenza A viruses. Accumulation of mutations in the surface proteins of seasonal 
influenza viruses (antigenic drift) and the occasional zoonotic introduction of novel 
influenza viruses into the human population (antigenic shift) complicate the timely 
production of ‘classical’ influenza vaccines that antigenically match seasonal or 
pandemic viruses132,133,317-319. Furthermore, in case of a pandemic outbreak caused 
by a newly emerging influenza virus, novel technology is required to rapidly produce 
large batches of vaccines. rMVA vaccines expressing one or multiple influenza virus 
antigens could potentially fulfill both of these needs. Currently, rMVA-based vaccines 
expressing various wild-type and modified influenza virus antigens are evaluated in 
animal models and clinical trials and have shown promising results209,250,280.
A potential drawback for the use of orthopoxvirus-based vaccines is that a proportion 
of the adult human population has immunity against the vaccine vector due to 
smallpox vaccination campaigns that were conducted until the mid 1970s and 
ultimately led to the eradication of smallpox320. In general, orthopoxvirus-specific 
immunity induced by smallpox vaccination is long-lived with slowly declining T cell 
responses (half-life of 8-15 years) and antibody responses that are maintained 
up to 75 years after vaccination321. In addition to orthopoxvirus-specific immunity 
induced by the historic use of smallpox vaccines, efficient induction of immunity 
by rMVA-based vaccines often requires repeated administration, which induces 
immunity not only to the antigen of interest but also against the vaccine vector260. 
There is considerable concern for interference of orthopoxvirus-specific pre-existing 
immunity with subsequent rMVA-based vaccinations, resulting in reduced vaccine 
immunogenicity and efficacy.
Previously, pre-existing vaccine vector-specific immunity was shown to interfere with 
VACV-322, fowlpox virus-323 and adenovirus-based vaccines212,213. In contrast to MVA, 
these vector-based vaccines are replication-competent in their respective hosts and 
therefore potentially more sensitive to pre-existing vaccine vector-specific immunity. 
Thus far, evidence for interference of pre-existing orthopoxvirus-specific immunity 
with rMVA vaccination is ambiguous. Some studies in mice and macaques showed 
that pre-existing immunity induced by either VACV or MVA had a negative effect 
on the induction of antigen-specific humoral and/or cellular immune responses by 
rMVA-based vaccines. However, despite the observed negative effects, pre-existing 
orthopoxvirus-specific immunity was not considered to interfere with rMVA-based 
vaccination268,324-326. Furthermore, results obtained in humans are also contradictory: 
orthopoxvirus-specific immunity was boosted by multiple rMVA vaccinations and was 
shown to have a negative effect on the magnitude of the antigen-specific humoral 
and cellular immune response. However, in all cases individuals responded to 
vaccination by either initial induction or boosting of antigen-specific immunity260,327. 
This indicates that rMVA-based vaccines remain immunogenic, even in the presence 
of vector-specific pre-existing immunity. Thus, despite the fact that claims of potential 
interference by pre-existing vector immunity on immunogenicity of rMVA-based 
vaccines are made in the literature, the topic has not been addressed sufficiently.
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In this study, we addressed the effect of pre-existing immunity to MVA, VACV or 
influenza virus on the performance of rMVA-based influenza vaccines by evaluating 
induction of immune responses and the protective capacity from a lethal challenge 
with an influenza virus. Furthermore, (cross-)neutralizing activity of MVA- or VACV-
specific antibodies against rMVA-based vaccines was assessed using mouse and 
human sera. Importantly, the protective capacity of an rMVA vaccine expressing 
a hemagglutinin (HA) gene homologous to the H5N1 challenge virus was not 
hampered by the presence of pre-existing immunity to MVA, VACV or influenza virus. 
However, pre-existing orthopoxvirus-specific immunity interfered with induction of 
antigen-specific antibody responses under specific suboptimal conditions and had a 
detrimental effect on the induction of antigen-specific T cell responses. 
Results
VACV and H1N1pdm09 virus dose-finding
Sub-lethal doses of VACV and pandemic influenza virus (H1N1pdm09) were 
determined in dose-finding experiments in C7BL/6 mice. Inoculation of mice with 
104-107 plaque-forming units (PFU) VACV-Elstree by tail scarification led to weight 
loss, concurrent with the appearance of blisters at the site of inoculation in all mice 
(Fig. S1A-B). Similar levels of VACV-specific antibody responses were detected in 
all groups two weeks after inoculation (Fig. S1C). In addition, VACV- and MVA-
specific CD4+ and CD8+ T cell responses were detected with a trend for stronger T 
cell responses at increasing infectious doses (Fig. S1D-E). A dose of 107 PFU VACV 
was considered the optimal sub-lethal priming dose for subsequent experiments. 
In contrast to VACV, intranasal (IN) inoculation of mice with incrementing doses of 
H1N1pdm09 virus resulted in more severe weight loss (Fig. S2A). Mortality was 
observed in mice inoculated with 105 and 106 50% tissue-culture infectious dose 
(TCID50) of H1N1pdm09 virus (Fig. S2B). Optimal induction of hemagglutination 
inhibition (HI) antibody responses (Fig. S2C) and T cell responses (Fig. S2D) 
without mortality was observed after inoculation with 104 TCID50, which was therefore 
considered the optimal dose for subsequent sub-lethal priming infections.
Induction of pre-existing orthopoxvirus-specific and influenza virus-specific immunity
According to the indicated priming regimens (Table 1, week 0 and/or 4) mice were 
inoculated with the pre-determined optimal doses of wild-type (wt)MVA (vaccine 
vector without transgene) or VACV in order to induce orthopoxvirus-specific 
immunity, or H1N1pdm09 influenza virus to induce influenza virus-specific immunity. 
Four weeks after the last priming inoculation (week 8), induction of orthopoxvirus- 
or influenza virus-specific immunity was assessed by measuring serum antibody 
responses by protein array (PA) and ELISA. Priming with wtMVA or H1N1pdm09 
influenza virus induced homologous antibody responses measured by PA (Fig. 
1A). Serum antibodies from VACV-primed mice did not cross-react with wtMVA in 
PA, thus VACV-specific antibodies could not be detected in this assay. Therefore, 
induction of VACV-specific antibodies by VACV priming was confirmed by ELISA (Fig. 
1B). Conversely, serum antibodies directed to wtMVA did cross-react with VACV. 
Orthopoxvirus- or influenza virus-specific antibody responses were not detected in 
unprimed mice (Fig. 1A-B). 
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In addition to detection of serum antibodies, H1N1pdm09 virus infection was 
confirmed by monitoring body weight of mice for two weeks post-priming (Table 1, 
subgroup d). H1N1pdm09-virus inoculated mice lost body weight up to 7 days post-
inoculation (dpi) but regained their original weight at 11 dpi (Fig. 1C). In summary, 
priming with wtMVA, VACV or H1N1pdm09 was successful and induced the desired 
pre-existing immunity against the respective viruses in C57BL/6 mice. 
Table 1. Experimental design. 
Group Week 0 Prime 1
Week 4
Prime 2
Week 8
Vaccination 1
Week 12
Vaccination 2
Week 16
Challenge
1
a) -
b) wtMVA
c) -
d) -
a) - 
b) wtMVA 
c) VACV  
d) H1N1pdm09
rMVA-NP rMVA-NP X
2
a) -
b) wtMVA
c) -
d) -
a) - 
b) wtMVA 
c) VACV  
d) H1N1pdm09
rMVA-H5 rMVA-H5 X
3
a) -
b) wtMVA
c) -
d) -
a) -
b) wtMVA
c) VACV
d) H1N1pdm09
rMVA-H1 rMVA-H1 H5N1
4
a) -
b) wtMVA
c) -
d) -
a) -
b) wtMVA
c) VACV
d) H1N1pdm09
rMVA-H3 rMVA-H3 H5N1
5
a) -
b) wtMVA
c) -
d) -
a) - 
b) wtMVA 
c) VACV  
d) H1N1pdm09
PBS rMVA-H5 H5N1
6
a) -
b) wtMVA
c) -
d) -
a) -
b) wtMVA
c) VACV
d) H1N1pdm09
rMVA-H5* rMVA-H5 H5N1
7
a) -
b) wtMVA
c) -
d) -
a) - 
b) wtMVA 
c) VACV  
d) H1N1pdm09
rMVA-H1 rMVA-H5 H5N1
C57BL/6 mice (n=6 per subgroup) were unprimed (subgroups a) or primed with 108 PFU wtMVA (two 
primings, subgroups b), 107 PFU VACV (one priming, subgroups c) or 104 TCID50
 H1N1pdm09 (one 
priming, subgroups d). At week 8 and 12, mice were vaccinated with 108 PFU of the indicated rMVA-based 
vaccine expressing influenza virus nucleoprotein (NP) or HA. Groups 1 and 2 were euthanized at week 13 
and 14, respectively, to assess the effect of priming on induction of antigen-specific T cells by vaccination. 
The remainder of the mice was challenged with a lethal dose of 103 TCID50 A/Vietnam/1194/04 (H5N1) 
influenza virus at week 16. * Mice were vaccinated with 107 PFU rMVA-H5.
Pre-existing orthopoxvirus-specific immunity had limited effect on induction of 
antigen-specific antibody responses by rMVA
To determine the effect of pre-existing immunity on rMVA vaccine immunogenicity, 
unprimed and primed mice were subsequently vaccinated with rMVA expressing 
influenza virus nucleoprotein (NP) or HA (Table 1). Serum antibody responses 
against wtMVA and various HA1 subunits (HA from H1N1pdm09, H3N2 isolate 
from 2003 and 2011, and a selection of H5Nx viruses) after one rMVA vaccination 
were determined using PA. As expected, rMVA vaccination consistently boosted 
the MVA-specific antibody response in mice primed with wtMVA or VACV (Fig. 2A). 
Furthermore, boosting of H1N1pdm09-specific antibodies was observed in mice 
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primed with H1N1pdm09 virus and subsequently vaccinated with rMVA-H1 (Fig. 2A, 
group 3 and 7).
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Figure 1. Induction of orthopoxvirus-specific or influenza virus-specific immunity by priming. (A) 
Sera from individual mice obtained 4 weeks after the last priming (week 8) were assessed by PA for 
presence of wtMVA- or H1N1pdm09-specific antibodies. MVA-specific antibodies were detected with a 
wtMVA-infected cell lysate, mock-infected baby hamster kidney (BHK)-21 cell lysate was included as 
negative control. Each horizontal line represents an individual animal. Antigens (x-axis) and priming 
groups (y-axis) are indicated. Scale shows 2-log transformed titers. (B) VACV-specific serum antibody 
responses were determined by ELISA using VACV-infected HeLa cell lysate. The background signal 
on mock-infected cell lysate was subtracted. Individual sera from VACV-primed mice were used where 
possible. Serum from unprimed, wtMVA-primed or H1N1pdm09-primed mice was pooled due to 
limited serum availability. Mean per priming group is indicated. Statistically significant differences were 
determined using a one-way ANOVA with multiple comparisons. **** p<0.0001. (C) Mean body weight 
per group (n=6, group 7 n=5) after IN inoculation with 104 TCID50 H1N1pdm09. No statistically significant 
differences between the groups were detected with a repeated measures ANOVA model.
Serum antibody responses against the corresponding antigen – H1pdm09 and H3 
(2003) – induced by one rMVA-H1 or rMVA-H3 vaccination, respectively, were not 
hampered by either orthopoxvirus- or influenza virus-specific pre-existing immunity 
(Fig. 2A). Antibodies against the heterologous H3 (2011) were not detected after a 
single vaccination with rMVA-H3. In contrast, heterologous antibody responses were 
detected after a single vaccination with rMVA-H5. Lower antibody titers specific for 
HA1 of all H5 clades tested, including the homologous A/Vietnam/1194/04 (H5N1, 
clade 1), were detected in wtMVA-primed mice, compared to unprimed, VACV- or 
H1N1pdm09-virus primed mice. This effect was especially observed when a low, 
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suboptimal dose of rMVA-H5 (107 PFU, Table 1, group 6 at week 12) was used for 
the initial vaccination and to a lesser extent with the use of a higher vaccine dose (108 
PFU, Table 1, group 5 at week 16) (Fig. 2A-B). These results were confirmed with 
an HI assay, which is a good proxy for influenza virus neutralization. MVA-specific 
pre-existing immunity negatively affected the HI antibody response to influenza virus 
A/Vietnam/1194/04 induced after a single rMVA-H5 vaccination, particularly when a 
low dose was used (Fig. 2C).
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Figure 2. Effect of pre-existing immunity on induction of serum antibody responses by a single 
rMVA vaccination. (A-B) Serum antibody responses against wtMVA and HA1 from H1N1pdm09, 2003 
H3N2, 2011 H3N2 or H5 influenza viruses from the indicated clades were determined using PA 4 weeks 
after the first vaccination (group 3, 4, 6 & 7 week 12, group 5 week 16). Mock-infected BHK-21 cell lysates 
were used as negative control for the wtMVA-infected cell lysates. Each horizontal line represents an 
individual animal. Antigens (x-axis), vaccine groups and priming subgroups (y-axis) have been indicated. 
Scale represents 2-log titers as determined by PA. (B) PA titers against H5 from A/Vietnam/1194/04 (clade 
1) four weeks after rMVA-H5 vaccination with a high dose (108 PFU, group 5, week 16) or a low dose (107 
PFU, group 6, week 12). Mean per priming group is indicated. Statistically significant differences were 
determined using a one-way ANOVA with multiple comparisons. * p=0.0257, ** p<0.0017. (C) HI titers 
against influenza virus A/Vietnam/1194/04 were determined for each individual animal four weeks after 
rMVA-H5 vaccination with a high dose (108 PFU, group 5, week 16) or a low dose (107 PFU, group 6, 
week 12). Mean is indicated. Statistically significant differences were determined using a Kruskal-Wallis 
test. * p=0.0401.
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Figure 3. Effect of pre-existing immunity on induction of serum antibody responses after two rMVA 
vaccinations. (A-B) Serum antibody responses against wtMVA and HA1 from H1N1pdm09, 2003 H3N2, 
2011 H3N2 or H5 influenza viruses from the indicated clades were determined using protein array 4 weeks 
after the second vaccination (week 16). Each horizontal line represents an individual animal. Antigens 
(x-axis), vaccine groups and priming subgroups (y-axis) have been indicated. Scale represents the 2-log 
as determined by protein array. (B) Protein array titers for each individual animal against an antigenically 
similar H3 from 2003 or distinct H3 from 2011 four weeks after the second rMVA-H3 vaccination (group 
4). Mean per priming group is indicated. Statistically significant differences were determined using a one-
way ANOVA with multiple comparisons. ** p<0.0086, *** p=0.0003. (C) HI titers against influenza virus A/
Vietnam/1194/04 were determined for each individual animal four weeks after the second vaccination with 
rMVA. Mean per priming group is indicated.
A second vaccination with rMVA (Table 1, week 16) boosted serum antibody 
responses to MVA and influenza viruses. Similar to antibody responses induced by a 
single vaccination, antibody responses against the corresponding antigen after two 
vaccinations with rMVA-H1 or rMVA-H3 were not affected by pre-existing immunity 
(Fig. 3A-B, group 3-4). The second vaccination with rMVA-H3 also induced cross-
reactive antibody responses against an antigenically distinct H3 (2011), that were 
hardly observed after the initial vaccination. Notably, this cross-reactive response 
was detected in all subgroups, but was lower in mice with MVA-specific pre-existing 
immunity (Fig. 3A-B). Furthermore, in contrast to the antibody response after a 
single rMVA-H5 vaccination, the responses after two rMVA-H5 vaccinations (Table 
1, group 6) or an rMVA-H1 vaccination followed by an rMVA-H5 vaccination (Table 
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1, group 7) detected by PA or HI were not affected by pre-existing immunity to the 
vector (Fig. 3A, C). In conclusion, an effect of pre-existing MVA-specific, but not 
VACV- or influenza virus-specific, immunity on induction of humoral responses by 
rMVA vaccination was observed under specific conditions.
Induction of antigen-specific T cell responses by rMVA is prevented by pre-existing 
orthopoxvirus-specific immunity
To determine the effect of pre-existing immunity on rMVA-induced antigen-specific T 
cell responses, splenocytes were obtained from unprimed and primed mice one or 
two weeks after the second rMVA-NP or rMVA-H5 vaccination, respectively (Table 
1, group 1-2). Antigen-specific CD8+ T cell responses were determined by measuring 
the number of interferon (IFN)-ɣ producing splenocytes after stimulation with synthetic 
peptide NP366-374, an immunodominant CD8
+ T cell epitope. Furthermore, H5-specific 
CD4+ T cell responses were determined after stimulation with full-length HA protein 
from H5N1 influenza viruses A/Vietnam/1194/04 (clade 1) or A/Indonesia/5/05 (clade 
2.1).
rMVA-NP vaccination efficiently induced antigen-specific CD8+ T cell responses in 
unprimed and H1N1pdm09-primed mice, but failed to induce NP-specific CD8+ T 
cells in mice with orthopoxvirus-specific pre-existing immunity, induced by either 
wtMVA or VACV priming (Fig. 4A). Similar observations were made in animals 
efficiently vaccinated with rMVA-H5: unprimed and H1N1pdm09 primed animals 
developed HA-specific CD4+ T cell responses against both the homologous (A/
Vietnam/1194/04) and heterologous HA (A/Indonesia/5/05), but pre-existing 
orthopoxvirus-specific immunity had a detrimental effect on the induction of H5-
specific CD4+ T cell responses (Fig. 4B).
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Figure 4. Pre-existing orthopoxvirus-specific immunity inhibits rMVA-induced antigen-specific 
T cell responses. (A) Splenocytes collected one week after the second rMVA-NP vaccination were 
unstimulated or stimulated with NP366-374 synthetic peptide. The number of IFN-ɣ producing CD3
+ CD8+ 
splenocytes was measured. (B) Splenocytes collected two weeks after the second rMVA-H5 vaccination 
were unstimulated or stimulated with purified HA protein from H5N1 influenza virus A/Vietnam/1194/04 or 
A/Indonesia/5/05. The number of IFN-ɣ producing CD3+ CD4+ splenocytes was measured. Mean of each 
priming group is indicated. Statically significant differences per simulant were determined using a Kruskal-
Wallis test. * p<0.0478, ** p<0.0076.
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Pre-existing orthopoxvirus-specific immunity impaired the protective efficacy of 
rMVA-based vaccines against a heterologous but not homologous virus challenge
Four weeks after the final vaccination, rMVA-H1, rMVA-H3 and rMVA-H5 vaccinated 
mice were challenged with a lethal dose of influenza virus H5N1 (A/Vietnam/1194/04) 
in order to determine the effect of pre-existing immunity on the protective capacity 
of rMVA-based influenza vaccines (Table 1, group 3-7). As expected, rMVA-H1 and 
rMVA-H3 vaccination did not fully protect against an H5N1 influenza virus challenge, 
which was reflected by loss of body weight, lower survival rates and high viral 
loads in the lungs (Fig. 5, Table 2). However, a limited level of cross-protection 
was observed after rMVA-H1 or rMVA-H3 vaccination in unprimed and H1N1pdm09-
primed animals, which was not observed in mice primed with VACV or wtMVA (Fig. 
5, Table 2). Notably, pre-existing orthopoxvirus-specific or influenza virus-specific 
immunity did not interfere with the protective capacity of rMVA vaccines expressing 
the homologous HA gene of the H5N1 challenge virus since all mice that received 
at least one rMVA-H5 vaccination were fully protected from lethal H5N1 challenge 
(Fig. 5, Fig. S3, Table 2).
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Figure 5. Pre-existing immunity does not impair protective capacity of rMVA-H5 vaccination. Four 
weeks after the last rMVA vaccination (week 16), mice were challenged with a lethal dose H5N1 influenza 
virus. (A) Body weight over time for each of the priming groups for group 3 (two rMVA-H1 vaccinations), 
group 4 (two rMVA-H3 vaccinations) and group 6 (two rMVA-H5 vaccinations). Mean and standard 
deviation (SD) per priming group are shown. (B) Viral load in the lungs shown as TCID50 per gram lung 
for each individual animal for group 3, group 4 and group 6. Mean of each priming group is shown. 
Statistically significant differences were determined using a Kruskal-Wallis test. * p=0.0152, ** p<0.0065.
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Table 2. Survival after lethal H5N1 influenza virus challenge. 
Prime: Unprimed wtMVA VACV H1N1pdm09
Survival 
(#)
Survival 
(%)
Survival 
(#)
Survival 
(%)
Survival 
(#)
Survival 
(%)
Survival 
(#)
Survival 
(%)
2x rMVA-H1
(group 3) 3/6 50% 0/6 0% 2/6 33% 4/6 66,7%
2x rMVA-H3
(group 4) 5/6 83,3% 3/5 50% 1/6 16,7% 6/6 100%
1x rMVA-H5
(group 5) 6/6 100% 6/6 100% 6/6 100% 6/6 100%
2x rMVA-H5
(group 6) 6/6 100% 5/5 100% 6/6 100% 6/6 100%
1x rMVA-pH1
1x rMVA-H5
(group 7)
6/6 100% 6/6 100% 6/6 100% 5/5 100%
Four weeks after the final vaccination (week 16), mice were challenged with a lethal dose H5N1 influenza 
virus. The absolute number (#; live mice/total mice) and the percentage (%) of live animals at seven days 
post-challenge have been indicated. Mice were euthanized at >25% body weight loss.
Pre-existing MVA-specific, but not VACV-specific, antibodies have MVA-neutralizing 
capacities
In order to gain insight into the possible mechanism underlying the observed effects of 
pre-existing orthopoxvirus-specific immunity on rMVA-based vaccine immunogenicity, 
(cross-)reactivity of the orthopoxvirus-specific antibodies was analyzed. A single 
exposure to either MVA or VACV did not induce any detectable MVA-specific serum 
antibody responses in mice. In contrast, in mice that were exposed at least twice 
to MVA or once to VACV followed by at least one rMVA vaccination, MVA-specific 
antibodies were detected. Notably, the MVA-specific antibody response was not 
boosted in response to extra exposures after the third MVA exposure (Fig. 6A). The 
antibody responses induced by MVA efficiently cross-reacted with VACV (Fig. 6B). 
Furthermore, although VACV priming did not induce detectable antibody responses 
cross-reactive with MVA, homologous VACV-specific antibodies were detected (Fig. 
6B). A booster effect of rMVA-based vaccination after VACV priming was observed 
in both MVA- and VACV-specific antibody responses (Fig. 6A-B). Of special 
interest, sera from mice exposed to MVA, but not mice exclusively exposed to VACV, 
orthopoxvirus-specific antibody responses showed the capacity to neutralize MVA in 
vitro (Fig. 6C), thereby potentially affecting subsequent rMVA vaccinations.
Human pre-existing MVA-specific, but not VACV-specific, antibodies have MVA-
neutralizing capacities
Next, the presence and neutralizing capacity of serum obtained from humans 
vaccinated with either VACV or rMVA was assessed. Pre- and post-vaccination 
sera from a phase 1/2a clinical trial with rMVA-H5 were obtained260. MVA-specific 
antibody responses were detected four weeks after the third vaccination in 
individuals that were vaccinated with 108 PFU rMVA-H5 (Fig. 7A). Furthermore, sera 
from VACV-vaccinated individuals (born between 1970-1971) and unvaccinated 
controls (born between 1976-1978) were probed for the presence of VACV- and 
MVA-specific antibodies328. Almost four decades after vaccination, VACV-specific 
antibodies were still detected in VACV-vaccinated individuals, but not in the controls 
that were born 2-4 years after the smallpox vaccination campaign was terminated
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Figure 6. MVA-specific antibodies showed neutralizing capacity. MVA and VACV-specific antibody 
responses were determined in sera obtained four weeks post-priming (week 8) or post-vaccination (week 
12&16). (A) MVA-specific serum antibody responses were determined using wtMVA-infected BHK-21 
cell lysates on PA. The mean and SD are indicated. Statistical differences were determined relative to 
the ‘0x MVA’ sample using a Kruskal-Wallis test. **** p<0.0001. (B) Serum antibody responses against 
VACV were measured by ELISA using VACV-infected HeLa cell lysate. The background signal on mock-
infected HeLa cell lysates was subtracted. Due to limited serum availability serum was pooled (n=3-6) per 
subgroup. The mean of n=2-17 pools is shown, except for ‘3x MVA’ which shows data from a single pool. 
(C) Serum antibody responses in group 5 (one vaccination with rMVA-H5) and group 6 (two vaccinations 
with rMVA-H5) were examined for wtMVA neutralizing capacity by a plaque reduction assay on CEF. Due 
to limited serum availability serum was pooled (n=2-5) per subgroup. The mean of n=2 pools is shown, 
except for ‘3x MVA’ and ‘1x VACV, 0x MVA’ which show data from a single pool.
(Fig. 7B). Notably, these VACV-specific antibodies displayed limited cross-reactivity 
with MVA (Fig. 7A) and were not capable of neutralizing an MVA infection in vitro (Fig. 
7C). In contrast, MVA-specific antibodies did reduce plaque formation by MVA (Fig. 
7C). Taken together, in both mice and humans, pre-existing MVA-specific antibodies 
induced by MVA, but not by VACV, had MVA-neutralizing capacities in vitro.
Discussion
Although it has been frequently suggested that pre-existing immunity to 
orthopoxviruses can interfere with the immunogenicity and efficacy of rMVA-based 
vaccines, the issue has not been addressed sufficiently. In this study, we investigated 
the performance of rMVA-based influenza vaccines in the presence or absence of 
pre-existing immunity to orthopoxviruses or influenza virus in mice and evaluated 
human orthopoxvirus-specific immune responses after MVA or VACV vaccination. 
Induction of MVA- or VACV-specific antibodies upon priming mice with wtMVA or 
VACV was confirmed by PA and ELISA using wtMVA- or VACV-infected cell-lysates 
as antigens. Interestingly, VACV-specific antibodies did not cross-react with MVA, 
whereas MVA-specific antibodies clearly cross-reacted with VACV. These results are 
in accordance with a previous study329 and similar results were obtained with human 
sera, where VACV-specific antibody responses cross-reacted with MVA only to a 
limited extent. In our study, the differential response can be explained by the fact that 
mice MVA-primed mice received a booster immunization inducing a MVA-specific 
recall response opposed to induction of a primary responses in VACV-primed mice. 
Indeed, a single vaccination with rMVA expressing H1, H3 or H5 in unprimed mice did 
not induce detectable levels of MVA-specific antibodies, whereas rMVA vaccination
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Figure 7. Human rMVA-based, but not VACV, induced MVA-specific neutralizing antibody 
responses. (A-B) Serum antibody responses against MVA (A) and VACV (B) were measured by ELISA 
using infected BHK-21 or HeLa cell lysates, respectively. The background of the respective mock-
infected cell lysate was subtracted. (C) Neutralizing capacity of orthopoxvirus-specific antibodies was 
determined by a plaque reduction assay on CEF using rMVA-GFP. The data shown are representative 
of three independent experiments. The mean per group is indicated. Statistical significant differences 
were determined using a Wilcoxon matched-pairs signed rank test (rMVA vaccination samples) or Mann-
Whitney test (VACV vaccination samples). * p<0.0312. ** p=0.0022.
of VACV-primed mice led to a boosting of MVA-specific antibodies. This corresponds 
to data obtained in humans, which show that MVA-specific antibodies were boosted 
upon MVA vaccination of either smallpox or rMVA vaccinated individuals260,329. 
Pre-existing orthopoxvirus-specific immunity in mice affected humoral immune 
responses induced by rMVA influenza vaccines to a limited extent. Effects were 
exclusively observed in wtMVA-primed mice and only under ‘suboptimal’ conditions. 
First, when a low rMVA-H5 vaccine dose was used, wtMVA-primed mice showed 
lower antibody titers to all tested H5 clades compared to the other priming groups. 
The reduced H5-specific antibody response observed in mice with MVA-specific 
pre-existing immunity was overcome by a second immunization with 108 PFU of 
rMVA-H5, as was previously reported268. Second, in wtMVA-primed mice the response 
to antigenically distinct H3N2 viruses was significantly lower after two rMVA-H3 
vaccinations than that of unprimed animals. However, pre-existing immunity had 
no effect on the magnitude of the antibody response to a corresponding H3 antigen 
induced by one or two rMVA-H3 vaccinations. Importantly, VACV-specific pre-existing 
immunity never had a negative effect on the induction of antigen-specific antibody 
responses induced by rMVA.
In addition to antibody responses, the induction of antigen-specific T cell responses 
after rMVA vaccination in the absence or presence of pre-existing immunity was 
assessed. Virus-specific T cells contribute significantly to protective immunity against 
virus infections and can reduce duration and severity of disease330-332. Induction of 
T cells to influenza virus by vaccines is particularly attractive, since these mainly 
recognize epitopes in conserved internal proteins and can therefore afford cross-
protection against various influenza viruses of different subtypes (heterosubtypic 
immunity)82,108,194,196. Our results indicated that induction of influenza virus-specific T 
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cell responses was severely hampered by presence of MVA- or VACV-specific pre-
existing immunity in mice. These findings are in concordance with previous studies 
that examined the immunogenicity of rMVA expressing human immunodeficiency 
virus (HIV) antigens in both mice333 and macaques326,334 in the presence of pre-
existing vector-specific immunity. In contrast, a recent clinical trial reported efficient 
induction of cytomegalovirus (CMV)-specific T cell responses with rMVA in VACV-
vaccinated individuals. The authors claimed that pre-existing VACV-specific 
immunity did not affect immunogenicity of rMVA, however, only a limited number 
of study subjects with pre-existing immunity was studied and their orthopoxvirus 
immune status was solely defined by date of birth335. Furthermore, rMVA expressing 
NP and matrix 1 (M1) genes from influenza virus has been shown to induce T cell 
responses in humans269,272, even in the elderly that potentially have orthopoxvirus-
specific immunity271. Although this suggests that T cell responses can be induced in 
humans with VACV-specific immunity, the immune status of study subjects was not 
verified in these studies and appropriate control groups were lacking.
To assess effects of pre-existing immunity on rMVA protective efficacy, mice 
vaccinated with rMVA-H5 in the presence or absence of pre-existing immunity 
were challenged with a lethal dose of H5N1 influenza virus. As expected, pre-
existing orthopoxvirus- or influenza virus-specific immunity did not affect protection 
and survival from the homologous challenge infection. Protection was most likely 
mediated by antigen-specific neutralizing antibodies, which have been shown to be 
the main correlate of protection induced by the rMVA-H5 vaccine256,258-260,262, and were 
unaffected by the presence of pre-existing immunity at week 16. In contrast, mice 
that were vaccinated with either rMVA-H1 or rMVA-H3 were only partially protected 
from lethal H5N1 influenza virus challenge. A limited level of protection against 
H5N1 influenza virus infection was observed in unprimed or H1N1pdm09-primed 
mice, most likely mediated by cross-reactive antibody or T cell responses against 
influenza virus induced by priming and/or vaccination. Notably, mice with pre-existing 
orthopoxvirus-specific immunity had higher viral loads in the lungs and more severe 
weight loss compared to unprimed or H1N1pdm09 primed mice. In accordance with 
the described immunogenicity results, we hypothesize that orthopoxvirus-specific 
pre-existing immunity prevented the induction of antibody and/or T cell responses by 
rMVA-H1 or rMVA-H3 vaccination that are cross-reactive with H5.
It has been shown previously that VACV or MVA-based vaccination efficiently 
induces both orthopoxvirus-specific antibodies and T cell responses260,321,327,336-339 
(reviewed by B. Moss340). Hypothetically, vector-specific antibodies induced by 
previous immunizations could capture and neutralize rMVA virus particles upon (re-)
vaccination, but non-neutralizing antibodies or orthopoxvirus-specific T cells could 
also play a role in interference. Interestingly, VACV-induced immunity only interfered 
with induction of antigen-specific T cell responses but not antibody responses whereas 
MVA-induced immunity could interfere with both. VACV was shown to induce cross-
reactive MVA-specific T cells, but not antibody responses. Therefore, it is likely that 
interference of MVA-induced pre-existing immunity with induction of antigen-specific 
antibody responses is mediated by vector-specific antibodies. Indeed, antibodies 
induced by exposure of mice to MVA, but not to VACV, showed MVA-neutralizing 
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capacity in vitro. Similar results were obtained in humans, where VACV-induced 
antibodies hardly cross-reacted with MVA and only MVA-induced antibodies had 
MVA-neutralizing capacity. Follow-up adoptive transfers studies should be performed 
to identify the exact mechanism of interference of orthopoxvirus-specific immune 
responses with performance of MVA-based vaccinations.
It is important to note that our study in mice reflects a ‘worst-case scenario’, since a 
time interval of only four weeks between induction of pre-existing immunity and initial 
vaccination with rMVA was maintained, not allowing for waning of orthopoxvirus-
specific immunity. This does not accurately reflect the human situation, where 
smallpox vaccination was discontinued in the mid 1970s320. Even though VACV-
specific antibody responses were still detected in the serum of vaccinated individuals, 
these antibodies did not have MVA-neutralizing capacity in vitro. However, the 
timing used in this study does reflect the ‘standard’ interval of rMVA vaccination 
regimens, in which four week intervals are frequently observed between sequential 
vaccinations234,260,335. Our results show that repeated rMVA vaccination of humans 
does induce MVA-specific antibodies, which have neutralizing capacities in vitro and 
therefore may interfere with the immunogenicity of subsequent vaccinations.
The present study fills a gap in our understanding regarding immunogenicity of MVA-
based vaccines in the presence of orthopoxvirus-specific immunity. Importantly, pre-
existing immunity induced by VACV inoculation did not interfere with the induction 
of antigen-specific antibodies by rMVA vaccination. In sera obtained from both 
mice and humans, VACV-induced antibody responses could not neutralize MVA. In 
contrast, wtMVA-priming reduced the antigen-specific antibody response induced 
by vaccination with a low dose of rMVA-H5 in mice, an effect that was prevented 
or overcome when higher vaccine doses were used. Furthermore, the induction of 
antigen-specific CD4+ and CD8+ T cell responses was severely hampered by the 
presence of either MVA- or VACV-specific pre-existing immunity. Importantly, the 
presence of orthopoxvirus-specific immunity induced by VACV or MVA did not affect 
the protective efficacy of an rMVA-H5 vaccine against a lethal homologous challenge 
infection with H5N1 influenza virus. Although the responses to homologous influenza 
virus HA were not affected by pre-existing orthopoxvirus specific immunity, cross-
reactivity with antigenic variants was reduced as shown by vaccination with rMVA-H1 
and rMVA-H3. In conclusion, the present study shows that rMVA is still immunogenic 
in the presence of orthopoxvirus-specific immunity, however, it is essential to 
consider the orthopoxvirus immune status of vaccine recipients, the interval between 
vaccinations in case of repeated rMVA-based vaccination, the vaccine dose used 
and the main correlate of protection induced by rMVA-based vaccines.
Materials & Methods
Experimental design
To assess the effect of pre-existing orthopoxvirus-specific or influenza virus-specific immunity on rMVA 
vaccine immunogenicity, C57BL/6 mice were primed with either wtMVA, VACV or H1N1pdm09, and then 
vaccinated with rMVA expressing the influenza virus NP or HA gene. The effect of pre-existing immunity 
induced by priming on vaccine induced antigen-specific antibody and T cell responses was assessed, 
as well as the effect on the protective efficacy against a lethal H5N1 influenza virus challenge (Table 1). 
Furthermore, antibody responses against MVA and VACV were analyzed in sera from MVA- and VACV-
exposed mice and humans, in order to establish the presence of MVA-specific neutralizing antibodies.
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Ethics statement
Animal experiments were conducted in strict compliance with European guidelines (EU directive on animal 
testing 2010/63/EU). The animal protocol was approved by an independent animal experimentation 
ethical review committee (Erasmus MC permit number EUR3277-02). Animal welfare was observed on 
a daily basis, and all invasive animal handling was performed under anesthesia using 4% isoflurane in 
oxygen to minimize animal suffering. Human sera pre- and post-rMVA vaccination (three vaccinations at 
week 0 and 56 with 108 PFU rMVA-H5, n=6) were obtained during a randomized, double-blind phase 1/2a 
study at the Erasmus MC, Rotterdam, the Netherlands. The study involved adult volunteers (male/female, 
between ages 18-28) who provided informed consent. The study design was reviewed and approved by 
the Central Committee on Research involving Human Subjects in the Netherlands260. Furthermore, serum 
samples from VACV vaccinated (n=6) and unvaccinated (n=6) healthy individuals (male/female) were 
collected during a cross-sectional population-based study performed in the Netherlands from February 
2006 until June 2007 (PIENTER2 study)328. Smallpox vaccination campaigns lasted until September 
1974 in the Netherlands. To limit the inevitable age bias, sera from individuals born between 1970-1971 
and 1976-1978 were selected for the VACV vaccinated and unvaccinated group, respectively. The work 
described here has been carried out in accordance with the code of ethics of the world medical association 
(declaration of Helsinki).
Cell lines
Madin-Darby Canine Kidney (MDCK) cells were cultured in Eagle’s Minimum Essential Medium (EMEM, 
Sartorius Stedim BioWhittaker) supplemented with 10% fetal bovine serum (FBS, Greiner Bio-One), 20mM 
HEPES (Lonza BioWhittaker), 0.1% CHNaO3 (Lonza BioWhittaker), and 100μg/ml penicillin, 100U/ml 
streptomycin and 2mM L-Glutamine (P/S/G, Lonza). CEF were isolated from 11-day-old chicken embryos 
(Drost Loosdrecht BV) and passaged once before use as described previously256. CEF were cultured 
in Virus Production-Serum Free Medium (VP-SFM, Gibco) containing P/S. HeLa cells were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM, Lonza) supplemented with 10% FBS, 20mM HEPES, 0.1% 
CHNaO3 and P/S/G. Baby Hamster Kidney (BHK)-21 cells were cultured in DMEM supplemented with 
10% FBS, 20mM HEPES, 0.1% CHNaO3, 0.1mM non-essential amino acids (NEAA, Lonza) and P/S/G. 
HeLa cells were cultured in DMEM supplemented with 10% FBS, 20mM HEPES and 0.1% CHNaO3 and 
P/S/G. All cells were cultured at 37°C in a humidified atmosphere with 5% CO2.
Viruses
rMVA expressing the NP gene of influenza virus A/Puerto Rico/8/34 (PR8, rMVA-NP), the HA gene of A/
Vietnam/1194/04 (rMVA-H5) or A/Netherlands/213/03 (rMVA-H3) under the control of the psynII promotor, 
rMVA expressing the HA gene of influenza virus A/California/4/09 (rMVA-H1) under control of the PH5 
promotor and rMVA expressing GFP under control of the P11 promotor were prepared as described 
previously253,256,341,342. To generate final vaccine preparations of MVA-F6 (empty vector, wtMVA) or rMVA, 
the viruses were propagated in CEF, purified by ultracentrifugation through 36% sucrose and resuspended 
in 120mM NaCl 10mM Tris-HCl pH 7.4. rMVA constructs were validated by PCR analysis, sequencing 
and/or plaque titration. Furthermore, expression of antigens was validated by western blot and/or flow 
cytometry. The VACV strain Elstree was grown in HeLa cells as described above for the rMVA constructs 
on CEF cells. Influenza A viruses A/Netherlands/602/09 (H1N1pdm09) and A/Vietnam/1194/04 (H5N1) 
were propagated and titrated (TCID50) in MDCK cells as described previously
343. 
Mice
Specified pathogen free (SPF) female C57BL/6 mice 6-8 weeks of age were purchased from Charles 
River. The animals were housed at biosafety level (BSL-)2 in individual ventilated cage (IVC) units during 
priming and vaccination (week 0-15). During the H5N1 influenza virus challenge, mice were housed in 
filter-top cages in negatively pressured BSL-3 isolators (week 16-17). At all times, mice had access to 
food and water ad libitum. 
H1N1pdm09 virus and VACV-Elstree dose-finding
Four groups of mice (10-12 weeks old, n=6) were inoculated with 104, 105, 106 or 107 PFU VACV-Elstree 
in 10μl PBS by intradermal (ID) tail scarification with a 25-29G needle344 or with 103, 104, 105 or 106 TCID50 
H1N1pdm09 in 50μl PBS by the IN route. Clinical signs, weight loss and survival were recorded for 14 
days, mice were euthanized 14 dpi or earlier when pre-defined humane endpoint criteria were met (>25% 
body weight loss).
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Priming, rMVA vaccination and challenge
Mice (6-8 weeks old) were divided into seven groups (n=24) with four subgroups (n=6) each (Table 
1). Animals were either unprimed (subgroup a) or were primed with 108 PFU wtMVA in 100μl PBS 
intramuscularly (IM, two shots, four-week interval [week 0 and 4], subgroup b), 107 PFU VACV-Elstree 
(single exposure, week 4, subgroup c) or 104 TCID50 H1N1pdm09 (single exposure, week 4, subgroup 
d). VACV-Elstree and H1N1pdm09 were administered as described above at the optimal priming dose 
determined in the dose-finding experiments. After priming, mice received one or two IM vaccinations at 
week 8 and/or 12 with 108 PFU of rMVA-NP, rMVA-H1, rMVA-H3 and/or rMVA-H5 in 100μl PBS. Of note, 
107 PFU rMVA-H5 was administered at week 8 to the mice of group 6 (Table 1) to establish if pre-existing 
immunity affects low dose rMVA-HA vaccination and if a boost with a high dose could overcome potential 
negative effects. After vaccination, a proportion of the mice vaccinated with rMVA-NP or rMVA-H5 were 
not challenged and were euthanized one (week 13) or two weeks (week 14) after the second vaccination, 
respectively (Table 1, group 1-2). The remainder of the animals (Table 1, group 3-7) was challenged 
IN with 103 TCID50 A/Vietnam/1194/04 (H5N1) influenza virus four weeks after the second vaccination 
(week 16) and monitored twice daily. Mice were euthanized when pre-defined humane endpoint criteria 
(>25% body weight loss) were reached or at seven days post-challenge (week 17). Blood, spleen and/or 
lung samples were harvested during necropsy. A single mouse in the wtMVA-primed subgroup of the 2x 
rMVA-H5 challenge group (group 6, subgroup b) had to be euthanized due to a wound unrelated to the 
experiment at week 4. One mouse in the H1N1pmd09-prime group of the 1x rMVA-H1 and 1x rMVA-H5 
group (group 7, subgroup d) had to be euthanized 10 days after priming because humane endpoint 
criteria were met. These mice were excluded from further analysis.
Virus isolation from lungs
Directly after necropsy, all lungs were snap frozen and stored at -80oC for processing at a later time point. 
To perform virus isolations, lungs were thawed, lung weight was recorded and lungs were homogenized 
with a Polytron homogenizer (Kinematica AG) in MDCK infection medium (EMEM supplemented with 
20mM HEPES, 0.1% CHNaO3 and P/S/G). Quadruplicate ten-fold serial dilutions of these samples in 
MDCK infection medium supplemented with 0.002% TPCK-Trypsin (Lonza) were used to determine the 
virus titers on MDCK cells as described previously343.
Stimulation and intracellular cytokine staining of splenocytes 
During necropsy spleens were collected in Iscove’s Dulbecco’s Medium (IMDM, Lonza) supplemented 
with 5% FBS and P/S/G for direct preparation of single cell suspensions using 100µm strainers (Falcon). 
Erythrocytes were removed from single cell suspensions by treatment with red blood cell lysis buffer 
(Roche diagnostics). For intracellular cytokine staining, splenocytes were stimulated with 5µM synthetic 
peptide (epitope NP366-374: ASNENVEIM [Fig. S2] or ASNEMMETM [Fig. 4]) or 1µg / 250.000 cells 
recombinant HA protein from H5N1 influenza virus A/Vietnam/1203/04 or A/Indonesia/5/05 (Protein 
Sciences) in IMDM supplemented with GolgiStop and incubated for 6h at 37oC. Mock-treated splenocytes 
and splenocytes stimulated with 50ng/ml PMA (Sigma-Aldrich) and 0.5µg/ml ionomycin (Sigma-Aldrich) 
served as appropriate negative and positive controls. After stimulation, splenocytes were incubated with 
fluorochrome-labeled antibodies to CD3eAPC-Cy7 (BD Pharmingen), CD8bFITC (BD Pharmingen), CD4PerCP 
(BD Pharmingen) and viable cells were identified with Aqua LIVE/DEAD (Invitrogen). Subsequently, cells 
were fixed and permeabilized using BD Cytofix/CytopermTM Plus (BD Biosciences), and incubated with 
anti-IFN-ɣPacificBlue (Biolegend). Samples were acquired on a FACS Canto II and data was analyzed as 
described previously341,345 using FACS Diva software (BD Biosciences).
Protein Array (PA) assay
Mouse sera collected at week 8 and 16 (Table 1) were used to determine the presence of antibodies 
to selected antigens by PA as described previously346,347. In short, recombinant HA1 derived from 
influenza viruses A/California/6/09 (pH1), A/Wyoming/3/03 (H3 2003), A/Victoria/361/11 (H3 2011), A/
Hong Kong/156/97 (H5 clade 0), A/Vietnam/1194/04 (H5 clade 1), A/Cambodia/R045050/07 (H5 clade 
1.1), A/Indonesia/5/05 (H5 clade 2.1), A/Turkey/15/06 (H5 clade 2.2), A/Turkey/Germany-MV/R2472/14 
(H5 clade 2.3.4.4), A/goose/Guiyang/337/06 (H5 clade 4) and A/chicken/Vietnam/NCVD-016/08 (H5 
clade 7), as well as uninfected and wtMVA infected BHK-21 cells lysed in 1% Triton-X100 (Sigma) in 
PBS supplemented with mini cOmplete™ EDTA free protease inhibitor tablet (Roche) were printed onto 
nitrocellulose slides by asciFlexarraver (Scienion). Sera were incubated on the slides in Blotto Blocking 
Buffer (Thermo Fisher Scientific Inc.) supplemented with 0.1% Surfactant-Amps (Thermo Fisher Scientific 
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Inc.). Subsequently, goat-anti-human IgG labelled with AlexaFluor647 (Jackson ImmunoResearch 
Laboratories Inc.) was used as conjugate and fluorescent signals were measured using a Powerscanner 
(Tecan Group Ltd). The titer of each serum sample was defined as the interpolated serum concentration 
generating the 50% point using a four-parameter logistic nonlinear regression model using R (R Statistical 
Computing, version 3.1.0. Measured titers were corrected for the positive control included on each slide.
Detection of MVA- or VACV-specific antibodies by ELISA
For detection of VACV-specific antibodies, HeLa cells were mock-treated or infected with VACV-Elstree 
at MOI 1 and harvested in 1% Triton-X100 in PBS supplemented with mini cOmplete EDTA free protease 
inhibitor tablet. Similar procedures were used to obtain BHK-21 cell lysates mock-treated or infected 
with wtMVA. Sera used for detection of MVA- or VACV-specific antibodies were pre-cleared O/N at 4oC 
in a 96-well plate with confluent BHK-21 or HeLa cells, respectively. For ELISA, 96-well plates (Corning 
Costar) were coated overnight at 4oC with 10-25µl cell lysate per well in 0.05M Carbonate/Bicarbonate pH 
9.6. Plates coated with cell lysate were washed and all plates were blocked for 1h at room temperature 
(RT) with blocking buffer consisting of PBS supplemented with 0.05% Tween-20 (PBST, Merck-solutions) 
and 2% milk powder (w/v, Campina). Subsequently, a 3-log dilution series of serum in blocking buffer 
was prepared, starting dilution 1:10 or 1:30, and 50μl was transferred to wells of the antigen-coated 
plates and incubated for 1-1.5h at RT. Blocking buffer and VACV-positive serum served as appropriate 
negative or positive control, respectively. Plates were washed with PBST and incubated for 1h at RT with 
HRP-conjugated goat-anti-mouse IgG (DAKO) or goat-anti-human IgG (Southern Biotech). Plates were 
washed with PBST and incubated for 10min with 50µl TMB peroxidase substrate (KPL) after which the 
reaction was stopped with 0.5M H2SO4 (Merck). Absorbance was measured at 450nm using a Tecan 
infinite F200. The OD450 values at a single dilution in the linear area of the curve were determined and 
analyzed. Due to limited amounts of serum, sera were pooled per subgroup (Table 1, n=3-6). Sera of 
VACV-primed animals were tested individually in VACV ELISA as much as possible, although in some 
groups a few samples had to be pooled (indicated in figure legends). The OD450 value obtained with mock-
infected BHK-21 or HeLa cell lysate was subtracted from the OD450 value obtained with the respective 
infected cell lysate to determine a net OD450 response.
Hemagglutination inhibition (HI) assay
Sera were treated with a receptor-destroying enzyme (cholera filtrate) overnight at 37oC, followed by 
heat-inactivation for 1h at 56oC. HI assay was performed in a 2-fold serial dilution in duplicate following a 
standard protocol using 1% turkey erythrocytes and four HA units of an H5N1 reverse genetics influenza 
virus with HA (without multibasic cleavage site) and NA gene segments of A/Vietnam/1194/04 and the 
remaining gene segments of influenza virus A/Puerto Rico/8/34 (6+2)348.
Plaque reduction assay
Mouse sera were pooled per subgroup (Table 1, n=2-5) due to limited serum availability. Sera were 
heat-inactivated for 30min at 56oC. A 2-log dilution series – starting dilution 1:10 – was prepared in CEF 
culture medium and incubated for 2h with 200 PFU/well wtMVA (mouse sera) or rMVA-GFP (human 
sera) in a 1:1 ratio at 37oC. Human serum with antibodies against MVA was used as a positive control. 
Subsequently, the serum-virus mixture was incubated for 2h at 37oC on a confluent monolayer of CEF 
cells in 96-wells culture plates. Cells were washed with PBS and incubated for 44-48h 37oC. CEF used for 
serology of mouse samples were fixed with acetone:methanol in a 1:1 ratio (Sigma-Aldrich). Plates were 
blocked with 3% FBS in PBS for 1h. Subsequently, plaques were stained with rabbit anti-VACV (Lister 
strain, Acris) followed by goat-anti-rabbit HRP-conjugate (Jackson ImmunoResearch Laboratories Inc.). 
Samples were developed using True Blue (KPL). The percentage of area covered by stained plaques 
was measured using a CTL immunospot reader with CTL biospot software. CEF used for serology of 
human samples were fixed with 2% paraformaldehyde (PFA) for 10min after which fluorescent plaques 
were detected using a Typhoon™ FLA9500 (GE Healthcare). Plaques were counted using ImageQuant 
TL Colony v8.1 software (GE Healthcare). The MVA-neutralization titer was determined as the reciprocal 
of the highest dilution at which the area covered by plaques was below 50% of the average percentage of 
the area covered (mouse sera, Fig. S4A) or counted spots (human sera, Fig. S4B) in n=12 wells without 
any added serum. 
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Statistical analysis
Longitudinal body weight data after H1N1pdm09 priming from different groups were analyzed using a 
repeated measures ANOVA model, with time as within factor. One way ANOVA with multiple comparisons 
was used to compare the normally distributed (according to the Shapiro-Wilk test) VACV-specific antibody 
responses after priming (week 8), H5-specific PA antibody responses after one vaccination and the 
2003/2011 H3-specific PA antibody responses in mice. A Kruskal-Wallis test was used to compare the 
not normally distributed HI titers against A/Vietnam/1194/04 after a single vaccination, NP- or H5-specific 
T cell responses and viral lung titers. HI titers below the detection limit (titer 40) were set to a titer of 
20 (the highest possible titer below 40). Statistical differences in the MVA-specific PA response were 
determined relative to the ‘0x MVA’ control sample using a Kruskal-Wallis test. Furthermore, the ELISA 
and neutralization titers in human serum samples were compared using a Wilcoxon matched-pairs signed 
rank test (MVA sera) or a Mann-Whitney test (VACV sera). Neutralization titers in the plaque reduction 
assay below the detection limit (10) were set to a titer of 5 (the highest possible titer below 10).
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Figure S1. VACV-Elstree dose-finding. C57BL/6 mice (n=6 per group) were inoculated with 104, 105, 
106 or 107 PFU via tail scarification. (A) Mean body weight post-inoculation per group. (B) Representative 
images of blister formation at 2, 8 and 14 days post-inoculation (dpi). (C) VACV-Elstree specific antibody 
responses at 14 dpi were measured by ELISA using VACV-infected HeLa cell lysate. The background 
signal on mock-infected cell lysate was subtracted. The mean is indicated. (D-E) Percentage of interferon 
(IFN)-ɣ producing CD3+ CD4+ (D) and CD3+ CD8+ (E) splenocytes after stimulation with wild-type (wt)MVA 
or VACV at 14 dpi. Unstimulated samples were included as negative control and are shown in grey. The 
mean is indicated.
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Figure S2. H1N1pdm09 dose-finding. C57BL/6 mice (n=6 per group) were inoculated with 103, 104, 105 
or 106 TCID50 influenza virus H1N1pdm09. (A) Mean body weight post-inoculation per group. (B) Survival 
curves per group. (C) HI antibody titers against H1N1pdm09 of individual mice at 14 dpi. The mean is 
indicated. (D) Number of IFN-ɣ producing CD3+ CD8+ splenocytes of individual mice after stimulation with 
NP366-374 peptide. Unstimulated samples were included as negative control and are shown in grey. The 
mean is indicated.
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Figure S3. Pre-existing immunity does not impair protective capacity of a single rMVA-H5 
vaccination. (A) Body weight for each of the priming groups after challenge with a lethal dose H5N1 
influenza virus, shown for group 5 (one rMVA-H5 vaccination) and group 7 (one rMVA-H1 and one 
rMVA-H5 vaccination). Mean and standard deviation (SD) are indicated per priming group. (B) Viral load 
in the lungs shown as TCID50 per gram lung for each individual animal. Mean is indicated per priming 
group.
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Figure S4. Quantification of MVA neutralization in plaque reduction assay. Two-fold serial dilutions of 
mouse sera (A) or human sera (B) were incubated with 200 PFU/well wtMVA or rMVA-GFP, respectively. 
After 2h, the serum-virus mixtures were transferred to CEF cells and incubated for 44-48h. (A) For 
the plaque reduction assay using mouse sera, cells were fixated with acetone and methanol in a 1:1 
ratio, followed by staining with rabbit anti-VACV and a goat-anti-rabbit HRP conjugate. Substrate was 
revealed using True Blue. Shown is a representative image of an CTL immunospot scan. (B) For the 
plaque reduction assay using human sera, cells were fixated with 2% PFA and directly scanned for GFP 
fluorescence. Shown are representative images of a Typhoon scan. Neutralization titer was determined 
as the reciprocal of the highest dilution at which the area covered by plaques was below background 
(defined as 50% of the average percentage of the area covered in n=12 wells without any added serum). 
Wells with values below the cutoff are indicated with a bold outline. #1-4 = number of mouse or human 
samples, x = no serum added.
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CHAPTER 3.1
Increased protein degradation improves influenza virus nucleoprotein-
specific CD8+ T cell activation in vitro but not in C57BL/6 mice
AF Altenburg, CE van de Sandt, SE van Trierum, HLM De Gruyter, PRWA van Run,
RAM Fouchier, K Roose, X Saelens, A Volz, G Sutter, RD de Vries & GF Rimmelzwaan
Journal of Virology, 2016; 90(22): 10209-10219
Due to antigenic drift of influenza viruses, seasonal influenza vaccines need 
to be updated annually. These vaccines are based on predictions of strains 
likely to circulate in the next season. However, vaccine efficacy is greatly 
reduced in the case of a mismatch between circulating and vaccine strains. 
Furthermore, novel antigenically distinct influenza viruses are introduced 
into the human population from animal reservoirs occasionally and may 
cause pandemic outbreaks. To dampen the impact of seasonal and pandemic 
influenza, vaccines that induce broadly protective and long-lasting immunity 
are preferred. Because influenza virus-specific CD8+ T cells are directed mainly 
against relatively conserved internal proteins, like nucleoprotein (NP), they are 
highly cross-reactive and afford protection against infection with antigenically 
distinct influenza virus strains, so-called heterosubtypic immunity. Here, we 
used Modified Vaccinia virus Ankara (MVA) as a vaccine vector for the induction 
of influenza virus NP-specific CD8+ T cells. To optimize the induction of CD8+ 
T cell responses, we made several modifications to NP, aiming at retaining 
the protein in the cytosol or targeting it to the proteasome. We hypothesized 
that these strategies would increase antigen processing and presentation 
and thus improve the induction of CD8+ T cell responses. We showed that NP 
with increased degradation rates improved CD8+ T cell activation in vitro if the 
amount of antigen was limited or if CD8+ T cells were of low functional avidity. 
However, after immunization of C57BL/6 mice, no differences were detected 
between modified NP and wild-type NP (NPwt), since NPwt already induced 
optimal CD8+ T cell responses.
IMPORTANCE – Due to the continuous antigenic drift of seasonal influenza 
viruses and the threat of a novel pandemic, there is a great need for the 
development of novel influenza vaccines that offer broadly protective 
immunity against multiple subtypes. CD8+ T cells can provide immunity 
against multiple subtypes of influenza viruses by the recognition of relatively 
conserved internal antigens. In this study, we aimed at optimizing the CD8+ T 
cell response to influenza A virus by making modifications to influenza A virus 
nucleoprotein (NP) expressed from the Modified Vaccinia virus Ankara (MVA) 
vaccine vector. These modifications resulted in increased antigen degradation, 
thereby producing elevated levels of peptides that can be presented on major 
histocompatibility complex (MHC) class I molecules to CD8+ T cells. Although 
we were unable to increase the NP-specific immune response in the mouse 
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strain used, this approach may have benefits for vaccine development using 
less-immunogenic proteins.
Introduction
Influenza virus infections have a major impact on public health worldwide. Influenza 
A (subtypes H1N1 and H3N2) and influenza B viruses cause epidemics annually, 
which can be attributed to their capacity to accumulate mutations in the two major 
influenza virus surface proteins, hemagglutinin (HA) and neuraminidase (NA), a 
process known as antigenic drift4,17,18. This allows these viruses to escape recognition 
by virus-neutralizing antibodies induced after previous infections or vaccination. In 
addition, zoonotic transmission of influenza A viruses of alternative subtypes, such 
as avian influenza viruses of the H5N1 and H7N9 subtypes, occurs sporadically. 
Occasionally, the introduction of an influenza A virus of a novel subtype, which 
usually emerges after a genetic reassortment event, causes a pandemic outbreak 
because virus-neutralizing antibodies to these novel viruses are virtually absent in 
the human population.
Upon infection with influenza viruses, neutralizing antibody responses are induced, 
which are directed mainly against the variable globular head domain of HA1. In 
addition, antibodies that are directed to the more conserved stem region of the HA 
molecule and that are more broadly neutralizing than those directed to the head 
region have been identified146,152,159-161. However, the contribution of stem region-
specific antibodies to the overall antibody response is limited349 and fails to reach 
protective levels after natural infection.
In addition, infection with influenza viruses results in the induction of virus-specific 
CD4+ and CD8+ T cell responses (reviewed by Altenburg et al.316). Upon recognition of 
viral epitopes presented by major histocompatibility complex (MHC) class I molecules 
on virus-infected cells, CD8+ T cells eliminate these cells and thus contribute to the 
clearance of infection316. Viral peptides are generated in infected cells through the 
processing of viral proteins by the proteasome in the cytosol. After transport into 
the endoplasmic reticulum (ER) by transporter associated with antigen processing 
(TAP), the peptides are loaded onto MHC class I molecules and transported to the 
cell surface for recognition by cytotoxic CD8+ T lymphocytes (CTLs) (reviewed by 
Hewitt et al.58). Because the majority of influenza virus-specific CD8+ T cells recognize 
epitopes located in more-conserved viral proteins, such as nucleoprotein (NP) and 
the matrix 1 (M1) protein73,107,350,351, they display a high degree of cross-reactivity. 
Indeed, it has been shown that CTLs raised after infection with human seasonal 
influenza A viruses cross-react with avian influenza A viruses of other subtypes and 
contribute to so-called heterosubtypic immunity53,54,57,72,82,193,352,353.
Currently used seasonal and pandemic influenza vaccines aim at the induction 
of mainly HA-specific antibodies and do not efficiently induce CD8+ T cell 
responses136,137. However, if there is an antigenic mismatch between vaccine strains 
and circulating influenza virus strains, the vaccines offer little or no protection, as 
was the case for the H3N2 vaccine component during the 2014-2015 influenza 
season317-319. Furthermore, the production of sufficient vaccine doses is a time-
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consuming process, as was demonstrated during the influenza pandemic of 2009 
caused by H1N1pdm09 virus, when in most countries, vaccines became available 
after the peak of the pandemic132,133. Therefore, the availability of influenza vaccines 
that induce more broadly protective immune responses and/or novel technologies 
that allow more rapid production of sufficient vaccine doses are highly desirable.
In order to induce protection against multiple subtypes of influenza viruses, vaccines 
ideally induce cross-reactive T cell responses. For the efficient induction of CD8+ 
T cell responses, proteins need to be processed endogenously for MHC class 
I-restricted antigen presentation, which requires the delivery of vaccine antigens 
to the cytosol of antigen-presenting cells (APCs). Modified Vaccinia virus Ankara 
(MVA) is a vaccine vector that has been shown to efficiently induce T cell responses 
in various animal models and in humans235,266-269,271-275. Other advantages include 
the rapid production of an MVA-based vaccine, the easy and stable insertion of a 
transgene of interest, intrinsic adjuvant capacities, and an excellent safety record, 
even in immunosuppressed macaques and elderly people260,271,279,280. Thus, MVA 
is considered an ideal vector system for the delivery of conserved influenza virus 
proteins.
We hypothesized that the immunogenicity of NP expressed from an MVA vector could 
be increased by enhancing the cytosolic degradation of this protein. In influenza virus-
infected cells, NP is imported into the nucleus via interactions of host cell proteins 
with nuclear localization signals (NLSs) in NP. In the nucleus, NP binds to newly 
replicated viral RNA (reviewed by Eisfeld et al.354). In order to achieve increased 
antigen degradation355, we modified the NLS of influenza virus NP to prevent import 
into the nucleus and to retain the protein in the cytosol356,357 or fused NP to ubiquitin 
(Ubq) to target the protein for degradation by the proteasome358-364. Although we 
observed differential recognition by human virus-specific CD8+ T cells in vitro, the 
modifications did not alter the virus-specific CD8+ T cell response or the protective 
efficacy of recombinant MVA (rMVA) expressing NP in C57BL/6 mice.
Materials and Methods
Ethics statement
Animals were housed and experiments were conducted in strict compliance with European guidelines 
(European Union directive on animal testing 2010/63/EU). The protocol was approved by an independent 
animal experimentation ethical review committee in Driebergen, the Netherlands (Erasmus MC permit 
number EUR3277). Animal welfare was observed daily, and to minimize animal suffering, all animal 
handling was performed under anesthesia using 4% isoflurane in oxygen.
Cell culture
Madin-Darby Canine Kidney (MDCK) cells were cultured in Eagle’s Minimum Essential Medium (EMEM; 
Lonza) supplemented with 10% fetal bovine serum (FBS, Greiner Bio-One); 20mM HEPES (Lonza); 
0.1% CHNaO3 (Lonza); and 100μg/ml penicillin, 100U/ml streptomycin, and 2mM L-glutamine (P/S/G; 
Lonza). Chicken Embryo Fibroblasts (CEFs) were isolated from 11-day-old chicken embryos (Drost 
Loosdrecht BV) and passaged once before use. CEFs were cultured in virus production serum-free 
medium (VP-SFM, Gibco) containing penicillin and streptomycin (P/S). Baby Hamster Kidney 21 (BHK-
21) cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Lonza) supplemented with 10% 
FBS, 20mM HEPES, 0.1% CHNaO3, 0.1mM non-essential amino acids (NEAA, Lonza), and P/S/G. HeLa 
cells were cultured in DMEM supplemented with 10% FBS, 20mM HEPES, 0.1% CHNaO3, and P/S/G. 
B lymphoblastoid cell lines (BLCLs) were prepared as described previously365. BLCLs were cultured in 
RPMI 1640 (Lonza) containing 10% FBS and P/S/G. All cell lines were cultured at 37°C with 5% CO2.
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Influenza virus
Influenza virus A/Puerto Rico/8/34 (PR8) was propagated in MDCK cells for in vitro experiments and in 
embryonated chicken eggs for in vivo experiments, as described previously54,353. Infectious virus titers 
were determined in MDCK cells as described previously343.
Generation of recombinant MVA
The respective (modified) NP nucleotide sequences (PR8 [GenBank accession number NC_002019]) were 
purchased from Baseclear BV. rMVA constructs expressing various NP molecules (rMVA-NP constructs) 
under the control of the PsynII promoter were prepared by mCherry-dependent plaque selection on CEFs 
after infection with MVA clonal isolate F6 and transfection with 1μg pMKIII-Red carrying the respective 
NP gene, as described previously256. rMVA-NP genomes were analyzed by PCR to verify the NP gene 
insertion and genetic stability. To generate a final vaccine preparation, the virus was amplified in CEFs, 
purified by ultracentrifugation through 36% sucrose, and reconstituted in a solution containing 10mM Tris-
HCl (pH 9) or 120mM NaCl + 10 mM Tris-HCl (pH 7.4).
NP protein expression from recombinant MVA
BHK-21 cells were uninfected (mock-treated) or infected with the indicated rMVA-NP constructs at a 
multiplicity of infection (MOI) of 10. After 24h, cells were harvested in 1% NP-40 (Sigma-Aldrich) 0.1% 
sodium dodecyl sulfate (SDS, Invitrogen) lysis buffer supplemented with a cOmplete Protease Inhibitor 
Cocktail tablet (Roche) and resolved by SDS-PAGE. Blots were probed with a monoclonal anti-NP 
antibody (clone HB65 IgG2a, American Type Culture Collection) and subsequently probed with goat anti-
mouse (GaM)-IRDye (Li-Cor Biosciences). The blot was scanned by using an Odyssey Li-Cor instrument 
(Westburg BV) and Odyssey 2.1 software. Image colors were inverted, and the contrast was linearly 
enhanced by using Adobe Photoshop CC.
Intracellular localization of NP determined by confocal microscopy
HeLa cells were seeded onto glass coverslips and left uninfected (mock) or infected with influenza 
virus PR8 or with the respective rMVA-NP constructs at an MOI of 1. At the indicated time points, cells 
were fixed by using 4% paraformaldehyde (PFA, Sigma-Aldrich), permeabilized with 0.1% Triton X-100 
(Sigma-Aldrich), and stained with an anti-NP antibody or IgG2a isotype-matched control antibody (R&D 
Systems), followed by GaM-fluorescein isothiocyanate (FITC, BD Bioscience) under pre-determined 
optimal conditions. Subsequently, coverslips were mounted onto slides by using ProLong Gold with 
4’,6-diamidino-2-phenylindole (DAPI, Invitrogen). Samples were analyzed with a confocal laser scanning 
microscope with an LSM700 system fitted onto an Axio Observer Z1 inverted microscope (Zeiss). Images 
were generated by using Zen software. The contrast was linearly enhanced by using Adobe Photoshop 
CC.
Radiolabeling and immunoprecipitation experiments
HeLa cells were left uninfected (mock) or were infected with the respective MVA constructs at an MOI of 
3. After 6h, the cells were harvested by using 0.05% trypsin–EDTA (Gibco) and resuspended in DMEM 
without methionine-cysteine (Gibco) supplemented with 10% dialyzed FBS (Invitrogen), 20mM HEPES, 
and P/S. The cells were pulsed with 30μCi/106 cells [35S] cysteine-methionine (PerkinElmer Life Sciences) 
for 10min. Subsequently, the cells were washed and incubated in HeLa culture medium. Zero hours or 
11h after pulse-labeling, the cells were washed with phosphate-buffered saline (PBS) and resuspended 
in lysis buffer containing 0.75% Triton X-100 and 0.25% NP-40. The lysate was precleared for 1h at 
4°C with 0.5μg IgG2a isotype antibody and protein G-Sepharose (GE Healthcare). Subsequently, the 
samples were incubated with 1μg anti-NP (Hb65) plus protein G-Sepharose. The beads were washed 
three times and resuspended in lysis buffer plus Laemmli buffer. Samples were resolved by SDS-PAGE 
and visualized by autoradiography.
Activation of CD8+ T cell clones in vitro
Infected target cells were prepared by inoculating HLA-A*01:01+ B*27:05+ BLCLs with the respective 
MVA constructs at an MOI of 0.3 or 3. As a positive control, cells were pulsed with 10μM either the 
HLA-A*01:01-restricted synthetic peptide spanning NP residues 44 to 52 (NP44–52, CTELKLSDY) or the 
HLA-B*27:05-restricted NP383–391 synthetic peptide (SRYWAIRTR). The inoculum was removed after 1h, 
and the cells were cocultured with either the NP44–52- or the NP383–391-specific CD8
+ T cell clone (TCC) at 
an effector-to-target cell (E:T) ratio of 1:5 in the presence of GolgiStop (4μl/6ml, BD Biosciences) and a 
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fluorochrome-labeled antibody to CD107a. The cells were cultured at 37°C for 10h, a time carefully chosen 
based on previous work366, allowing us to investigate early events of T cell activation. Subsequently, 
cells were stained with fluorochrome-labeled CD8FITC (Dako), CD3PerCP (BD Biosciences), CD107aV450 (BD 
Biosciences), and IFN-ɣAPC (BD Biosciences) antibodies and a marker for excluding dead cells (Aqua 
Live/Dead; Invitrogen). Samples were analyzed by flow cytometry using FACSCanto II and FACSDiva 
software.
Vaccination-challenge experiments
Specific-pathogen-free female C57BL/6 mice were purchased from Charles River and were 6 to 8 weeks 
of age at the start of the experiment. Animals were housed in individual ventilated cage (IVC) units and 
had access to food and water ad libitum. Groups of 20 mice each (n=10 for the PBS and wild-type MVA 
[wtMVA] control groups, which were combined for statistical purposes) were vaccinated intramuscularly 
(i.m.) twice at a time interval of 4 weeks with 108 PFU MVA in the two hind legs (50μl/leg). Four weeks 
after the second vaccination, mice were challenged intranasally (i.n.) with 5 x 102 50% tissue culture 
infective doses (TCID50) of influenza virus PR8 in 50μl. Four mice (week 5) or eight mice (4 or 7 days post-
challenge) were euthanized, and spleen and lung samples were harvested for analysis.
Intracellular cytokine staining of splenocytes after peptide stimulation
Spleens were collected during necropsy in Iscove’s modified Dulbecco’s medium (IMDM, Lonza) 
supplemented with 5% FBS and P/S/G for direct preparation of single-cell suspensions using 100μm 
strainers (Falcon). Spleen single-cell suspensions were treated with red blood cell lysis buffer (Roche 
Diagnostics). Splenocytes were mock treated, stimulated with 5μM synthetic peptide (NP366–374 epitope 
[ASNEMMETM]) or with 50pg phorbol myristate acetate (PMA, Sigma-Aldrich) and 500pg ionomycin 
(Sigma-Aldrich) as positive controls in IMDM supplemented with GolgiStop, and incubated for 6h at 37°C. 
Cells were stained with fluorochrome-labeled CD3eAPC-Cy7 (BD Pharmingen), CD8bFITC (BD Pharmingen), 
CD4PerCP (BD Pharmingen), and IFN-ɣPacific Blue (PB; BioLegend) antibodies and Aqua Live/Dead stain. 
Subsequently, cells were fixed and permeabilized by using BD Cytofix/Cytoperm Plus (BD Biosciences) 
and stained for IFN-ɣ. Samples were analyzed by flow cytometry using a FACSCanto II instrument.
Virus isolation form lungs
Directly after harvest, lungs (n=6 per group at 4 and 7 days post-infection [dpi]) were snap-frozen by using 
dry ice with ethanol and stored at -80°C for processing at a later time point. Lungs were homogenized 
with a Polytron homogenizer (Kinematica AG) in MDCK culture medium supplemented with 0.002% 
tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-trypsin (Lonza). Quadruplicate 10-fold serial 
dilutions of these samples were used to determine virus titers in MDCK cells as described previously343.
Histopathological examination of lungs
Lungs (n=2 for each group at week 5 and at 4 and 7 dpi) were inflated in situ with 10% neutral buffered 
formalin. After fixation in formalin and embedding in paraffin, lungs were sectioned at 3μm and stained 
with hematoxylin and eosin (HE) for histological evaluation. Furthermore, influenza A virus-infected cells 
were detected by staining tissues with a primary antibody against NP as described previously, followed 
by GaM-IgG2a-HRP (Southern Biotech)367. An IgG2a isotype control was included as a negative control. 
Samples were analyzed by using an Olympus BX51 light microscope. Images were taken by using a 20x 
ocular and Olympus cell^A software.
Statistical analysis
Differences in CD8+ T cell clone activation (Fig. 4C-F) were analyzed by one-way analysis of variance 
(ANOVA) with a Tukey test, which compares the mean for each column to the mean for every other 
column. Parametric tests did not apply for mouse lung titrations (Fig. 5C-D) or peptide-stimulated CD3+ 
CD8+ mouse splenocyte samples (Fig. 5F-H) according to the D’Agostino-Pearson omnibus normality 
test, either due to a small number of samples or because data were not normally distributed. Therefore, 
the Kruskal-Wallis test with Dunn’s correction was used. From multiple previous experiments, it was 
observed that the PBS and wtMVA control groups gave similar results. These two control groups were 
combined for statistical purposes to reduce the number of animals used in this study, as required by the 
animal experimentation ethical review committee.
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Results
Construction of rMVA-based vaccines driving expression of NP with or without 
modifications
In order to increase antigen processing and presentation and improve subsequent 
CD8+ T cell activation, modifications were made to NP from influenza virus A/Puerto 
Rico/8/34 (PR8). First, NP genes in which the NLS was mutated (NPmut) or deleted 
(NPΔNLS) were designed356,357 (Fig. 1A). Second, Ubq was fused to the N-terminus 
of NP (UbqNP). The C-terminus of ubiquitin was mutated to prevent hydrolysis362-364 
(Fig. 1A). rMVA constructs driving the expression of wild-type NP (NPwt) or modified 
NP genes were generated. The identity of the rMVA-NP constructs was confirmed 
by PCR analysis (data not shown), nucleotide sequencing (data not shown), and 
assessment of protein expression (Fig. 1B). NP has a caspase cleavage site at 
amino acid position 16, resulting in full-length (56 kDa) and truncated (53 kDa) 
versions of the protein368-370. Due to the deletion of the NLS, NPΔNLS is the same 
size as the truncated NPwt protein. The full-length UbqNP fusion protein has an 
increased molecular mass of 64.5 kDa (Fig. 1B).
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Figure 1. Modifications of NP and confirmation of expression by rMVA. (A) In order to promote 
cytosolic localization, the NLS of NP was mutated (NPmut) or deleted (NPΔNLS). Additionally, a ubiquitin-
NP (UbqNP) fusion construct was made, in which the C-terminal glycine of ubiquitin was mutated to 
valine in order to prevent hydrolysis. (B) rMVAs expressing the different (modified) NP molecules were 
generated. Expression of NP in infected BHK-21 cells was demonstrated by western blot probed with an 
NP-specific antibody. Full-length NPwt and NPmut are 56 kDa. Full-length NPΔNLS and truncated NPwt, 
NPmut, and UbqNP are 53 kDa. Full-length UbqNP is 64.5 kDa. The image is representative of results 
from at least 3 independent experiments.
Modifications of NP have the anticipated effect on cellular localization
Mutation and deletion of the NLS were done with the aim of retaining the protein in 
the cytosol. Therefore, the cellular localization of NP expressed by the respective 
rMVA constructs was analyzed by using confocal microscopy. During influenza virus 
PR8 infection, NP localizes to the nucleus at 4 and 6h post-infection (hpi), and after 
24h, NP has translocated to the cytosol (Fig. 2A). NPwt expressed by rMVA shows 
a cellular localization similar to that of NP expressed during infection with influenza 
virus PR8 (Fig. 2B). Mutation or deletion of the NLS of NP prevented the translocation 
of the protein to the nucleus almost completely (Fig. 2C-D). Similarly, the UbqNP 
fusion protein was present predominantly in the cytosol at 4 and 6 hpi. However, low 
levels of UbqNP were also detected in the nucleus. Hardly any UbqNP protein was 
detected at 24 hpi. (Fig. 2E). These results confirm that the modifications had the 
intended effect on the cellular localization of NP.
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Figure 2. Cellular localization of (modified) NP expressed from rMVA. HeLa cells were infected with 
influenza virus PR8 or one of the indicated rMVA constructs. (A) During PR8 infection, NP localizes to 
the nucleus at 4 and 6 hpi. After 24h, NP localizes mainly to the cytosol. (B) NPwt expressed from MVA 
behaves similarly to NP expressed during PR8 infection. (C-D) Mutation or deletion of the NLS retains NP 
in the cytosol. (E) NP fused to ubiquitin is dispersed throughout the cell and hardly detectable after 24h. 
(F) Uninfected control. (G) Control infected with rMVA-NPwt and stained with an isotype antibody. Images 
were taken by using a 100x ocular. Images are representative of results from at least 3 independent 
experiments.
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Deletion of the NLS or fusion of ubiquitin to NP results in increased protein degradation
In order to assess whether the degradation of the modified NPs was faster than that 
of NPwt, a metabolic radiolabeling experiment was performed. Over a time span 
of 11h, NPwt levels were relatively stable (Fig. 3). Mutation of the NLS (NPmut) 
did not affect protein stability. In contrast, deletion of the NLS (NPΔNLS) strongly 
accelerated the degradation of NP. Furthermore, fusion of NP to ubiquitin resulted in 
an even more rapid degradation of NP than for the NP molecule without NLS (Fig. 
3). This indicates that the deletion of the NLS and fusion of ubiquitin to NP increased 
degradation and thus potentially enhanced the liberation of peptides from the protein 
for improved antigen presentation.
75
50
kDa
chase (h) 0 11 0 11 0 11 0 11 0 11 0 11
mock wtMVA NPwt NPmut NPΔNLS UbqNP
Figure 3. NPΔNLS and UbqNP display enhanced degradation. At 6 hpi, HeLa cells were pulsed with 
[35S]cysteine-methionine for 10min, chased for 0 and 11h, and immunoprecipitated with an NP-specific 
antibody. Mock- or wtMVA-infected cells indicate the background.
Removal of the NLS or fusion to ubiquitin has differential effects on T cell activation 
in vitro
To address whether increased NP protein turnover indeed improves the CD8+ T cell 
response against NP in vitro, the activation of NP-specific CD8+ TCCs was measured 
after 10h of co-culture with human leukocyte antigen (HLA)-matched rMVA-NP-
infected BLCLs. CD107a, a degranulation marker371, and IFN-ɣ cytokine levels 
were used as a marker for CD8+ T cell activation (Fig. 4A). Two TCCs of different 
functional avidities, specific for the NP44–52 and NP383–391 epitopes, were tested
372. 
After infection at a low MOI, NPmut, but especially NPΔNLS and UbqNP, activated 
TCCs of low (NP44–52) and high (NP383–391) functional avidities more efficiently than 
did NPwt (Fig. 4B-E). In contrast, after infection with the respective rMVAs at a 
high MOI, the differences in the activation of TCCs specific for the NP383–391 epitope 
were no longer detectable (Fig. 4C, E). The differential activation of low-avidity CD8+ 
T cells specific for the NP44–52 epitope was still apparent (Fig. 4B, D). The results 
were consistent for both the CD107a and IFN-ɣ activation markers. Thus, under 
suboptimal conditions, when antigen amounts are limited (low MOI) or when CD8+ T 
cells are of low functional avidity (NP44–52), modifying NP by deleting the NLS or by 
fusion to ubiquitin improved the CD8+ T cell response in vitro.
Immunization of C57BL/6 mice with rMVA-NP constructs affords protection against 
lethal challenge infection but does not reveal differences between the NP constructs
After in vitro validation, the various rMVA-NP vaccine candidates were tested in vivo. 
C57BL/6 mice were vaccinated twice, 4 weeks apart (Fig. 5A). One week after the 
second vaccination, mice were euthanized to assess the vaccine-induced CD8+ T 
cell response (Fig. 5G). Although not statistically significant, the results indicate 
that vaccination with rMVA-NPΔNLS, rMVA-NPmut, and, to a lesser extent, rMVA 
expressing NPwt or UbqNP induces an NP-specific CD8+ T cell response (Fig. 5G).
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Figure 4. Increased NP degradation leads to stronger activation of TCCs in vitro at a low MOI 
or TCCs of low functional avidity. BLCLs were infected with the indicated rMVA constructs and 
subsequently cocultured with HLA-matched NP-specific TCCs. Mock-infected cells, TCCs alone, or 
cells expressing an empty vector (wtMVA) were used as negative controls. (A) Gating strategy. Live, 
single CD3+ CD8+ T cells were gated, from which the percentage of CD107a- or IFN-ɣ-positive cells was 
determined. Representative dot plots for mock- or MVA-infected cells are shown. FSC, forward scatter. 
(B-C) Percentage of CD107a-positive cells of NP44–52-specific (B) or NP383–391-specific (C) TCCs within the 
CD3+ CD8+ T cell population. (D-E) Percentage of IFN-ɣ-positive cells of NP44–52-specific (D) or NP383–391-
specific (E) TCCs within the CD3+ CD8+ T cell population (n=4). The graph shows means and standard 
deviations. * p=0.0251; ** p<0.0010; *** p<0.0032; **** p<0.0001.
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Figure 5. rMVA-NP vaccination reduces disease severity and lethality in vivo. (A) Mice were 
vaccinated twice, 4 weeks apart, with PBS or wtMVA (combined as controls) or with one of the four 
rMVA-NP constructs. Four weeks later, mice were challenged with a lethal dose of influenza virus PR8. 
One week after the second vaccination (week 5) and at 4 and 7 dpi, mice were euthanized. (B) Weight 
loss after challenge with a lethal dose of PR8. Body weight on the day of challenge was set at 100%. 
The graph shows means and standard deviations. (C-D) Viral load in TCID50 per gram lung at 4 dpi (C) 
and 7 dpi (D). Bars indicate means. * p<0.0187; ** p=0.037. (E) Representative immunohistochemistry 
images of lungs from control or vaccinated mice at 4 and 7 dpi. Lungs were stained for influenza virus 
NP (red) and counterstained with hematoxylin. (F-I) Splenocytes were pulsed with the NP366–374 peptide. 
IFN-ɣ production by CD3+ CD8+ splenocytes was used as a readout for CD8+ T cell activation. (F) Gating 
strategy. The CD3+ CD8+ population was first selected from the live, single-cell lymphocyte population, 
after which the numbers of IFN-ɣ-producing cells were determined. Representative images for control 
groups and vaccine groups are shown. (G-I) CD8+ T cell activation at week 5 (G), 4 dpi (H), and 7 dpi 
(I). Of note, y axis scales vary between graphs in panels G to I. Bars indicate means. ** p<0.0074; *** 
p=0.0005; ****, p<0.0001. Each symbol represents data for an individual mouse.
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Four weeks after the second vaccination, mice were inoculated with a lethal dose of 
influenza virus PR8 and euthanized at 4 or 7 dpi (Fig. 5A). Although both the control 
and vaccinated groups initially lost weight after inoculation, the body weight of mice 
vaccinated with rMVA-NP constructs stabilized and even increased again after 4 days 
and onward, whereas the control groups continued to lose weight (Fig. 5B). The viral 
loads in the lungs were similar between control groups and vaccinated groups at 4 
dpi; however, rMVA-NP-vaccinated mice had reduced lung viral titers at 7 dpi (Fig. 
5C-D). This correlated with the detection of virus-infected cells in the lungs, which 
were detected in both the control and rMVA-NP-vaccinated groups at 4 dpi but were 
detected only in the control groups at 7 dpi (Fig. 5E). Consistent with these data, an 
NP-specific CD3+ CD8+ T cell response was detected in vaccinated mice at 7 dpi but 
not yet at 4 dpi (Fig. 5H-I). Thus, vaccination with the rMVA-NP constructs reduced 
disease severity and protected mice from lethal challenge with an influenza A virus. 
However, no differences between the various rMVA-NP constructs were detected.
Discussion
In the present study, MVA-based vaccine candidates expressing influenza virus NP 
with or without modifications aiming at increasing antigen processing and presentation 
were designed, constructed, and tested in vitro and in vivo. We hypothesized that 
retention of NP in the cytosol of APCs or targeting of the protein to the proteasome 
would result in accelerated processing and improved activation of NP-specific CD8+ 
T cells. The modifications that we made to influenza virus NP had the anticipated 
effects regarding cellular localization, as demonstrated by confocal microscopy 
(Fig. 2). Despite retention in the cytosol, the rate of degradation of NPmut was not 
enhanced compared to that of NPwt. In contrast, we observed that increased protein 
degradation can be achieved by the removal of the NLS or, in agreement with data 
from previous studies, by N-terminal fusion to ubiquitin358-360,362-364,373. The increased 
degradation of NPΔNLS might be caused by defective folding of the protein due to the 
removal of a stretch of amino acids. An N-terminal fusion of ubiquitin to the substrate 
may lead to a rapid hydrolysis of ubiquitin from the substrate, thereby exposing 
an N-terminal amino acid that is not a methionine. By the so-called “N-end rule”, 
the protein is marked as faulty and degraded359,360,374. However, in our rMVA-UbqNP 
construct, hydrolysis was prevented by the introduction of a C-terminal mutation 
into the ubiquitin molecule. Therefore, the ubiquitin moiety most likely serves as the 
first molecule in the polyubiquitin chain, flagging the fusion protein as a proteasomal 
degradable product358,362-364,373.
Both mutation and deletion of the NLS prevented the transport of NP into the nucleus. 
However, the most substantial effect on the degree of CD8+ T cell activation in vitro 
was observed with NP variants that were degraded more rapidly due to a deletion 
of the NLS or fusion to ubiquitin. These findings are in agreement with previously 
reported observations that indicate that enhanced antigen processing leads to 
stronger CD8+ T cell activation in vitro359,360,363,364. Thus, enhanced degradation of NP, 
as observed for NPΔNLS and UbqNP, resulted in stronger CD8+ T cell activation, 
which was not observed for NPwt or NPmut, which is retained in the cytosol but does 
not display enhanced degradation (Fig. 4).
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Of interest, as described in previous studies with ubiquitin fusion proteins, we 
observed a differential effect on CD8+ T cell activation, depending on the specificity of 
the CD8+ T cells that were used359,360,364,375. A larger increase in CD8+ T cell activation 
was measured for the NP44–52 epitope than for the NP383–391 epitope. This difference 
may be explained by differences in the functional avidities of CD8+ T cells specific 
for these two epitopes: NP44–52-specific CD8
+ T cells are of relatively low functional 
avidity compared to CD8+ T cells specific for the NP383–391 epitope
372. Thus, especially 
for CD8+ T cells of low functional avidity, modifications that lead to more-rapid protein 
degradation improve their activation. For CD8+ T cells of high functional avidity, 
which thus require lower concentrations of the peptide for their activation, there may 
not be a window of opportunity because the minimal threshold for their activation is 
reached more readily.
After immunization of C57BL/6 mice with the respective rMVA-NP constructs, 
increased CD8+ T cell responses to the H2-Db-restricted NP366–374 epitope were 
observed for NP with a modified NLS. Mice vaccinated with rMVA-UbqNP showed 
hardly any CD8+ T cell reactivity 7 days after the second vaccination, although, due 
to the enhanced degradation rates and potentially increased antigen presentation 
kinetics, we could have missed the peak of the CD8+ T cell response to this protein 
(Fig. 5G). Following subsequent challenge infection with influenza virus PR8, no 
differences in anamnestic NP366–374-specific CD8
+ T cell responses were observed, 
which correlated with the lack of differences in clinical protection from weight loss 
or reduction of virus replication: all NP-immunized mice were equally protected 
compared to control mice (Fig. 5). The lack of differences in NP-specific CD8+ T 
cell responses may be explained by the same reasoning as that outlined above for 
the in vitro activation of different human NP-specific CD8+ T cells. The CD8+ T cell 
response to influenza viruses in C57BL/6 mice is dominated by NP366–374-specific 
CD8+ T cells376-378. Therefore, it is likely that in this mouse strain, with the rMVA dosage 
used, NPwt already reached minimal thresholds for an optimal CD8+ T cell response 
to the NP366–374 epitope. It would be of interest to study CD8
+ T cell responses after 
vaccination with the respective rMVA-NP constructs in other mouse strains, e.g. 
BALB/c mice, which mount NP-specific CD8+ T cell responses to epitopes that are 
less dominant than those observed in C57BL/6 mice, or to study the effect of the 
modification of less-immunogenic proteins.
Previously, it was suggested that cross-priming by professional APCs is important 
for the efficient induction of virus-specific CD8+ T cells. This would require a 
prolonged presence of the viral protein and antigen presentation for optimal CD8+ 
T cell responses, as opposed to increased protein degradation (reviewed by J.W. 
Yewdell379)363,380,381. Our in vitro data obtained with human TCCs suggested that 
infection of APCs and rapid proteasomal degradation favor the rapid activation of 
CD8+ T cells. However, the results obtained with the mouse model do not support this; 
thus, both cross-priming and direct antigen presentation by MVA-infected APCs may 
contribute to the induction of NP-specific CD8+ T cell responses. Of interest, upon 
immunization with rMVA, especially dendritic cells and macrophages are targeted, 
which subsequently express transgenes of interest342. Thus, direct infection of these 
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professional APCs most likely contributes to the induction of specific CD8+ T cell 
responses substantially, but cross-priming cannot be excluded.
Collectively, using rMVA expressing wild-type and modified influenza virus NPs, we 
have shown that retention of NP in the cytosol by mutation of the NLS (NPmut) 
does not significantly affect antigen processing and presentation and subsequent 
CD8+ T cell activation. However, deletion of the NLS or N-terminal fusion to ubiquitin 
increases NP degradation compared to that of NPwt. These modifications result 
in the improved activation of NP-specific CD8+ T cells, especially those with low 
functional avidity for their epitope. Furthermore, vaccination with rMVA expressing 
NPwt, NPmut, NPΔNLS, or UbqNP protected C57BL/6 mice from lethal challenge 
with influenza A virus, and no differences in CD8+ T cell responses between 
experimental groups were observed. In C57BL/6 mice, the immunodominant CD8+ 
T cell response to the NP366–374 epitope may have obscured the differential CD8
+ 
T cell activation observed in vitro with human NP-specific CD8+ T cells. Thus, the 
strategy of modifying proteins may have limited use for proteins that already mount 
immunodominant CD8+ T cell responses of high avidity but may be useful for poorly 
immunogenic proteins or when suboptimal vaccine doses are used.
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CHAPTER 3.2
Protein- and Modified Vaccinia virus Ankara-based influenza virus 
nucleoprotein vaccines are differentially immunogenic in BALB/c mice
AF Altenburg*, SE Magnusson*, F Bosman, L Stertman, RD de Vries & GF Rimmelzwaan
*Authors contributed equally
Clinical & Experimental Immunology, 2017; 190(1): 19-28
Because of the high variability of seasonal influenza viruses and the eminent 
threat of influenza viruses with pandemic potential, there is great interest in 
the development of vaccines that induce broadly protective immunity. Most 
probably, broadly protective influenza vaccines are based on conserved 
proteins, such as nucleoprotein (NP). NP is a vaccine target of interest as it 
has been shown to induce cross-reactive antibody and T cell responses. Here, 
we tested and compared various NP-based vaccine preparations for their 
capacity to induce humoral and cellular immune responses to influenza virus 
NP. The immunogenicity of protein-based vaccine preparations with Matrix-M™ 
adjuvant as well as recombinant viral vaccine vector Modified Vaccinia 
virus Ankara (MVA) expressing the influenza virus NP gene, with or without 
modifications that aim at optimization of CD8+ T cell responses, was addressed 
in BALB/c mice. Addition of Matrix-M™ adjuvant to NP wild-type protein-based 
vaccines significantly improved T cell responses. Furthermore, recombinant 
MVA expressing the influenza virus NP induced strong antibody and CD8+ T 
cell responses, which could not be improved further by modifications of NP to 
increase antigen processing and presentation.
Introduction
Influenza A (H1N1 and H3N2) and B viruses are responsible for seasonal epidemics 
in the human population and cause substantial morbidity and mortality in high-risk 
groups such as elderly people. The antigenic properties of these viruses change 
regularly due to accumulation of mutations in the two major surface proteins, 
haemagglutinin (HA) and neuraminidase (NA), resulting in escape from pre-existing 
virus-neutralizing antibodies induced by previous infections or vaccinations (antigenic 
drift)4,17,18. In addition to seasonal influenza viruses, avian and swine influenza A 
viruses – for example, viruses of the A(H5N1)382, A(H5N6)383 and A(H7N9)384 subtype 
– cause occasional human infections. These zoonotic influenza viruses have the 
potential to cause pandemic outbreaks, as the human population is immunologically 
virtually naïve.
Currently used inactivated vaccines against seasonal influenza viruses 
predominantly induce neutralizing antibodies against the globular head-domain of 
HA that neutralize homologous influenza viruses efficiently4. However, the breadth 
of reactivity of these antibodies is limited due to the high degree of variability in the 
head-domain of the HA glycoprotein between different influenza viruses, resulting in 
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reduced vaccine efficacy in case of a vaccine mismatch with epidemic strains4,317-319. 
Due to the antigenic drift of seasonal influenza viruses, vaccines need to be updated 
almost annually120. Furthermore, in case of a pandemic outbreak it is essential that a 
tailor-made vaccine can be produced rapidly, which proved to be difficult during the 
pandemic of 2009. Thus, alternative cross-reactive correlates of protection induced 
by a ‘universal’ influenza vaccine with the capacity to provide intra- or intersubtypic 
immunity, such as virus-specific T cells, have gained renewed interest.
Virus-specific CD8+ cytotoxic T cells predominantly recognize internal viral antigens, 
such as matrix (M1) and nucleoprotein (NP), that are relatively conserved and 
contain epitopes shared by various subtypes of influenza virus. These cells are 
induced by natural infection but are induced inefficiently by inactivated influenza 
vaccines316,82,136,137. It has been shown that cross-reactive virus-specific CD8+ 
cytotoxic T cells contribute to reduction of disease duration and severity after infection 
with a heterologous influenza virus76,82. In addition, antibodies directed against the 
conserved stalk-domain of HA have been identified, which display cross-protective 
potential against infection with heterologous influenza viruses146,152,160,169,349. Thus, the 
development of vaccines that induce broadly protective HA stalk-specific antibodies 
and/or cellular immune responses against conserved proteins such as NP or M1 is 
highly desirable and is listed high on the research agenda385,386,387.
Viral vaccine vectors, such as Modified Vaccinia virus Ankara (MVA), have been 
shown to efficiently induce antigen-specific humoral and cellular responses209,280. 
Recombinant (r)MVA vaccines have been tested extensively in various animal 
models and multiple clinical trials against different pathogens, including influenza 
virus, and has proved that the use of rMVA-based vaccines is safe209,250,278,388. As it is 
relatively easy to insert genes encoding antigens of interest into the genome of MVA, 
recombinant (r)MVA-based vaccines can be rapidly produced.209,280. rMVA drives de 
novo synthesis of one or multiple antigens of interest, leading to endogenous antigen 
processing and major histocompatibility complex (MHC) class I antigen presentation, 
which is important for the efficient induction of CD8+ T cells58.
Humoral and cellular immunity could also be improved by the use of adjuvants in 
combination with for example virosomal, trivalent, split virion and inactivated influenza 
vaccines389-396. Addition of Matrix-M™ adjuvant, made of saponins extracted from 
the tree Quillaja saponaria Molina397, to influenza vaccines enhances significantly 
humoral responses and the induction of virus-specific T cells in mice, ferrets and 
humans391-394,398-400. Furthermore, Matrix-M™ adjuvant has been evaluated in three 
clinical Phase I studies using seasonal and pandemic (H5N1 and H7N9) influenza 
vaccines391,399,401,402. All studies showed promising results with increased humoral 
and cellular responses along with good safety data.
Most adjuvanted influenza vaccine studies have focused upon the immune response 
towards HA403. Additionally, a couple of studies have shown that adjuvanted 
recombinant influenza virus NP protein vaccines are able to induce T helper type 1 
(Th1)-skewed CD4+ T cell response and protect C57BL/6 mice from influenza A virus 
challenge404,405. Here, we explore the effect of Matrix-M™ adjuvant on a recombinant 
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influenza virus NP protein-based vaccine and compare it to rMVA-NP vaccines 
in BALB/c mice. Accordingly, the immunogenicity of unadjuvanted or Matrix-M™ 
adjuvanted wild-type NP (NPwt) protein-based vaccines and rMVA-based vaccines 
expressing NPwt or modified NP, optimized for proteasomal processing341, were 
investigated. With rMVA expressing modified NP, enhanced activation of a human 
CD8+ T cells in vitro was observed previously, but the use of these constructs did not 
improve NP-specific CD8+ T cell responses compared to NPwt in the C57BL/6 mouse 
model341. As we speculated that the immune response in C57BL/6 mice was directed 
mainly against the immunodominant NP366–374 epitope
341,376, we next addressed the 
immunogenicity of rMVA vaccines expressing either NPwt or modified NP in BALB/c 
mice, which do not mount a response to this immunodominant NP epitope.
In this study, we show that Matrix-M™ adjuvant can improve the immunogenicity 
of protein-based NPwt vaccines substantially. Comparison of the two types of 
recombinant NP vaccines showed that while Matrix-M™ adjuvant improved 
the immunogenicity of NPwt vaccine by enhancing the antibody titer and T cell 
responses compared to unadjuvanted NPwt vaccine, rMVA-NPwt vaccines also 
induced antigen-specific interferon (IFN)-ɣ-positive CD8+ T cells and higher IgG2a 
NP-specific antibody titers. However, rMVA-driven expression of NP modified to 
increase antigen processing did not improve the NP-specific CD8+ T cell response 
in BALB/c mice.
Materials and methods
NPwt protein preparation
The NP was expressed in Escherichia coli BL21 as a His-tagged maltose binding protein (MBP) fusion 
protein containing a DEVD sequence as cleavage site for murine (m)caspase3. Expression of the tagged 
MBP-NP fusion protein was induced by addition of 1mM isopropyl β-D-1-thiogalactopyranoside (IPTG). 
After 4h induction at 28ºC the cells were harvested, lysed by sonication at 4ºC followed by centrifugation. 
The supernatant was loaded on Ni-Sepharose 6 FF (GE Healthcare) and proteins were eluted by applying 
an imidazole gradient. The 50mM imidazole fractions containing the MBP-NP fusion protein were pooled 
and after incubation for 1h at 37ºC in the presence of 0.06mg mcaspase3/mg fusion protein reloaded 
on Ni-IMAC resin. Analysis by sodium dodecyl sulphate-polyacrylamide gel electrophoresis/Coomassie 
Brilliant Blue (SDS-PAGE/CBB) staining and western blot showed that more than 90% pure NP was 
recovered in the flow-through. NP was concentrated to 1mg/ml and dialyzed against 25mM HEPES, 
300mM NaCl pH 7.5. The lipopolysaccharide (LPS) content (<0.25EU/µg NP) was determined with 
EndoSafe-PTS test (Charles River).
Matrix-M™ adjuvant
Novavax proprietary Matrix-M™ adjuvant is a saponin-based adjuvant consisting of two individually 
formed 40nm-sized particles, each with a different and well-characterized saponin fraction (fraction-A and 
fraction-C, respectively). The Matrix-A and C particles are formed by formulating purified saponin from the 
tree Quillaja saponaria Molina with cholesterol and phospholipid406.
Generation of recombinant MVA
The rMVA constructs expressing NP under control of the early/late PsynII promotor were prepared as 
described recently341. In short, the respective (modified) NP nucleotide sequences (PR8-based, Accession 
number NC002019) were synthesized by Baseclear BV and clonal rMVA viruses were prepared through 
transient mCherry-dependent plaque selection in chicken embryo fibroblasts (CEF)256,341. To generate 
a final vaccine preparation, virus was propagated in CEF, purified by ultracentrifugation through 36% 
sucrose and reconstituted in 120mM NaCl 10mM Tris-HCl pH 7.4. rMVA-NP constructs were previously 
extensively characterized in vitro by sequencing, western blot, confocal microscopy and radiolabelling 
experiments341.
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Vaccination of BALB/c mice
Specified pathogen-free female BALB/c mice were purchased from Charles River Laboratories and were 
8-10 weeks of age at the start of the experiment. Animals were housed in Makrolon type 3 cages, had 
access to food and water ad libitum and animal welfare was observed on a daily basis. All experiments 
were conducted in strict compliance with European guidelines (EU directive on animal testing 2010/63/
EU) and the protocol was approved by an independent animal experimentation ethical review committee 
(Uppsala djurförsöksetiska nämnd). Experiments were performed in two sets, the first set focused on 
the comparison of protein vaccines with MVA-based vaccines (Table 1) and the second set focused 
on the comparison of NPwt with modified NP expressed by MVA (Table 2). BALB/c mice received two 
vaccinations (time interval of 4 weeks) with 108 plaque-forming units (PFU) rMVA, 10µg NPwt protein or 
1 or 10µg NPwt protein adjuvanted with 5 or 10µg Matrix-M™ adjuvant. All vaccines were administered 
subcutaneously in 100µl at the base of the tail. Blood was sampled 21 days after the first vaccination 
and before mice were euthanized; 14 or 10 days after the second vaccination for the first and second 
set, respectively. Spleens were collected in phosphate-buffered saline (PBS) during necropsy and 
subsequently single-cells suspensions were prepared as described previously393.
Detection of NP-specific antibodies
Maxisorp microplates (Nunc) were coated O/N at 4ºC with 50ng/well NPwt protein (AmatsiQ-Biologicals) 
in 0.05M carbonate/ bicarbonate (Sigma Aldrich) buffer pH 9.6. Plates were blocked for 1h at room 
temperature using PBS with 0 05% Tween-20 (PBST; Thermo Fisher Scientific) pH 7.2-7.6 supplemented 
with 2% (W/V) milk powder (Semper). A three- or fivefold dilution series of the sera was prepared in blocking 
buffer starting at 1:30 and incubated on the coated plates for 1h. Blocking buffer and anti-NP positive 
serum were used as a negative or positive control, respectively. Plates were washed with PBST and 
incubated with anti-IgG1 (Star 132P; AbD Serotec) or anti-IgG2a (Star 133P; AbD Serotec) horseradish 
peroxidase (HRP)-conjugated antibodies – indicative for a Th2 or Th1 response, respectively407 – for 1h. 
Subsequently, plates were washed with PBST and 100µl 3,3’,5,5’-tetramethylbenzidine (TMB) peroxidase 
substrate (Svanova Biotech) was added. Reactions were stopped by adding 1.8M H2SO4 and absorbance 
was measured subsequently at 450nm using a SpectraMax Plus 384 Microplate Reader (Molecular 
Devices Corporation). Immunoglobulin (Ig)G1 and IgG2a anti-NP titers were calculated using a four-
parameter logistic equation (Softmax software; Molecular Devices). The inflection point of the titration 
curve, i.e. half maximal effective concentration (EC50) titer, was used for analysis.
FluoroSpot analysis of protein- or peptide-stimulated splenocytes
The number of interleukin (IL-)2 and IFN-ɣ-producing cells in single-cell suspensions of the spleen was 
analysed using FluoroSpot assay (Mabtech), according to the manufacturer’s instructions. In brief, single-
cell suspensions were seeded in triplicate on filter plates at 0.25 x 106 cells/well in Roswell Park Memorial 
Institute (RPMI) medium (Sigma Aldrich) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS; Sigma Aldrich), 100U/ml penicillin / 100µg/ml streptomycin / 2mM L-glutamine (P/S/G; Sigma 
Aldrich) and stimulated with 1µg NP (AmatsiQ-Biologicals) or 5µM synthetic peptide (epitope NP147–155, 
TYQRTRALV273) per well. Concanavalin A (Sigma Aldrich) and RPMI supplemented with 10% FBS were 
used as positive and negative controls, respectively. Samples were incubated for 20h at 37ºC after which 
spots were developed and analysed using an AID ELR02 reader (Autoimmune Diagnostika GmbH).
Intracellular cytokine staining (ICS) of peptide-stimulated splenocytes
Single-cell suspensions of splenocytes were mock-treated, stimulated with 5µM synthetic peptide (epitope 
NP147–155) or stimulated 20ng/ml phorbol myristate acetate (PMA) and 1µg/ml ionomycin as positive control 
in Iscove’s modified Dulbecco’s medium (IMDM; GIBCO) supplemented with 5% FBS (Sigma Aldrich), 
P/S/G and GolgiStop. Stimulation lasted 12h at 37ºC, which is longer than the optimal 6h incubation with 
GolgiStop. However, enough viable events were measured for reliable analysis. Cells were stained with 
fluorochrome-labelled antibodies CD3eAPC–Cy7 (BD Pharmingen), CD8bFITC (BD Pharmingen, San Diego, 
CA, USA), CD4PerCP (BD Pharmingen) and Aqua LIVE/DEAD (Invitrogen). Subsequently, cells were fixed 
and permeabilized using BD Cytofix/Cytoperm™ Plus (BD Biosciences) and stained with IFN-ɣPacific Blue 
(Biolegend). Samples were analysed by flow cytometry using a FACS Celesta flow cytometer and FACS 
DIVA software (BD Biosciences).
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Statistical analysis
NP-specific antibody responses were analysed by a one-way analysis of variance (ANOVA) to establish 
statistically significant differences. FluoroSpot and ICS data were first assessed with a D’Agostino & 
Pearson omnibus normality test. Non-normally distributed data (FluoroSpot set 1 and ICS set 2) were 
analysed using a Kruskal–Wallis rank test. If a normal distribution was assumed, a one-way ANOVA was 
performed to determine statistical significance (FluoroSpot set 2).
Results
Matrix-M™ adjuvant enhanced immunogenicity of NPwt protein-based vaccine
As Matrix-M™ adjuvant has been shown to induce high levels of biologically 
active antibodies, balanced type Th1 and Th2 immune responses, multi-functional 
T cells and cytotoxic CD8+ T lymphocytes in combination with various subunit 
vaccines400,408-410, we addressed the effect of addition of Matrix-M™ adjuvant to 
NPwt protein-based vaccines and compared this to unadjuvanted NPwt protein and 
rMVA-NPwt vaccination. To this end, mice were vaccinated twice with one of three 
different NPwt protein 1 Matrix-M™ adjuvant combinations, NPwt protein alone or 
rMVA-NPwt (Table 1).
Table 1. Vaccines used to assess the effect of Matrix-M™ adjuvant on protein-based wild-type 
nucleoprotein (NPwt) vaccine immunogenicity. 
Vaccine n Formulation Adjuvant
Protein 5 10µg NPwt -
8 1µg NPwt 5µg Matrix-M™ adjuvant
8 10µg NPwt 5µg Matrix-M™ adjuvant
8 1µg NPwt 10µg Matrix-M™ adjuvant
rMVA 8 108 PFU rMVA-NPwt -
BALB/c mice were vaccinated twice at a 4-week interval with the respective vaccines. Mice were 
euthanized 14 days after the second vaccination; n indicates the number of animals per group. PFU = 
plaque-forming units; rMVA = recombinant Modified Vaccinia virus Ankara.
Vaccine immunogenicity was assessed by determining NP-specific antibody titers 
after one or two vaccinations (Fig. 1). NP-specific antibody responses induced 
by the protein-based vaccines, with or without Matrix-M™ adjuvant, could not 
be detected after a single vaccination (Fig. 1A-B). In contrast, 21 days after the 
primary vaccination an NP-specific IgG2a response was detected after vaccination 
with rMVA-NPwt (Fig. 1B). At 14 days after either protein or rMVA-NPwt booster 
vaccination NP-specific antibody responses were detected. Protein-based NPwt 
vaccines predominantly induced an IgG1 antibody response, whereas rMVA-NPwt 
induced both IgG1 and IgG2a NP-specific antibodies with a bias towards IgG2a 
(Fig. 1C-D). The NP-specific IgG1 responses induced by protein-based vaccines 
and rMVA-NPwt were comparable (Fig. 1C). Although not statistically significant, the 
immunogenicity of the protein-based NPwt vaccines was enhanced by the addition 
of Matrix-M™ adjuvant to the vaccine formulation, particularly for 10µg NPwt + 5µg 
Matrix-M™ adjuvant (Fig. 1C-D).
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Figure 1. Nucleoprotein (NP)-specific antibody responses after NP wild-type (NPwt) protein (with 
or without Matrix-M™ adjuvant) or recombinant Modified Vaccinia virus Ankara (rMVA)-NPwt 
vaccination. The immunoglobulin (Ig)G1 and IgG2a NP-specific antibody responses 21 days after the 
primary vaccination (A-B) or 14 days after the booster vaccination (C-D). IgG1 (A & C) or IgG2a (B & 
D) serum antibodies were detected using purified NPwt protein and anti-IgG1 or anti-IgG2a horseradish 
peroxidase (HRP)-conjugated antibodies. Mean of each group is indicated. MM = Matrix-M™ adjuvant. 
**** p<0.0001.
Next, the vaccine-induced NP-specific T cell responses were evaluated. T cell 
activation was measured by stimulation of splenocytes obtained 14 days after 
the booster vaccination and subsequent detection of IL-2-, IFN-ɣ- or IL-2/IFN-ɣ-
producing NP-specific splenocytes. NP-specific T cell responses induced by protein-
based vaccine formulations were enhanced significantly by Matrix-M™ adjuvant 
(Fig. 2). Furthermore, Matrix-M™ adjuvanted NPwt protein vaccines induced more 
IL-2-producing T cells compared to rMVA-NPwt vaccination (Fig. 2A). In contrast, 
no differences in IFN-ɣ- or IL-2/IFN-ɣ-producing cells between the Matrix-M™ 
adjuvanted NPwt protein vaccines and the rMVA-NPwt vaccine were observed (Fig. 
2B-C). Collectively, NPwt protein vaccines, especially with the Matrix-M™ adjuvant, 
and rMVA-NPwt were immunogenic in BALB/c mice. In general, rMVA-NPwt 
induced stronger IgG2a and similar IgG1 NP-specific antibody responses compared 
to protein-based vaccines. Addition of Matrix-M™ adjuvant to protein-based NP 
vaccine improved T cell responses significantly, but not antibody responses.
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Figure 2. Vaccination with wild-type nucleoprotein (NPwt) protein with Matrix-M™ adjuvant or 
recombinant Modified Vaccinia virus Ankara (rMVA)-NPwt induced NP-specific splenocyte 
responses. Spleens obtained 14 days after the booster vaccination were stimulated with purified NPwt 
protein. The number of interleukin (IL-)2 (A), interferon (IFN-)ɣ (B) and IL-2/IFN-ɣ (C)-producing T cells 
was used to determine NP-specific splenocyte activation in spot-forming units (SFU)/106 cells. Samples 
were tested in triplicate. Mean of each group is indicated. MM = Matrix-M™ adjuvant. * p<0.0306; 
** p<0.0082; *** p=0.0005.
Modification of NP does not enhance NP-specific cytotoxic T cells in BALB/c mice
In order to optimize the NP-specific CD8+ cytotoxic T cell response, modifications 
were made to the NP protein that aimed at increasing protein processing and 
subsequent antigen presentation. Various NP mutant constructs were generated. 
First, the nuclear localization signal (NLS) of NP was mutated (NPmut) or deleted 
(NPΔNLS) to retain the protein in the cytosol and increase the amount of protein 
available for proteasomal processing341,356,357. Secondly, NP was fused to ubiquitin 
(UbqNP), a small molecule marking proteins for proteasomal degradation341,362. 
Previously, we have shown that these modified proteins could be expressed by rMVA 
and were immunogenic in C57BL/6 mice341. To determine whether the modified NP 
constructs are capable of inducing stronger NP-specific T cell responses than NPwt 
in BALB/c mice, animals were vaccinated twice with rMVA-NPwt, rMVA-NPmut, 
rMVA-NPΔNLS or rMVA-UbqNP. Wild-type (wt)MVA was used as a negative empty-
vector control. The rMVA-based vaccines were compared to vaccination with 10µg 
NPwt protein formulated with 5µg Matrix-M™ adjuvant (Table 2).
NP-specific antibody responses were determined using serum collected 21 and 
10 days after the first and booster vaccination, respectively. Similar to the results 
obtained in the initial experiment, vaccination with NPwt protein + Matrix-M™ 
adjuvant did not induce an NP-specific antibody response after a single vaccination. 
However, after two vaccinations both IgG1 and IgG2a NP-specific antibodies were 
detected with a bias towards IgG1 (Fig. 3A, C). The IgG1 response of the adjuvanted 
protein vaccine was significantly higher than the response induced by the rMVA-
NP constructs (Fig. 3C). rMVA-NPwt induced NP-specific IgG2a antibodies after a 
single vaccination. Similar results were obtained for vaccination with rMVA-NPmut. 
In contrast, rMVA expressing NPΔNLS (not statistically significant) or UbqNP 
seemed less immunogenic (Fig. 3B). The differences in the induction of NP-specific 
IgG2a antibodies by the various rMVA-NP constructs was not detected after two 
vaccinations (Fig. 3D). NP-specific antibody responses induced by the empty vector 
(wt)MVA were never observed (Fig. 3).
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Table 2. Recombinant Modified Vaccinia virus Ankara (rMVA)-based vaccines expressing (modified) 
nucleoprotein (NP) used to address optimization of the NP-specific CD8+ T cell response. 
Vaccine n Formulation
Protein 10 10µg NPwt + 5µg Matrix-M™ adjuvant
rMVA 5 108 PFU wtMVA
10 108 PFU rMVA-NPwt
10 108 PFU rMVA-NPmut
10 108 PFU rMVA-NPΔNLS
10 108 PFU rMVA-UbqNP
BALB/c mice were vaccinated twice at a 4-week interval with the respective vaccines. Mice were 
euthanized 10 days after the booster vaccination; n indicates the number of animals per group. PFU = 
plaque-forming units.
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Figure 3. Nucleoprotein (NP)-specific antibody responses induced by vaccination with NP wild-
type (NPwt) protein + Matrix-M™ adjuvant or the respective recombinant Modified Vaccinia virus 
Ankara (rMVA)-NP constructs. Immunoglobulin (Ig)G1 and IgG2a NP-specific antibody responses in 
mice 21 days after the primary vaccination (A-B) or 14 days after booster vaccination (C-D). IgG1 (A & 
C) or IgG2a (B & D) serum antibodies were detected using purified NPwt protein and anti-IgG1 or anti-
IgG2a horseradish peroxidase (HRP)-conjugated antibodies. Mean for each group is indicated. MM = 
Matrix-M™ adjuvant. * p<0.0432; ** p<0.0068; *** p<0.0009; **** p<0.0001.
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Subsequently, NP-specific T cell responses induced by vaccination with 10µg NPwt 
protein with 5µg Matrix-M™ adjuvant or the respective rMVA-NP vaccines were 
addressed using two different assays. Using the FluoroSpot assay, the induction 
of specific T cells was demonstrated by detection of IL-2-, IFN-ɣ- or IL-2/IFN-ɣ-
producing cells after splenocyte stimulation with an NP147–155 peptide, representing 
a CD8+ T cell epitope. wtMVA vaccination was used as a negative control and did 
not induce any NP147–155-specific T cell responses (Fig. 4). NP147–155-specific IL-2-, 
IFN-ɣ- or IL-2/IFN-ɣ-producing T cells were detected for all rMVA-NP vaccine groups 
(Fig. 4A-C). In general, the number of IL-2-, IFN-ɣ- or IL-2/IFN-ɣ-producing cells 
induced by the respective rMVA-NP vaccines were similar, although the number of 
virus-specific T cells induced by rMVA-NPΔNLS seemed slightly elevated and by 
rMVA-UbqNP seemed slightly reduced compared to rMVA-NPwt (Fig. 4A-C). Similar 
to the first experiment, NPwt protein + Matrix-M™ adjuvant vaccination induced 
similar numbers of IL-2- or IL-2/IFN-ɣ-producing cells compared to rMVA-NPwt. In 
contrast, the numbers of IFN-ɣ-producing cells after protein-based vaccination was 
significantly lower than after rMVA-NP vaccination (Fig. 4B).
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Figure 4. Vaccine-induced nucleoprotein (NP)-specific T cell responses. (A-C) Splenocytes were 
stimulated with the NP147–155 peptide after which the number of interleukin (IL-)2 (A), interferon (IFN-)ɣ (B) 
or IL-2/IFN-ɣ (C) spot-forming units (SFU)/106 splenocytes were determined. Samples were measured 
in triplicate. The mean for each group is indicated. (D) Splenocytes were stimulated with the NP147–155 
peptide for 12h. Using flow cytometry, live splenocytes were selected and subsequently CD3+, CD8+ and 
IFN-ɣ+ cells were gated. Representative graphs of mice vaccinated with wild-type Modified Vaccinia virus 
Ankara (wtMVA) as a control or recombinant MVA (rMVA)-NPwt are shown. (E) IFN-ɣ production of CD3+ 
CD8+ splenocytes per 106 events measured using flow cytometry. Mean for each group is indicated. MM 
= Matrix-M™ adjuvant. * p<0.0227; ** p=0.0073; *** p=0.0005; **** p<0.0001.
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The vaccine-induced NP-specific T cell responses were also assessed using flow 
cytometry. IFN-ɣ production after stimulation of splenocytes with NP147–155 peptide 
was used to measure induction of NP-specific CD3+ CD8+ T cells (Fig. 4D). A 
similar pattern to the FluoroSpot data was observed; all rMVA-NP vaccine groups 
induced NP-specific CD3+ CD8+ IFN-ɣ-producing cells and, although not statistically 
significant, rMVA-NPΔNLS induced slightly elevated and rMVA-UbqNP slightly 
reduced numbers of IFN-ɣ-producing T cells compared to rMVA-NPwt (Fig. 4E). 
The use of NPwt protein, in combination with Matrix-M™ adjuvant, induced an 
NP147–155-specific CD8
+ T cell response inefficiently (Fig. 4E). Thus, vaccination with 
rMVA-NP induced stronger NP-specific cytotoxic CD8+ T cells than with adjuvanted 
recombinant NP preparation. However, MVA-driven expression of NP modified in 
order to increase its processing and presentation did not result in increased T cell 
responses in BALB/c mice.
Discussion
In this study, we investigated the immunogenicity of various influenza virus NP-
based vaccines. Influenza virus NP is relatively conserved and an interesting target 
for the induction of (cross-)protective immune responses to influenza virus. Both NP-
specific antibodies188,189,411 and T cells412 have been shown to contribute to protective 
immunity to influenza virus infections. Here, we compared the immunogenicity of 
unadjuvanted and Matrix-M™ adjuvanted protein and rMVA expressing NPwt or 
modified NP for their capacity to induce influenza virus NP-specific antibody and T 
cell responses in BALB/c mice.
Differential induction of NP-specific antibodies was observed after protein or MVA-
based NP vaccination (Fig. 1). As rMVA expresses full-length NP similar to the way it 
is expressed in influenza virus infection, it is likely that NP is exposed on the surface 
of rMVA-NP infected cells, leading potentially to more efficient induction of antibody 
responses after a single vaccination compared to vaccination with NPwt protein. The 
effect of this differential induction of antibody responses on a challenge infection was 
not addressed in this study.
As MVA is a replication-deficient virus capable of infecting cells it has intrinsic 
adjuvant capacities, such as activation of the innate immune system413,414 – including 
activation of Toll-like receptors (TLRs)243. Matrix-M™ adjuvant also recruits and 
activates innate immune cells, but does not activate TLRs. The Matrix-M™ adjuvant 
increases antigen uptake and processing406,415,416, resulting in a significant increase 
in the cellular immune response to NP, as demonstrated by the detection of IL-2- 
and/or IFN-ɣ-producing splenocytes that were stimulated with NP in vitro. Also, after 
vaccination with rMVA-NPwt, potent cellular immune responses were observed 
dominated by IFN-ɣ- or IL-2/IFN-ɣ-producing cells, although the number of cells 
that produced IL-2 only seemed lower compared to vaccination with Matrix-M™ 
adjuvanted NP (Fig. 2). Of note, the concentration of protein or adjuvant used for 
vaccination did not make a significant difference in vaccine immunogenicity.
In an attempt to optimize the NP-specific CD8+ T cell response induced by vaccination, 
we previously generated rMVA constructs expressing modified NP. We have shown 
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that deletion of the NLS or fusion of NP to ubiquitin increased degradation of NP 
and enhanced activation of NP-specific T cells in vitro. However, these modifications 
did not improve CD8+ T cell responses in vivo or protection from a lethal challenge 
with influenza A virus in C57BL/6 mice341. We hypothesized that MVA-NPwt already 
induced an optimal T cell response in C57BL/6 (H-2Kb/Db) mice, because these 
mice mount a highly dominant CD8+ T cells response to a single epitope located in 
NP (NP366–374), which might mask any potential positive effects of the modifications. 
As this epitope is not recognized in in BALB/c mice (H-2Kd/Db), we addressed if 
differences in immunogenicity of the various rMVA-NP constructs could be detected in 
this mouse model and compared it to NPwt + Matrix-M™ protein-based vaccination.
The NP-specific IgG1 response induced by NPwt protein with Matrix-M™ adjuvant 
was significantly higher than the response induced by the rMVA-NP constructs (Fig. 
3C), similar to the trend in the first experiment (Fig. 1C). Furthermore, NPΔNLS 
and particularly UbqNP modifications resulted in lower IgG2a responses after a 
single vaccination, and lower IgG1 responses after two vaccinations compared to 
NPwt (Fig. 3B-C). As these vaccines were designed to enhance NP degradation, 
the amount of antigen and the time window that these antigens are available for 
antibody recognition and induction of B cell responses is limited. Therefore, induction 
of lower antibody responses by these constructs is not surprising. However, after two 
immunizations comparable IgG2a responses were observed.
The induction of NP-specific CD8+ T cells was detected after stimulation of splenocytes 
with the H-2Kd restricted CD8+ T cell epitope NP147–155 using the FluoroSpot assay 
and flow cytometry after intracellular IFN-ɣ staining. IFN-ɣ responses measured 
by the FluoroSpot assay were significantly higher after vaccination with rMVA-NP 
constructs compared to NPwt + Matrix-M™ vaccination, whereas comparable low 
numbers of IL-2- and IFN-ɣ/IL-2-producing cells were detected. Using flow cytometry, 
no NP147– 155-specific CD8
+ T cells were detected after vaccination with NPwt + 
Matrix-M™ adjuvant, indicating that the protein vaccine generates a mainly antigen-
specific CD4+ T cell response. This can be concluded from the experiment shown in 
Fig. 2, in which splenocytes were stimulated with NP protein which predominantly 
activates CD4+ T cells.
Both in the FluoroSpot assay and using flow cytometry, rMVA-NPwt induced a NP-
specific CD8+ T cell response that could not be improved by modifying the NP protein 
(Fig. 4). Notably, rMVA-UbqNP even induced slightly lower levels of NP-specific T 
cells compared to rMVA expressing NPwt, NPmut or NPΔNLS (Fig. 4), possibly in 
contrast to our hypothesis, the result of reduced availability of NP for direct antigen 
processing and presentation or cross-presentation363,379,417. We have shown previously 
in pulse-chase experiments that the degradation kinetics vary for the different NP 
constructs; NPΔNLS and particularly UbqNP had a higher degradation rate than 
NPwt and NPmut341. Therefore, the kinetics of the induction of the T cell response 
could differ between the different rMVA-NP constructs. In general, experiments in 
C57BL/6 and BALB/c mice show that NPwt is already optimally processed and 
presented, and that this cannot be improved by increasing the number of peptides 
available for presentation to T cells.
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In conclusion, addition of the Matrix-M™ adjuvant to NPwt protein-based vaccines 
enhanced immunogenicity significantly, resulting in the induction of IgG2a as well as 
IgG1 antibody responses and increased T cell responses. Furthermore, rMVA-based 
NP vaccines seem to be capable of inducing a more diverse antibody (IgG1 and 
IgG2a) and cellular (IL-2, IFN-ɣ, IL-2/IFN-ɣ) response compared to protein-based 
NP vaccines, and only a single vaccination is enough to induce IgG2a antibody 
responses. The humoral and cellular immune response induced by rMVA expressing 
NPwt in BALB/c mice could not be enhanced further by increasing NP protein 
degradation. These results show that NP does not need any modifications to induce 
an optimal immune response.
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CHAPTER 3.3
Matrix-M™ adjuvant enhances immunogenicity of both protein- and 
Modified Vaccinia virus Ankara-based influenza vaccines in mice
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Influenza viruses continuously circulate in the human population and escape 
from recognition by virus neutralizing antibodies induced by prior infection 
or vaccination through the accumulation of mutations in the surface proteins 
hemagglutinin (HA) and neuraminidase (NA). Various strategies to develop an 
influenza vaccine that provides broad protection against different influenza 
A viruses are currently under investigation, including the use of recombinant 
viral vectors and adjuvants. The replication-deficient Modified Vaccinia virus 
Ankara (MVA) is a promising vaccine vector with an excellent safety record 
that can efficiently induce B- and T-lymphocyte responses specific for an 
antigen of interest. It is generally assumed that live vaccine vectors do not 
require an adjuvant to be immunogenic because the vector already mediates 
recruitment and activation of immune cells. In order to address this topic, 
BALB/c mice were vaccinated with either protein- or recombinant (r)MVA-
based hemagglutinin (HA) influenza vaccines, formulated with or without 
the saponin-based Matrix-M™ adjuvant. Co-formulation with Matrix-M™ 
adjuvant significantly increased HA vaccine immunogenicity, resulting in 
antigen-specific humoral and cellular immune responses comparable to those 
induced after vaccination with unadjuvanted rMVA-HA. Of special interest, the 
immunogenicity of rMVA-HA was also enhanced by the addition of Matrix-M™ 
adjuvant, as was demonstrated by enhanced hemagglutinin inhibition antibody 
titers and cellular immune responses. Matrix-M™ adjuvant added to either 
protein- or rMVA-based HA vaccines mediated recruitment and activation of 
antigen-presenting cells and lymphocytes to the draining lymph node at 24 
and 48 hours post-vaccination. Taken together, these results suggest that 
adjuvants can not only be used with protein-based vaccines, but also in 
combination with rMVA to increase vaccine immunogenicity, which may be a 
step forward to generate new and more effective influenza vaccines. 
Introduction
Influenza A (H1N1 and H3N2) and B viruses cause respiratory tract infections and 
are responsible for substantial morbidity and mortality during seasonal epidemics, 
particularly in patients at high risk, such as the elderly. Due to accumulation of 
mutations in the surface proteins hemagglutinin (HA) and neuraminidase (NA), 
the antigenic properties of the virus change continuously, resulting in escape from 
recognition by neutralizing antibodies induced by prior infection or vaccination4,17,18. 
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Furthermore, avian influenza viruses of various subtypes have been shown to infect 
humans sporadically382-384. Since virus neutralizing antibodies to these viruses are 
virtually absent in the human population, they are considered to have pandemic 
potential. 
Currently used inactivated influenza vaccines contain components from seasonal 
influenza viruses and aim at the induction of HA-specific neutralizing antibodies1,418. 
Despite annual assessment of virus strains to be included in the seasonal influenza 
vaccine, a mismatch between circulating influenza viruses and the vaccine strains 
occasionally occurs, resulting in reduced vaccine effectiveness317-319. Furthermore, 
novel tailor-made influenza vaccines need to be developed momentarily in case 
of an influenza virus pandemic. Clearly, there is a need for improved influenza 
vaccines that can be produced rapidly and are highly immunogenic, inducing broadly 
protective immunity to various influenza viruses.
Novel vaccine targets, adjuvants and delivery systems are under currently 
investigation to develop ‘next-generation’ influenza vaccines. Recombinant viral 
vaccine vectors, including Modified Vaccinia virus Ankara (MVA) and adenoviruses, 
can be used to drive expression of any antigen of interest, resulting in efficient 
induction of antigen-specific B- and T-lymphocyte responses209,280. Particularly MVA 
is considered to be of interest since it has an excellent safety record in humans, 
including immunocompromised individuals209,234,280,419. Design and rescue of 
recombinant (r)MVA expressing one or more antigens is relatively easy and can 
be performed rapidly, and large numbers of vaccine doses can be produced280. 
Previously, several rMVA vaccines expressing HA from various influenza viruses 
have been evaluated in vitro and in vivo, and have shown to be immunogenic and 
capable of inducing protective immunity against homologous and heterologous 
influenza virus infections209.
Another approach to enhance influenza vaccine immunogenicity is the use of 
adjuvants420. Adjuvants such as MF59, AS03, Alum, ISCOMATRIX® and Matrix-M™ 
adjuvant have successfully been evaluated in clinical trials in combination with 
seasonal and pandemic influenza vaccines, including inactivated whole virus, split-
virion, virosomal and virus-like particle vaccines391,401,402,421-424. Furthermore, MF59 
and AS03 have been approved for use in a seasonal and pre-pandemic A(H5N1) 
influenza vaccine, respectively425. Matrix-M™ adjuvant, made of Quillaja saponins 
formulated with cholesterol and phospholipids into nanoparticles, is known to 
augment Th1 and Th2 responses, induce antibodies of multiple subclasses, enhance 
immune cell trafficking and allow antigen dose-sparing390,392,393,398,426-428. Importantly, 
Matrix-M™-adjuvanted vaccines have been shown to have an acceptable safety 
profile in clinical trials391,401,402. Compared to other adjuvants, Matrix-M™ performed 
as well or better in combination with influenza vaccines in mice393,429.
In contrast to protein-based vaccines, which are poorly immunogenic without 
adjuvant, vector-based vaccines are generally thought not to require adjuvants due 
to the intrinsic adjuvant activity of the vector backbone245. However, recently it was 
shown that immunogenicity of malaria and Rift Valley Fever virus antigens expressed 
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from adenovirus or MVA was improved by addition of Matrix-M™ adjuvant 430,431. In 
the present study, we show that the immunogenicity of both HA protein- and MVA-
based influenza vaccines was enhanced by Matrix-M™ adjuvant. Co-formulation of 
either vaccine with Matrix-M™ adjuvant increased absolute immune cell numbers 
and activation in the lymph node (LN) draining the site of vaccination. 
Material and Methods
Matrix-M™ adjuvant
Novavax proprietary Matrix-M™ adjuvant consists of two individually formed 40nm sized particles, each 
with a different and well-characterized saponin fraction (Fraction-A and Fraction-C). The Matrix-A and 
-C particles are formed by formulating purified saponin from the tree Quillaja saponaria Molina with 
cholesterol and phospholipid397.
Preparation of HA protein
Recombinant HA (H1N1, A/Puerto Rico/8/34 [PR8]) was produced in HEK293F cells as an amino-terminal 
His-tagged fusion protein containing a linker sequence (PGGPGS) and mcaspase3 cleavage site (DELD) 
but lacking the HA transmembrane sequence. The secreted (His6-PGGPGSDELD)-HA protein was 
purified by metal affinity chromatography. After mcaspase treatment (E/S mass ratio: 1/30), the protein 
solution was loaded on a Superdex G200 gel filtration column and the HA were fractions pooled. Analysis 
by SDS-PAGE/CBB staining and western blot showed that mature (cleaved) HA protein was obtained with 
a purity of at least 90%.
Generation of rMVA-HA
rMVA expressing HA under control of the early/late vaccinia virus promotor PsynII using the MVA clonal 
isolate F6, was produced as previously described256. In short, the codon-optimized HA nucleotide sequence 
(PR8, accession number CY033577) was purchased from Baseclear B.V. and rMVA was prepared 
through mCherry-dependent plaque selection in chicken embryo fibroblasts (CEF). To generate a final 
vaccine preparation, the virus was amplified in CEF, purified by ultracentrifugation through 36% sucrose 
and reconstituted in 120mM NaCl, 10mM Tris-HCl pH 7.4. rMVA-HA constructs were characterized by 
PCR, sequencing, plaque titration, western blot and in vitro infection of various cell types.
Vaccination of BALB/c mice
Specified pathogen free female BALB/c mice (8-10-week-old) were purchased from Charles River 
Laboratories (Germany). Animals were housed in Makrolon type 3 cages, had access to food and water 
ad libitum and animal welfare was observed daily. All experiments were conducted in compliance with 
European guidelines and the protocol approved by an independent animal experimentation ethical review 
committee (Uppsala djurförsöksetiska nämnd). Two separate experiments were performed. In the first 
experiment, mice (n=5 or 8/group) received two vaccinations with 108 plaque-forming units (PFU) of 
rMVA-HA or 1 or 10µg of HA, formulated with or without 5µg Matrix-M™, at a four-week interval. All 
vaccines were administered subcutaneously (s.c.) in 100µL at the base of the tail. Blood samples were 
obtained at day 21 and day 42. Spleens were collected in PBS during necropsy. In the second experiment 
mice (n=30/group) were immunized intramuscularly (i.m.) in the hind leg with a volume of 50µL containing 
108 PFU rMVA-HA or 10µg HA with or without 5µg Matrix-M™. The inguinal LN draining the hind leg 
muscle was collected in PBS at 4h, 24h or 48h post-vaccination(n=10/group/time-point).
Detection of IgG1 and IgG2a HA-specific serum antibodies
Quantification of HA-specific IgG1 and IgG2a antibodies was performed by ELISA as described 
previously393. Briefly, 96-well Maxisorp microplates (Nunc) coated overnight (O/N) at 4°C with 50ng/well 
HA protein in 0.05M Carbonate/Bicarbonate buffer (Sigma Aldrich). Serum from untreated mice and HA-
positive mouse serum was used as negative or positive control, respectively. IgG1 and IgG2a anti-HA 
titers were calculated using a four-parameter logistic equation (Softmax software, Molecular Devices). 
The inflection point of the titration curve (EC50 value) was taken as titer value.
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Hemagglutination Inhibition (HI) assay
Sera were treated with a receptor-destroying enzyme (filtrate of V. Cholera) O/N at 37oC followed by heat-
inactivation at 56oC. Sera were titrated in a 2-fold-serial dilution. The HI assay was performed in duplicate 
following a standard protocol with 1% turkey erythrocytes and four HA-units of influenza virus PR8, as 
described previously348.
Fluorospot analysis of antigen-stimulated splenocytes 
Single cell suspensions from spleens of individual mice, prepared as previously described393, were 
seeded on filter plates coated with anti-interleukin 2 (IL-2) and/or anti-interferon gamma (IFN-ɣ) 
antibodies (Mabtech), at 0.25 x 106 cells/well in culture medium (Roswell Park Memorial Institute, Sigma 
Aldrich) supplemented with 10% heat-inactivated fetal bovine serum (Sigma Aldrich) and 100U/ml 
penicillin, 100µg/ml streptomycin, 2mM L-glutamin (Sigma Aldrich), followed by stimulation with 0.5μg/
well HA protein. Concanavalin A (Sigma Aldrich) and culture medium were used as positive and negative 
controls, respectively. Triplicate samples were incubated for 18h at 37°C and IL-2 and/or IFN-ɣ spots were 
developed according to the manufacturer’s instructions (Mabtech). Spots were detected using an AID 
ELR02 ELISpot reader (Autoimmune Diagnostika GmbH).
Flow cytometry analysis of immune cells in the dLN
Single cell suspensions from the draining (d)LN, prepared as described previously393, were stained with 
FVS780 (BD Biosciences) for 15min at room temperature to exclude dead cells during analysis. Cells were 
washed and resuspended in FACS buffer (PBS with 0.5% bovine serum albumin, 2mM EDTA and 0.1% 
NaN3,) and incubated for 20min at 4°C with anti-mouse CD16/CD32 (2.4G2, BD Biosciences). 5x105 cells/
well were transferred to a 96-well microtiter plate (Nunc) and incubated with anti-mouse CD86FITC (GL1), 
I-A/I-EBV605 (M5/114), CD8aBV650 (53-6.7), CD19PerCP-Cy5.5 (1D3), CD3ePerCP-Cy5.5 (145-2C11), Ly-6GBV786 (1A8) 
(all BD Biosciences) and CD169AlexaFluor647 (3D6.112), CD11cBV650 (N418), Ly-6CAPC (HK1.4), CD69BV421 
(H1.2F3), CD3ePE (145-2C11), F4/80BV421 (BM8), CD11bPE (M1/70), CD49bAPC (DX5) and CD4BV785 (RM4-
5) (all Nordic Biosite) for 30min at 4°C. Fluorescence minus one controls were prepared for each antibody 
in all antibody panels at acquisition time points. Samples were analyzed on FACSCelesta with FACSDiva 
software (BD Biosciences).
Statistical analysis
Serological and cellular data were analyzed using one-way ANOVA with Tukey’s post test for multiple 
comparisons or Kruskal-Wallis with Dunn’s multiple comparisons test when applicable. 
Results
Addition of Matrix-M™ adjuvant enhanced HA-specific humoral responses
To assess HA-specific antibody responses after vaccination with either protein- or 
rMVA-based vaccines with or without Matrix-M™ adjuvant, mice were immunized at 
day 0 and 28. At 21 days after the primary vaccination, HA-specific serum antibody 
responses were detected in all groups. Strongest antibody responses of both IgG1 
and IgG2a were detected after vaccination with 10µg HA adjuvanted with Matrix-M™. 
Without Matrix-M™, protein-based HA vaccines induced IgG1 and IgG2a responses 
inefficiently. After one immunization with rMVA-HA, HA-specific IgG1 and IgG2a 
antibody responses were induced, which were not further enhanced by Matrix-M™ 
addition (Fig. 1A-B). Fourteen days after the second vaccination, HA-specific IgG1 
and IgG2a levels were boosted in all groups (Fig. 1C-D). Addition of Matrix-M™ to 
both HA doses significantly increased IgG1 responses compared to unadjuvanted HA 
or rMVA-HA vaccination with or without Matrix-M™ (Fig. 1C). The IgG2a responses 
after the second vaccination were comparable between Matrix-M™-adjuvanted HA 
groups and both rMVA-HA vaccine groups, and were elevated compared to the 
unadjuvanted HA group (Fig. 1D). Use of Matrix-M™ did not increase IgG1 or IgG2a 
responses after the second vaccination with rMVA-HA. 
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Figure 1. HA-specific antibody responses induced after vaccination with HA protein or rMVA-
HA with or without Matrix-M™ adjuvant. (A-B) IgG1 and IgG2a HA-specific antibody responses 21 
days after the primary vaccination. (C-D) IgG1 and IgG2a HA-specific antibody responses 14 days after 
the booster vaccination. IgG1 (A, C) or IgG2a (B, D) serum antibodies were detected by ELISA using 
purified HA protein and anti-IgG1 or anti-IgG2a HRP-conjugated antibodies. Data is shown as mean 
±95% confidence interval (CI). * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. MM = Matrix-M™ adjuvant.
Next, HI antibody titers were determined, which is considered a good proxy for the 
virus-neutralizing antibody response. In contrast to the IgG1 and IgG2a responses 
detected after primary vaccination, mice vaccinated with rMVA-HA displayed 
significantly elevated HI titers compared to those vaccinated with HA, regardless 
of antigen dose and use of adjuvant (Fig. 2A). After booster vaccination, HI titers 
were detected in mice receiving Matrix-M™-adjuvanted HA, whereas lower HI titers 
were detected in only two out of five mice receiving unadjuvanted HA. After two 
immunizations, Matrix-M™-adjuvanted HA induced similar HI titers as rMVA-HA 
vaccination (Fig. 2B). Of special interest, higher HI titers were observed in mice 
vaccinated with Matrix-M™-adjuvanted rMVA-HA compared to mice that received 
unadjuvanted rMVA-HA.
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Figure 2. Induction of HA-specific HI antibody responses after vaccination with rMVA-HA 
adjuvanted with Matrix-M™. HI serum antibody responses against influenza virus A/Puerto Rico/8/34 
(H1N1) were measured 21 days after the primary (A) or 14 days after the booster (B) vaccination. Data is 
shown as mean ±95% CI. * p<0.05, ** p<0.01, *** p<0.001. MM = Matrix-M™ adjuvant.
Addition of Matrix-M™ adjuvant enhanced HA-specific cellular responses
To investigate HA-specific T-lymphocyte responses after booster vaccination, 
splenocytes were stimulated with HA protein and the number of IL-2 and/or IFN-ɣ 
producing cells was measured. Matrix-M™-adjuvanted HA and rMVA-HA, with 
or without Matrix-M™, induced significantly more IL-2 and/or IFN-ɣ producing 
splenocytes than HA alone. Unadjuvanted HA hardly induced any IL-2 and/or IFN-ɣ 
splenocyte responses (Fig. 3A-C). In contrast, co-formulation of HA with Matrix-M™ 
resulted in higher IL-2 responses compared to rMVA-HA, adjuvanted or not, whereas 
rMVA-HA induced higher IFN-ɣ responses compared to adjuvanted HA (Fig. 3A-C). 
Mice vaccinated with Matrix-M™-adjuvanted rMVA-HA displayed stronger IL-2, IFN-ɣ 
and IL-2/IFN-ɣ double-positive responses compared those receiving unadjuvanted 
rMVA-HA, although the differences were exclusively statistically significant for the 
IL-2 response (Fig. 3A-C).
Figure 3. Enhanced HA-specific splenocyte responses by Matrix-M™ adjuvanted vaccines. 
Spleens obtained 14 days after the booster vaccination were stimulated with purified HA protein and the 
number of IL-2 (A), IFN-ɣ (B) and IL-2/IFN-ɣ (C) producing splenocytes was determined in spot-forming 
units (SFU)/106 cells by Fluorospot assay. Samples were tested in triplicate. The mean ±95% CI of each 
group is indicated. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. MM = Matrix-M™ adjuvant.
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Matrix-M™ adjuvanted vaccines increased cell numbers in the dLN
Since addition of Matrix-M™ adjuvant to either protein- or MVA-based vaccines 
increased both HA-specific humoral and cellular immune responses, the early cellular 
immune response in the dLN was evaluated after vaccination with the respective 
vaccines in presence or absence of Matrix-M™. Mice were vaccinated i.m. with HA 
or rMVA-HA, with or without Matrix-M™, and dLNs were collected 4h, 24h and 48h 
post-vaccination. At 4h post-vaccination the mean number of total cells in the dLN 
of all vaccine groups was similar (Fig. 4A). In contrast, after 24h and 48h the total 
cell count per dLN of mice vaccinated with adjuvanted HA or rMVA-HA showed more 
than a two-fold increase compared to the unadjuvanted groups (Fig. 4A). Of note, 
although not as strong as the Matrix-M™ adjuvanted vaccines, vaccination with 
unadjuvanted rMVA-HA also resulted an increase in cell count per dLN. 
A
C
el
l c
ou
nt
 / 
dL
N
 (x
10
5 )
C
C
el
l c
ou
nt
 / 
dL
N
 (x
10
4 )
D
C
el
l c
ou
nt
 / 
dL
N
 (x
10
6 )
HA
HA+MM
rMVA-HA
rMVA-HA+MM
Monocytes
****
************
********
** *******
0.0
2.5
5.0
7.5
10.0
12.5
15.0
0
1
2
3
4
5
6
Medullary sinus macrophages
******** ****
**** ****
**** ********
****
Total number of cells
5
10
15
20
****
******
******** *** ***********
0
4 24 48
hours post-vaccination
4h 24h 48h
H
A
H
A 
+ 
M
M
rM
VA
-H
A
rM
VA
-H
A+
M
M
B
NK cells
Neutrophils
Dendritic cellsB-lymphocytes
CD4+ T-lymphocytes
CD8+ T-lymphocytes Monocytes
Other
CD169+ macrophages
Figure 4. Matrix-M™ adjuvanted influenza vaccines induce influx of immune cells in the dLN with 
maintained composition of cellular subsets except for an increased monocyte population. (A) 
The total number of cells per dLN. (B) Contribution (%) of the indicated cellular subsets in the dLN was 
measured by flow cytometry at 4, 24 or 48 h after i.m. vaccination. (C-D) Total cell count of CD11b+ Ly6C+ 
monocytes (C) and CD169+ F4/80+ medullary sinus macrophages (D) was determined by flow cytometry. 
Data are shown as mean of 10 mice per group. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. MM = 
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The relative contribution of different cell populations (Fig. S1) to the total cell number 
in each dLN (n=10/group) was determined. At all time-points, regardless of vaccine 
type or use of adjuvant, CD4+ T-lymphocytes comprised the largest proportion of the 
total cell population, followed by CD8+ T- and B-lymphocytes (Fig. 4B). No significant 
difference in the percentage of neutrophils, macrophages, NK cells or DCs was 
observed (Fig. 4B). In contrast, mice vaccinated with Matrix-M™-adjuvanted HA or 
rMVA-HA, and to a lesser extent unadjuvanted rMVA-HA, showed a strong increase 
in proportion and total number of monocytes in the dLN over time, indicating 
recruitment and/or proliferation (Fig. 4B-C). Notably, the number of medullary 
sinus macrophages (CD169+ F4/80+) was increased by Matrix-M™-adjuvanted HA 
and rMVA-HA at 24h and 48h after vaccination compared to unadjuvanted vaccine 
preparations (Fig. 4D). At 48h the unadjuvanted rMVA-HA group showed an increase 
in medullary sinus macrophages compared to the unadjuvanted HA group, but to a 
lesser extent compared to adjuvanted vaccines.
Cell activation in the dLN after vaccination with Matrix-M™ adjuvanted vaccines
Activation of different cellular subsets was investigated by measuring expression 
of CD69 (early activation marker432), CD86 (T-lymphocyte co-stimulatory signal433) 
and/or MHC class II (often upregulated on antigen-presenting cells (APC) after 
activation). Expression of both CD69 and CD86 was upregulated on DCs, monocytes 
and B-lymphocytes 24h and 48h after vaccination with either Matrix-M™-adjuvanted 
HA or rMVA-HA compared to the respective unadjuvanted vaccine preparation (Fig. 
5A-B). Unadjuvanted rMVA-HA also induced an increase in CD69+ and CD86+ DCs, 
monocytes and B-lymphocytes compared to unadjuvanted HA at 24h and 48h post-
vaccination, however, only to a limited extent compared to the adjuvanted vaccines 
(Fig. 5A-B). In addition to the increase in CD69+ and CD86+ APCs, MHC class II 
expression in DCs was elevated at 24h and 48h post-vaccination with Matrix-M™-
adjuvanted vaccine preparations (Fig. 5C). CD69 expression was also assessed for 
T-lymphocytes and NK cells. The number of CD69+ NK cells and T-lymphocytes was 
significantly increased after vaccination with Matrix-M™-adjuvanted HA, or rMVA-
HA, compared to their unadjuvanted counterparts (Fig. 6A-C).
Altogether, rMVA-HA induced relatively more activation, recruitment and/or 
proliferation of APC and lymphocytes than unadjuvanted HA. However, addition 
of Matrix-M™ adjuvant to either protein- or MVA-based HA vaccines significantly 
increased activation and recruitment and/or proliferation for both vaccine preparations.
Discussion
Adjuvants increase vaccine immunogenicity via different mechanisms, including 
antigen delivery and general activation of innate immune responses434. Although use 
of adjuvants for protein-based vaccines is well established and essential for efficient 
immune responses, addition of adjuvants to vector-based influenza vaccines has 
not been previously studied. Here, the immunogenicity of influenza virus HA and 
rMVA-HA vaccines was tested in the presence and absence of Matrix-M™ adjuvant. 
Although unadjuvanted rMVA-HA was more immunogenic than unadjuvanted HA, 
co-formulation of either vaccine preparation with Matrix-M™ enhanced HA-specific 
immune responses and increased the cell number and activation in the dLN.
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For induction of proper HA-specific antibody responses of IgG1 (indicative of Th2 
responses) or IgG2a (indicative of Th1 responses) subclasses, addition of Matrix-M™ 
adjuvant to HA was required, but not to rMVA-HA. After two immunizations, adjuvanted 
HA induced significantly higher IgG1 antibody responses than rMVA-HA, whereas 
IgG2a antibody responses were similar. This is in line with previously published data 
showing that MVA-based vaccines preferentially induce Th1 responses209,280. The 
observed potentiating effect of Matrix-M™ on the IgG2a antibody responses has 
been shown previously with various vaccine preparations in mice392,393,398. Induction 
of potent IgG2a responses bares relevance, as murine IgG2 has key immunological 
effector functions, such as enhanced FcɣR binding important for protection against 
viral infection435. Accordingly, passive immunization with HA stalk-specific IgG2a 
antibodies has shown to protect mice against influenza virus infection, while HA 
stalk-specific IgG1 antibodies did not45. To induce functional antibodies a single 
vaccination with rMVA-HA was sufficient for generating acceptable HI antibody 
titers, whereas for HA, regardless of co-formulation with Matrix-M™ adjuvant, two 
vaccinations were required. This may reflect a better conformational integrity of HA 
expressed in vivo by rMVA-HA. Strikingly, addition of Matrix-M™ adjuvant to the 
rMVA-HA vaccine significantly increased the HI antibody response. 
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*** p<0.001, **** p<0.0001. MM = Matrix-M™ adjuvant.
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Addition of Matrix-M™ adjuvant to HA potentiated HA-specific IFN-ɣ and IL-2/IFN-ɣ 
cellular responses significantly compared to HA alone, in concordance with previous 
studies390,392,398,410. Interestingly, mice vaccinated with rMVA-HA showed stronger 
IFN-ɣ responses than those vaccinated with adjuvanted HA. The rMVA-HA induced 
cellular responses could be even further increased by addition of Matrix-M™. 
Although the phenotype of the responding cells was not determined, these are most 
likely CD4+ T-lymphocytes as exogenous HA protein was used for stimulation. 
It was previously shown in mice that injection with Matrix-M™ adjuvant alone led to 
increased numbers of activated immune cells in the dLN compared to PBS or other 
adjuvants393,428. Here, the absolute number of cells in the dLN of mice vaccinated with 
Matrix-M™-adjuvanted HA or rMVA-HA vaccines was significantly higher compared to 
mice vaccinated with unadjuvanted vaccines 24h and 48h post-vaccination, indicative 
of proliferation and/or recruitment. The dLN cell composition was stable, except for 
an increase in monocytes after vaccination with adjuvanted vaccine preparations. 
Recruited monocytes could mature into DCs and/or macrophages in situ and 
subsequently act as professional APC436, potentially improving vaccine efficacy. This 
could also be the effect of the increase in CD169+ medullary sinus macrophages also 
detected in the dLN after injection with Matrix-M™-adjuvanted vaccines. Recently, 
CD169+ macrophages were shown to be important for the adjuvant properties of 
the saponin-based adjuvant QS21437. CD169+ macrophages haven been shown to 
transport antigens trapped inside the LN follicle to B-lymphocytes, and can cross-
present antigen directly to CD8+ T-lymphocytes438-440. Thus, the increase in CD169+ 
macrophages may play a role in the improved adaptive immune responses induced 
by Matrix-M™-adjuvanted vaccines. 
Vaccination with unadjuvanted rMVA-HA induced a relative increase in monocytes 
accompanied by increased activation of CD86+ DC, CD86+ B-lymphocytes and 
CD169+ macrophages, confirming that MVA has intrinsic adjuvant properties. Of 
interest, it was recently shown that APCs can be infected by MVA and detected in 
the dLN of various species including non-human primates342. Thus, the observed 
adjuvant capacities of MVA may be explained by direct infection of APCs, which 
travel to the dLN, shaping the immune response. 
In conclusion, our results show that influenza vaccines based on HA or rMVA-HA can 
be potentiated by Matrix-M™ adjuvant, resulting in improved humoral and cellular 
responses. This is potentially mediated by recruitment and activation of immune 
cells in the dLN. Combination of a vector-based vaccine with Matrix-M™ adjuvant 
might prove a promising step towards next-generation influenza vaccines.
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Supplementary Material
Figure S1. Gating strategy to define different immune cell populations in the draining lymph 
node. Live cells were defined as FVS780−, from which singlet cells were selected. Subsequently, CD3+ 
and CD19+ cells were selected and B-lymphocytes were further defined as CD19+ MHC class II+. The 
B-lymphocytes activation was assessed by CD86 and/or CD69 expression. All defined cell populations 
were gated in the same way for CD86 and/or CD69 expression. The CD3+ cells were further defined as 
CD4+ or CD8+ T-lymphocytes. NK cells were defined as CD3− CD49b+. Furthermore, from the singlet gate, 
cells were selected for CD11c or CD11b expression and the CD11c+ cells further selected for MHC class 
II expression and defined as dendritic cells. The CD11b+ cells were further defined into either Ly6G+ cells, 
i.e. neutrophils, or Ly6C+ cells, i.e. monocytes. Furthermore, from the singlet cells, cells were selected 
as non-CD3+ CD19+ cells and these cells were further selected for CD11b and CD169 expression and 
defined as subcapsular sinus macrophages and further defined as medullary sinus macrophages based 
on F4/80 expression. Data is shown from a mouse vaccinated with Matrix-M™ adjuvanted HA protein that 
is representative of the other mice and groups from the experiment.
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CHAPTER 4.1
Induction of cross-clade antibody and T cell responses by an MVA-
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Highly pathogenic avian influenza viruses of the H5 subtype continue to 
circulate in poultry and wild birds and occasionally infect humans, sometimes 
with fatal outcome. To prepare for potential future pandemics caused by these 
viruses, the development of effective H5 vaccines is considered a high priority. 
However, influenza vaccine development is complicated by antigenic variation 
of the surface glycoprotein hemagglutinin (HA), the most important target for 
virus-neutralizing antibodies. Here, we report the analysis of (cross-reactive) 
immune responses induced by immunization of humans with recombinant 
Modified Vaccinia virus Ankara expressing the HA gene of the H5N1 influenza 
virus A/Vietnam/1194/04 (rMVA-H5). In a double-blind phase 1/2a clinical trial, 79 
young healthy adults were randomly assigned to one of eight groups, receiving 
one or two intramuscular injections with 107 or 108 plaque-forming units of 
rMVA-H5 or MVA-F6 (vector control). Twenty-seven study subjects received a 
booster immunization after one year. The breadth, magnitude and properties of 
vaccine-induced antibody and T cell responses were characterised. rMVA-H5 
induced broadly-reactive antibody responses as demonstrated by protein 
microarray, hemagglutination inhibition, virus neutralization and antibody-
dependent cellular cytotoxicity assays. The results confirmed induction of 
antibodies with neutralizing and non-neutralizing modes of action, directed 
to antigenically distinct H5 influenza viruses, including the recently emerged 
H5N6 and H5N8 viruses and vaccine strains representing circulating H5N1 
viruses. In addition, the induction of T cells specific for H5 viruses of two 
different clades was demonstrated. The rMVA-H5 vaccine induced antibody 
and T cell responses that cross-reacted with H5 viruses of various clades. 
These findings validate rMVA-H5 as vaccine candidate with efficacy against 
antigenically distinct H5 influenza viruses.
Introduction
Highly pathogenic avian influenza (HPAI) viruses of the H5 subtype continue to 
cause outbreaks in poultry in various countries. Sporadically, these viruses – in 
particular influenza A viruses (IAV) of the H5N1 and H5N6 subtypes – infect humans, 
resulting in disease with variable severity. Since the first case of human infection 
with an H5N1 influenza virus in 1997441-443, 859 human cases have been reported 
as of July 2017 of which 453 had a fatal outcome382. In addition to circulating H5N1 
viruses, several novel H5 influenza virus subtypes have emerged, including H5N2444, 
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H5N5445,446, H5N6447 and H5N8446. Recently, H5N8 and related viruses have caused 
large outbreaks in wild birds and poultry in Asia, Europe and North America. To date, 
no human infections with H5N8 virus have been reported, however, there is evidence 
for H5N2 virus infections in humans448. Furthermore, since the first report in 2015, 
severe infections of humans with H5N6 virus continue to be reported sporadically23.
Although influenza viruses of the H5N1 and H5N6 subtype can infect humans, they 
do not have the ability to be transmitted from human-to-human efficiently. Studies 
in ferrets, the ‘gold standard’ model used to study IAV replication, pathogenesis and 
transmission, have shown that only a limited number of mutations in viral proteins 
hemagglutinin (HA) and the polymerase subunit PB2 are required to facilitate 
airborne transmission of an H5N1 virus19,21. If these H5N1 viruses acquire the 
capacity to be transmitted from human-to-human, they have the potential to cause 
severe a pandemic since the human population at large has not been exposed to 
these viruses and therefore virus neutralizing (VN) antibodies to these viruses are 
virtually absent.
Vaccination is the most important measure against IAV infections and the availability 
of an effective H5 vaccine would be pivotal in preventing severe disease, mortality 
and interrupting potential human-to-human transmission of H5 influenza viruses. 
Although a mock-up dossier allowing for fast track licensing of inactivated influenza 
vaccines produced through conventional methods has been drafted in Europe449, 
vaccines became available too late in most countries during the 2009 pandemic 
caused by an H1N1 influenza virus132,133. In addition to problems with production 
and distribution of sufficient vaccine doses during the earliest stages of a pandemic, 
conventional H5N1 vaccine formulations suffer from other problems, including 
intrinsically low immunogenicity compared to seasonal influenza vaccines. To 
overcome this problem, repeated vaccinations, increased antigen doses or use of 
adjuvants are required450. Furthermore, H5 vaccine development is complicated by 
the genetic diversification of H5 viruses into various clades and subclades leading to 
large antigenic diversity of HA451. Collectively, this illustrates the need for novel (pre-)
pandemic H5 vaccines that can be produced rapidly at a large-scale and ideally 
confer broad protection against antigenically distinct H5 viruses.
Vector-based H5 influenza vaccines, such as those based on Modified Vaccinia 
virus Ankara (MVA), potentially fulfill the needs described above. Since generation 
of recombinant (r)MVA by insertion of genes encoding antigens of interest into the 
viral genome is relatively easy, rMVA vaccine candidates have been developed for 
numerous infectious diseases, including influenza (reviewed by Altenburg et al.280 
& de Vries et al.209). rMVA drives endogenous antigen production in cells infected 
by the vector, leading to efficient and processing and presentation, and subsequent 
induction of antigen-specific B- and T cell responses. Furthermore, many viral 
vectors, including MVA, allow for rapid and large-scale production of vaccine doses. 
MVA has an excellent safety record as was demonstrated in various animal models, 
including immune-suppressed non-human primates, and clinical trials277,279,280.
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Previously, rMVA expressing the HA-gene of the clade 1 influenza virus A/
Vietnam/1194/04 (VN/04, rMVA-H5) was generated and assessed in pre-clinical 
studies. This vaccine proved to be safe and immunogenic in both C57BL/6 mice 
and non-human primates256,258,262, and offered protection from a lethal challenge 
with either the homologous or the antigenically distinct clade 2.1 H5N1 virus A/
Indonesia/5/05 (IND/05)256,262. Subsequently, rMVA-H5 was assessed in a double-
blind phase 1/2a clinical trial and proved to be safe in humans260. The immunogenicity 
of rMVA-H5 was solely assessed by detection of hemagglutination inhibition (HI) 
and VN antibodies against the homologous and two heterologous viruses; IND/05 
and clade 2.3.4.4 H5N8 A/chicken/Netherlands/EMC-3/2014 (ch/H5N8/14)260,261. 
Here, we report a detailed analysis of the antibody and T cell responses induced by 
immunization of humans with rMVA-H5, with emphasis on cross-reactivity with H5 
viruses of antigenically distinct clades. Such cross-reactivity was identified as a key 
step on the pathway to a universal influenza vaccine452
Materials & Methods
Ethics statement
The study design was reviewed and approved by the Central Committee on Research involving Human 
Subjects in the Netherlands. All volunteers provided written informed consent, the trial was registered in 
the Netherlands’ trial register under NTR3401.
Study design
A randomised, double-blind phase 1/2a study was previously conducted at the Erasmus MC, Rotterdam, 
the Netherlands260. Briefly, N=79 healthy adult volunteers (aged 18-28 years) were included in the study 
and randomly assigned to one of eight groups (N=10) on basis of the number of immunizations (one or two), 
the immunization dose (107 or 108 plaque-forming units [PFU]) and the vaccine administered (rMVA-H5 
or MVA-F6). The group receiving a single dose 108 PFU rMVA-H5 consisted of N=9 individuals. The 
rMVA-H5 vaccine expressed the HA gene of influenza virus VN/04 under control of the PsynII promotor. 
Immunization with MVA-F6 (empty vector) was used as a control. Immunizations were administered 
as intramuscular (IM) injections on the first (week 0) and second (week 4) visit. Blood samples were 
obtained at week 0, 4, 8 and 20. To assess whether the H5-specific immune response could be boosted 
by an additional immunization, N=27 individuals who received the rMVA-H5 vaccine during the main 
study received an additional immunization one year after the first immunization. Blood was drawn before 
(week 52), and 4 and 20 weeks after the booster immunization (week 56 and 72, respectively). Serum 
and peripheral blood mononuclear cells (PBMC) were obtained from all blood samples, as described 
previously260, and stored at -20ºC and -135ºC, respectively.
Protein array (PA) assay
Sera collected at the respective time-points were used to determine the presence of antibodies directed 
to a large panel of antigens by protein array (PA) as described previously346,347. In short, recombinant HA1 
derived from a selection of IAV were printed onto nitrocellulose slides by a sciFlexarrayer SX (Scienion). 
Sera were incubated on the slides in Blotto Blocking Buffer (Thermo Fisher Scientific Inc.) supplemented 
with 0.1% Surfact-Amps (Thermo Fisher Scientific Inc.). Subsequently, AlexaFluor647-labelled goat-
anti-human IgG (Jackson ImmunoResearch Laboratories Inc.) was used as conjugate and fluorescent 
signals were measured using a Powerscanner (Tecan Group Ltd). The titer of each serum sample was 
defined as the interpolated serum concentration generating the 50% point using a four-parameter logistic 
nonlinear regression model. Measured titers were corrected for the positive control included on each 
slide. PA titers against 18 different H5 antigens were determined, in addition to a single seasonal H1 
(A/NewCaledonia/20/99 [sH1N1]) and H3 (A/Wyoming/3/03 [sH3N2]) antigen, using recombinant HA1 
from influenza virus VN/04, A/chicken/Jilin/9/04 (H5N1, not assigned to a clade, JI/04), A/Cambodia/
R0405050/07 (H5N1, clade 1.1, CAM/07), A/duck/Hunan/795/02 (H5N1, clade 2.1.3.2, HUN/02), 
A/chicken/Yamaguchi/7/04 (H5N1, clade 2.5, YAM/04), IND/05, A/Anhui/1/05 (H5N1, clade 2.3.4, 
Anhui/05), A/Egypt/N03072/10 (H5N1, clade 2.2.1, Egypt/10), A/HongKong/156/97 (H5N1, clade 0, 
HK/97), A/Vietnam/HN31432M/08 (H5N1, clade 2.3.4.2, VN/08), A/Hubei/1/10 (H5N1, clade 2.3.2.1, 
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Hubei/10), A/chicken/Egypt/0879-NLQP/08 (H5N1, clade 2.2.1.1, Egypt/08), A/goose/Guiyang/337/06 
(H5N1, clade 4, GUI/06), A/duck/Hokkaido/167/07 (H5N3, lowly pathogenic avian influenza [LPAI], 
H5N3/07), A/Turkey/15/06 (H5N1, clade 2.2, TUR/06), A/chicken/Vietnam/NCVD-016/08 (H5N1, clade 
7, ch/VN/08), A/turkey/Germany-MV/R2472/14 (H5N8, clade 2.3.4.4, tu/H5N8/14), A/duck/NY/191255-
59/02 (H5N8, LPAI, H5N8/02) (Table 1, Fig. 1B).
Phylogenetic analysis
Phylogenetic trees of influenza viruses were based on the nucleotide sequences of the HA1 domain of the 
influenza virus HA gene. A phylogenetic tree based on the HA1 amino acid sequence was also drawn and 
showed similar results (data not shown). Multiple sequence alignment was performed using the MUSCLE 
algorithm integrated into MEGA 6.06457. The phylogenetic tree was drawn according to the Maximum 
likelihood method using the best-fit model in MEGA 6.06. Bootstrap analyses with 1,000 re-samplings 
were performed to determine confidence values for groupings within the phylogenetic tree. The tree was 
visualized in FigTree version 1.3.1 (http://tree.bio.ed.ac.uk/software/figtree). The clade 2.3.4.4 H5N8 virus 
tu/H5N8/14 was not included in the analysis due to sequence unavailability.
Hemagglutination inhibition (HI) assay
Sera were thawed, treated with a receptor-destroying enzyme (cholera filtrate) overnight at 37oC followed 
by heat-inactivation at 56°C. Sera were initially tested for aspecific agglutination and were pre-treated 
with horse erythrocytes if required. Subsequently, sera were tested in a 2-fold-serial dilution in duplicate 
(starting dilution 1:10) following a standard protocol with 2% horse erythrocytes in PBS supplemented 
with 0.5% BSA and four HA units of influenza virus. Presence of HI antibodies was determined using six 
different IAV: VN/04, IND/05, A/Duck/Bangladesh/19097/13 (H5N1 clade 2.3.2.1, BANG/13), A/Egypt/
N01753/14 (H5N1 clade 2.2.1.2, Egypt/14), A/Guangzhou/39715/14 (H5N6 clade 2.3.4.4, H5N6/14) 
and A/Chicken/Netherlands/EMC-3/14 (H5N8 clade 2.3.4.4, ch/H5N8/14) (Table 1, Fig. 1B). Reverse 
genetics viruses of the selected H5 viruses were used348. Egypt/14 and BANG/13 contained only the 
HA gene segment (without multibasic cleavage site, 7+1 viruses), other viruses also contained the NA 
gene segment (6+2 viruses). The remaining gene segments were obtained from influenza virus A/Puerto 
Rico/8/34. Sera from ferrets and New Zealand white rabbits inoculated with the homologous H5 viruses 
were used as positive controls.
Virus neutralization (VN) assay
Sera were tested in a VN assay, performed with the same reverse-genetic viruses used in the HI assay 
as described above (Table 1, Fig. 1B). VN assay was performed as described previously453, with small 
adaptations. Briefly, a 2-log dilution series (starting dilution 1:5) was prepared in infection medium (Eagle’s 
Minimum Essential Medium [EMEM, Sartorius Stedim BioWhittaker] supplemented with 20mM HEPES 
[Lonza BioWhittaker], 0.1% CHNaO3 [Lonza BioWhittaker], and 100ug/ml penicillin, 100U/ml streptomycin 
and 2mM L-Glutamine [P/S/G, Lonza]) and incubated for 18h with 100 or 1000 PFU/well of the selected 
influenza viruses in a 1:1 ratio at 37oC. Sera from ferrets and New Zealand white rabbits inoculated 
with the homologous H5 viruses were used as positive controls. Subsequently, the serum-virus mixture 
was incubated for 1h at 37oC on a confluent monolayer of Madin-Darby canine kidney (MDCK) cells in 
96-wells culture plates. Cells were washed with PBS and incubated for 2-5 days at 37oC. Influenza virus 
neutralization was determined by performing an HA assay on the culture supernatant to detect residual 
virus replication. The neutralization titer was determined as the reciprocal of the highest dilution at which 
the culture supernatant did not contain detectable influenza virus.
Antibody-dependent cellular cytotoxicity (ADCC) assay
A solid-phase ADCC assay was performed as described previously to measure presence of ADCC 
mediating antibodies454,455. Briefly, sera were thawed, heat-inactivated, diluted 1:160 and incubated for 2h 
at 37ºC on high-binding 96-well flat-bottom plates (Immunolon) coated overnight at 4ºC with 200ng/well 
recombinant HA protein from influenza virus VN/04 or IND/05 (made available by Protein Sciences, Table 
1, Fig. 1B). Subsequently, plates were washed and incubated with 1 x 105 NK92.05-CD16 cells456 per 
well in the presence of mouse-anti-human CD107a-V450 (BD Biosciences), golgistop and golgiplug (BD 
Biosciences) for 5h at 37oC. To identify live NK cells, staining with fixable LIVE/DEAD (Molecular Probes) 
and CD56-PE (BD Biosciences) was performed. After staining, cells were fixed and acquired on FACS 
Canto II and analyzed using DIVA software (BD Biosciences). The percentages of CD107a+ (marker of 
degranulation) cells were determined within the respective LIVE CD56+ NK cell populations454.
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IFN-ɣ ELISpot assay
HA-specific interferon (IFN)-ɣ responses were assessed in PBMC collected at week 0, 4, 8, 52 and 56 
by performing an enzyme-linked immunosorbent spot (ELISpot) assay, which was performed according 
to the manufacturer’s instructions (Mabtech). Briefly, PBMC were thawed, seeded into 96-wells U-bottom 
plates at 125.000 cells/well (less cells were used if not enough cells were available), and stimulated 
overnight with 500ng/well recombinant HA protein from influenza virus VN/04 or IND/05 (made available 
by Protein Sciences, Table 1, Fig. 1B). These antigen presenting cells (APC) were subsequently co-
cultured with 125.000 (or an equal amount of less cells if not enough cells were available) autologous, 
unstimulated PBMC for 22-24h in triplicate on plates pre-coated with a monoclonal anti-IFN-ɣ antibody 
(Mabtech). IFN-ɣ spots were developed using a monoclonal anti-IFN-ɣ antibody, followed by 7-B6-1-biotin 
and streptavidin-ALP, and subsequent BCIP/NBT substrate revelation. The average number of spots per 
125.000 cells cultured in triplicate was determined using a CTL immunospot reader with CTL biospot 
software.
Statistical analysis
HI and VN titers against different viruses (not normally distributed as tested by D’Agostino Pearson 
normality test) were compared by a Friedman test on paired samples. All individuals vaccinated with 
rMVA-H5 were analyzed as a single group, despite different dosing regimens. Different treatment groups 
(not normally distributed) were compared by a Kruskal-Wallis test. ADCC percentages at different time-
points (not normally distributed) were compared by a Friedman test on paired samples. A comparison 
between rMVA-H5- and MVA-F6-vaccinated individuals was made by performing a Mann-Whitney test 
on samples obtained at week 0, 4 and 8. All individuals vaccinated with rMVA-H5 were regarded a single 
group, despite different dosing regimens. Different treatment groups (normally distributed at week 0, 4 
and 8, not normally distributed at week 52, 56 and 72) were compared by a one-way ANOVA or a Kruskal-
Wallis test, respectively. Numbers of IFN-ɣ producing spot-forming cells (SFC) between mock-stimulated 
and VN/04- or IND/05-stimulated PBMC (not normally distributed) were compared by a Friedman test on 
paired samples. Numbers of IFN-ɣ producing SFC at different time-points (not normally distributed) were 
compared by a Friedman test on paired samples. All individuals vaccinated with rMVA-H5 were regarded 
a single group, despite different dosing regimens. Different treatment groups (not normally distributed) 
were compared by a Kruskal-Wallis test.
Results
H5-specific antibodies induced by rMVA-H5 immunization showed broad reactivity
In order to assess the breadth of the antibody response induced by rMVA-H5 
immunization, the profile of antibody binding to HA1 derived from 18 different H5 
influenza viruses belonging to various clades (Fig. 1A-B) was determined by PA 
using sera collected at week 0, 4, 8, 52 and 56 post-immunization (p.i.). HA1 derived 
from sH1N1 and sH3N2 influenza viruses were included on the array as controls.
H5-specific antibodies were readily detected at week 8, especially in subjects that 
received two immunizations with a high dose of rMVA-H5. H5-specific antibodies 
were still detectable at week 52, albeit at lower titers in the recipients of the high 
dose rMVA-H5. Of special interest, four weeks after the booster immunization given 
at week 52 (week 56), H5-binding antibodies were detected in all subjects that 
received rMVA-H5 (Fig. 1A). These results correspond well to data from the original 
study260, which showed that low levels of HI and VN antibodies were induced after 
the first and second immunization and that the booster immunization at week 52 
resulted in a major increase in antibody titers. Antibody levels waned four months 
after the booster (week 72) in subjects that received the low vaccine dose (107 PFU). 
In contrast, high levels of H5-specific antibodies remained detectable in subjects 
immunized with the high dose (108 PFU) of rMVA-H5 (Fig. 1A).
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Table 1. Antigens used in various assays.
Strain name Abbreviation Subtype Clade Pathogenicity Assays
A/NewCaledonia/20/99 sH1N1 H1N1 - seasonal PA
A/Wyoming/3/03 sH3N2 H3N2 - seasonal PA
A/duck/Hokkaido/167/07 H5N3/07 H5N3 - LPAI PA
A/duck/NY/191255-59/02 H5N8/02 H5N8 - LPAI PA
A/HongKong/156/97 HK/97 H5N1 0 HPAI PA
A/Vietnam/1194/04 VN/04 H5N1 1 HPAI PA / HI / VN / ADCC / T cell
A/Cambodia/R0405050/07 CAM/07 H5N1 1.1 HPAI PA
A/Indonesia/5/05 IND/05 H5N1 2.1 HPAI PA / HI / VN / ADCC / T cell
A/duck/Hunan/795/02 HUN/02 H5N1 2.1.3.2 HPAI PA
A/Turkey/15/06 TUR/06 H5N1 2.2 HPAI PA
A/Egypt/N03072/10 Egypt/10 H5N1 2.2.1 HPAI PA
A/chicken/Egypt/0879-NLQP/08 Egypt/08 H5N1 2.2.1.1 HPAI PA
A/Egypt/N01753/14 Egypt/14 H5N1 2.2.1.2 HPAI HI / VN
A/Hubei/1/10 Hubei/10 H5N1 2.3.2.1 HPAI PA
A/duck/Bangladesh/19097/13 BANG/13 H5N1 2.3.2.1 HPAI HI / VN
A/Anhui/1/05 Anhui/05 H5N1 2.3.4 HPAI PA
A/Vietnam/HN31432M/08 VN/08 H5N1 2.3.4.2 HPAI PA
A/turkey/Germany-MV/R2472/14 tu/H5N8/14 H5N8 2.3.4.4 HPAI PA
A/Guangzhou/39715/14 H5N6/14 H5N6 2.3.4.4 HPAI HI / VN
A/chicken/Netherlands/EMC-3/14 ch/H5N8/14 H5N8 2.3.4.4 HPAI HI / VN
A/chicken/Yamaguchi/7/04 YAM/04 H5N1 2.5 HPAI PA
A/goose/Guiyang/337/06 GUI/06 H5N1 4 HPAI PA
A/chicken/Vietnam/NCVD-016/08 ch/VN/08 H5N1 7 HPAI PA
A/chicken/Jilin/9/04 JI/04 H5N1 - HPAI PA
LPAI: low-pathogenic avian influenza virus; HPAI: highly-pathogenic avian influenza virus; PA: protein 
array; HI: hemagglutination inhibition; VN: virus neutralization; ADCC: antibody-dependent cellular 
cytotoxicity.
Interestingly, antibodies induced by rMVA-H5 did not only bind to HA1 of the 
homologous influenza virus strain VN/04, but also to virtually all other H5 antigens 
tested (Fig. 1A). In general, the H5 antibody binding profiles could be subdivided 
into two clusters. First, antibody responses against 13 H5 antigens from various 
clades showed a similar binding profile as the homologous VN/04 antigen. Second, 
weaker antibody binding to the HA1 from VN/08, tu/H5N8/14, H5N3/07 and Egypt/08 
was observed (Fig. 1A). Of note, antibody binding to the control antigens of sH1N1 
and sH3N2 viruses was similar between all groups and time-points.
Genetic relationships between the antigens used in various assays were determined 
by performing a phylogenetic analysis based on the HA1 domain of the influenza 
virus HA gene (Fig. 1B). Among the H5 viruses, the two LPAI clustered separately, 
whereas all HPAI H5 clustered together as expected to their respective clades. 
Interestingly, the two antigenic clusters determined by PA (Fig. 1A) were not 
necessarily defined by differences in genetic clades (Fig. 1B). Collectively, antibody 
responses induced by rMVA-H5 immunization showed strong cross-reactivity with 
the HA of H5 influenza viruses from antigenically and genetically diverse clades.
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rMVA-H5 induced cross-reactive VN antibodies against H5N1, H5N6 and H5N8 
influenza viruses
To test rMVA-H5-induced cross-reactive antibodies, sera collected at week 56 post-
primary immunization (containing the highest level of H5-specific antibodies to the 
homologous virus) were used in HI (Fig. 2A) and VN (Fig. 2B) assays. Antibody 
reactivity with the homologous strain VN/04 and the heterologous strains IND/05 
and ch/H5N8/14 was tested previously260,261 and was confirmed in the present 
study. In addition, the activity against Egypt/14 and BANG/13, which are among the 
H5N1 vaccine strains selected by the WHO, and H5N6/14 (recently causing human 
infections) was tested.
HI antibodies specific for the homologous VN/04 virus were detected, which 
displayed considerable cross-reactivity with two other H5N1 viruses: IND/05 (clade 
2.1) and Egypt/14 (clade 2.2.1.2). Cross-reactivity with the viruses BANG/13 (clade 
2.3.2.1), ch/H5N8/14 and H5N6/14 (both clade 2.3.4.4) was also observed, but only 
to a limited extent (Fig. 2A, significantly lower titers than VN/04: p<0.0001). Although 
statistical significant differences between treatment groups were not observed, study 
subjects that received a high dose immunization prior to the booster immunization at 
week 52, displayed the highest HI antibody titers.
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◄ Figure 2. rMVA-H5 induced HI and VN antibodies reactive with homologous and antigenically 
distinct H5 viruses. Sera obtained four weeks after the booster immunization (week 56) were tested for 
the presence of HI (A) and VN (B) antibodies reactive with the homologous VN/04 and five antigenically 
distinct H5 viruses. (A) Reciprocal HI titers obtained by a 2-fold serum dilution series. Sera without HI 
activity or HI titer of 10 were set at a titer of <10. * p<0.0001 compared to reference virus VN/04. (B) 
Reciprocal VN titers obtained by a 2-fold serum dilution series, incubated with 100 or 1000 PFU of 
influenza virus. Sera without VN activity were set at a titer of <5. * p<0.0001, ** p=0.0002 and *** p=0.0031 
when different viruses were compared with reference VN/04. The symbols indicate the different treatment 
groups (1 or 2 immunizations, 107 or 108 PFU); geometric mean titers are displayed as bars.
Next, the week 56 sera were tested for VN activity against the same six influenza 
viruses (Fig. 2B). Although the titers observed in VN were higher than HI titers in 
general, similar findings were obtained. Serum antibodies efficiently neutralized the 
homologous VN/04 virus and cross-neutralized the clade 2.1, 2.2.1.2, 2.3.2.1 and 
2.3.4.4 viruses. As observed in HI, higher cross-neutralizing antibody titers were 
observed against IND/05 and Egypt/14 compared to BANG/13, ch/H5N8/14 and 
H5N6/14 (Fig. 2B, significantly lower titers than VN/04: p=0.031, p=0.0002 and 
p<0.0001 respectively). Again, statistical significant differences between treatment 
groups were not observed. Taken together, serum antibodies induced by immunization 
with rMVA-H5 are broadly-reactive and display cross-neutralizing capacity.
rMVA-H5 immunization induced ADCC-mediating antibodies
Sera obtained at the respective time-points p.i. were tested for the presence of 
antibodies that mediate ADCC. ADCC activity was never observed using negative 
control sera obtained from MVA-F6 immunized individuals at week 0, 4 and 8 
(p<0.0001, Fig. 3A-B). A single immunization with rMVA-H5 induced a significant 
raise in ADCC activity against HA of the homologous strain VN/04 (Fig. 3A). The 
level of ADCC-mediating antibodies was maintained until week 8, but was not further 
boosted by a second immunization. Subsequently, the level of ADCC-mediating 
antibodies waned at week 52, although the level of ADCC-mediating antibodies at 
this time-point was still significantly higher compared to week 0. Four weeks after 
the booster immunization (week 56), the ADCC activity substantially increased and 
showed limited waning over the following 4 months (week 72, Fig. 3A).
The ADCC-mediating antibody responses were comparable between the vaccine 
groups, regardless of the dose and number of rMVA-H5 immunizations the subjects 
received. Notably, cross-reactive ADCC-mediating antibodies were observed with 
the HA of the clade 2.1 influenza virus IND/05 in a similar pattern, although the 
percentages of activated CD107a+ NK cells were somewhat lower (Fig. 3B). The 
ADCC activity to HAs of VN/04 and IND/05 correlated significantly, which confirmed 
the cross-reactivity of the ADCC antibody response (Fig. 3C, linear regression 
r2=0.7584).
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Figure 3. Presence of ADCC-mediating antibodies reactive with homologous and an antigenically 
distinct H5N1 virus. (A-B) Presence of ADCC-mediating antibodies expressed as percentage of 
degranulating NK cells at a set serum dilution. Sera obtained at the indicated time-points were tested 
against VN/04 (A) and IND/05 (B). * p<0.0001 and ** p=0.0342 (compared with reference week 0). 
Symbols indicate the different treatment groups; geometric mean titer is displayed as bars. (C) Correlation 
between ADCC-mediating antibodies specific for VN/04 and IND/05. Symbols indicate the different time-
points. Linear regression r2=0.7584.
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rMVA-H5 immunization induced HA-specific T cell responses
In order to assess induction of HA-specific T cell responses at the respective time-
points p.i., PBMC were stimulated with full-length HA derived from influenza viruses 
VN/04 or IND/05. HA-specific T cells were detected in an IFN-ɣ ELISpot assay. As 
expected, H5-specific T cells were not detected in any of the samples after mock 
stimulation (Fig. 4A) or prior to immunization with rMVA-H5, with the exception of 
one subject (Fig. 4B-C). Four weeks after the first immunization, T cells specific for 
HA derived from the strain used in the vaccine (VN/04) were detected, particularly 
in the study subjects that received a high dose of rMVA-H5, although this increase 
was not statistically significant (Fig. 4B). The number of HA-specific T cells did not 
increase after a second immunization (week 8), and only limited cross-reactivity with 
the HA of the heterologous strain IND/05 was observed at week 4 and 8 (Fig. 4B-C). 
Interestingly, significantly higher numbers of T cells specific for HA of strain VN/04 or 
IND/05 were detected prior to the booster immunization at week 52, when compared 
to week 0 or mock stimulation. Subsequently, after the booster immunization, the 
number of H5-specific T cells further increased and substantial cross-reactivity was 
observed with the HA of the strain IND/05 (Fig. 4B-C). At all time-points, with the 
exception of week 0, T cells stimulated with VN/04 or IND/05 had significantly higher 
numbers of IFN-ɣ SFC compared to mock-stimulated cells. Similar to the rMVA-
H5-induced antibody responses, at week 52 and 56 a trend towards stronger T cell 
responses in study subjects that received the high dose of rMVA-H5 was detected 
(Fig. 4B-C).
Discussion
In this study, we performed a comprehensive immunological analysis on blood 
samples obtained during a phase 1/2a clinical trial260 with a (pre-)pandemic H5 
vaccine candidate based on the replication-deficient viral vector MVA. Immunization 
of healthy young adults with rMVA-H5 induced cross-reactive antibodies that not 
only bound to HA corresponding to the vaccine strain, but also to virtually any other 
antigenically distinct HA. The vaccine-induced antibodies cross-neutralized recently 
circulating H5N1 viruses, as well as the recently emerged clade 2.3.4.4 HPAI viruses 
of the H5N8 (as described previously by de Vries et al.261) and H5N6 subtypes. 
Furthermore, ADCC-mediating antibodies reactive with the homologous virus 
and an H5N1 virus from an antigenically distinct clade were induced by rMVA-H5 
immunization. In addition to humoral responses, rMVA-H5 efficiently induced (cross-
reactive) cellular responses, as both clade 1 and 2.1 H5-specific T cells were 
detected in PBMC of vaccine recipients.
Although avian H5 viruses do not spread efficiently from human-to-human, viruses 
of the H5N1 and the H5N6 subtype regularly infect humans and cause severe 
morbidity and mortality382,383. A limited number of mutations have been identified 
that potentially allow these viruses to become transmissible by air from human-to-
human19,21. These mutations can accumulate upon passage in mammalian species 
and some have already been identified in viruses circulating in birds21. The threat 
of a potential pandemic caused by influenza viruses of the H5 subtype emphasizes 
the need for the development of effective (pre-)pandemic vaccines. Conventional 
inactivated H5N1 vaccines are poorly immunogenic and repeated vaccinations, 
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Figure 4. rMVA-H5 induced HA-specific T-cell responses specific for homologous and an 
antigenically distinct H5 virus. Presence of HA-specific T-cells in PBMC obtained at the indicated time-
points was tested by IFN-ɣ ELISpot assay. PBMC mock-treated (A), or stimulated with purified HA protein 
from VN/04 (B) or IND/05 (C). Results are shown as number of spot-forming cells (SFC) per 125.000 
PBMC. * p<0.05 and ** p<0.0005. The symbols indicate the different treatment groups; mean SFC count 
is displayed as bars.
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relatively high doses or the use of adjuvants are required to induce protective 
antibody levels450,458. Furthermore, antibody responses induced by conventional 
vaccines often display limited cross-clade reactivity. Since H5 viruses have evolved 
into various (sub)clades, which are antigenically diverse451, novel vaccines that 
induce broadly-reactive immunity are highly desirable. Although a direct comparison 
between conventional H5 vaccines and rMVA-H5 was not performed, we show that 
the (pre-)pandemic vector-based vaccine candidate rMVA-H5 fulfills these needs 
through efficient induction of cross-reactive immune responses against two or more 
strains of influenza virus.
Broad reactivity of antibody responses induced by rMVA-H5 was initially demonstrated 
by PA. This technique is valuable, since it allows the detection of antibody responses 
against a large panel of antigens in a high-throughput fashion with minute amounts 
of serum, however there are some limitations. First, predominantly HA-head-specific 
antibodies were detected, since only the HA1 subunit was used for coating the 
slides. Because the HA-stalk is relatively conserved, and antigenic diversification 
of H5 is mainly based on mutations in proximity of the receptor binding site (RBS) 
of the HA-head domain, stalk-specific antibodies could significantly contribute to 
broadly-reactive immune responses. Nevertheless, the induction of cross-(sub)clade 
antibodies recognizing the HA-head of the homologous vaccine strain (clade 1) and 
of viruses belonging to clade 0, 1.1, 2.1, 2.1.3.2, 2.2, 2.2.1, 2.2.1.1, 2.3.2.1, 2.3.4, 
2.3.4.2, 2.3.4.4, 2.5, 4 and 7 was detected by PA assay. The reactivity detected in PA 
did not necessarily reflect specific genetic H5 clades, indicating that there is a clear 
distinction between antigenic and genetic differences.
The second limitation of the PA assay is that it exclusively measures binding of 
antibodies to HA1 and does not measure functional activity. Therefore, functional 
activity of rMVA-H5-induced antibodies was confirmed by HI and VN assays performed 
with a selection of viruses. For conventional inactivated influenza vaccines, a HI titer 
of 40 or higher is considered to provide protection in vivo459. In this study, induction of 
neutralizing antibodies against the homologous VN/04 and the heterologous IND/05 
and ch/H5N8/14 viruses by rMVA-H5 immunization was observed, as was described 
previously260,261. In addition, cross-neutralization against the recently emerged H5N6 
virus and two H5N1 vaccine strains selected by the WHO was observed in this study. 
Collectively, these data demonstrate that rMVA-H5 immunization induces antibodies 
that are capable of neutralizing recently emerged HPAI viruses of the H5N1, H5N6 
and H5N8 subtypes.
Antibodies directed to antigenic sites in proximity of the RBS have the capacity to 
neutralize influenza viruses. In addition to neutralization, virus-specific antibodies 
of particularly the IgG1 and IgG3 subclass can have other modes of action460. After 
binding to antigens displayed on virus-infected cells with the Fragment Antigen 
Binding (Fab)-domain, the Fragment crystallisable (Fc)-domain of antibodies can 
engage Fc-receptors on host effector cells, leading to killing of virus-infected cells 
through a mechanism known as ADCC44,45. The ADCC response against influenza 
virus is mainly mediated by the interaction between the Fc region of virus-specific 
antibodies and Fcγ-receptor IIIα (FcγRIIIα, CD16), present on NK cells. It was 
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recently shown that particularly antibodies specific for the HA-stalk are capable 
of mediating ADCC455,461-463. Since the HA-stalk is conserved among different 
subtypes of influenza viruses, ADCC-mediating antibodies may contribute to broadly 
protective immunity168,386,464. A single immunization with rMVA-H5 already induced 
ADCC-mediating antibodies reactive with the homologous and a heterologous H5N1 
influenza virus. Antibodies waned over a year after the primary immunization, but 
were readily boosted upon re-immunization. Thus, in addition to induction of broadly-
reactive neutralizing antibodies recognizing the HA-head, rMVA-H5 induced broadly-
reactive ADCC-mediating antibodies, most likely directed to the stalk region of HA.
In addition to antibody responses, rMVA-H5 immunization induced T cell responses 
specific for the homologous VN/04 and a heterologous IND/05 influenza virus. H5-
specific T cell responses were predominantly detected directly prior to and after 
the booster immunization one year after the initial immunization and particularly in 
subjects that received two prior immunizations (week 0 & 4) and/or a vaccine dose 
of 108 PFU.
A potential limitation of the use of influenza vaccines based on MVA (or other 
vectors) in humans is interference by pre-existing vector-specific immunity. In this 
study, subjects were young adults that had not been previously exposed to MVA or 
any other orthopoxvirus. However, a proportion of the adult human population does 
have immunity against the vector due to smallpox vaccination campaigns that were 
carried out until the mid 1970s320. Furthermore, pre-existing vector immunity can 
be induced by repeated MVA-based vaccinations260. Whether pre-existing immunity 
interferes with the immunogenicity and effectivity of MVA vaccination is not yet fully 
understood, however, antibodies induced by vaccination against smallpox did not 
have the capacity to neutralize MVA in vitro (Altenburg et al., submitted). In the 
present study, we showed that rMVA-H5 immunization elicits strong anamnestic HA-
specific antibody and T cell responses upon a second or third immunization, despite 
the induction of anti-vector immunity by the first (and second) immunization260.
In summary, we showed that rMVA-H5 efficiently induced humoral and cellular 
immune responses in humans that display remarkable cross-reactivity with H5 
viruses of various clades. One or two immunizations with rMVA-H5 at a four-week 
interval induced moderate immune responses, but primed individuals showed potent 
cross-reactive H5-specific antibody and T cell responses upon booster immunization 
administered after one year. Therefore, priming of immunologically naive individuals 
by pre-pandemic immunization with rMVA-H5 and subsequent boosting after the 
emergence of a pandemic H5 virus seems an attractive approach in the face of a 
pandemic outbreak with these viruses.
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Influenza viruses continuously circulate in the human population and are estimated 
to cause 3-5 million cases of severe respiratory illness annually worldwide of which 
250.000-500.000 have a fatal outcome7. Vaccination is the most efficient measure 
to control infectious diseases, however, vaccination against influenza viruses is 
complicated by their antigenic variability. Current seasonal influenza vaccines are 
comprised of components from influenza A(H1N1), A(H3N2) and B viruses that are 
expected to circulate in the next influenza season. These seasonal vaccines aim at 
the induction of virus neutralizing antibodies against HA and are efficient in providing 
protective immunity against antigenically similar influenza viruses. However, they 
afford little or no protection from infection with antigenically distinct seasonal or 
pandemic influenza viruses. In order to induce broadly protective immunity against 
multiple and antigenically distinct influenza viruses, novel vaccine targets and 
antigen delivery systems are investigated. Furthermore, novel techniques are under 
development to facilitate production of large quantities of vaccine doses in a short 
period of time. The vaccine vector MVA expressing one or multiple influenza virus 
antigens could potentially provide in these needs.
In this thesis, the development and use of rMVA-based influenza vaccines was 
addressed. Even though MVA has been tested extensively in various animal models 
and has been administered to >100.000 human volunteers, a few key questions 
regarding the MVA vaccine vector remained to be answered. To that end, the studies 
described in chapter 2 elucidated the in vivo cell tropism of MVA-based vaccines 
and assessed the potential risk of interference with rMVA-based vaccination by 
orthopoxvirus-specific pre-existing immunity. Furthermore, novel rMVA-based 
influenza vaccine candidates were developed and evaluated by pre-clinical and 
clinical testing in chapters 3 and 4.
In vivo tropism of MVA
Previously, several studies have been performed to assess MVA tropism in vitro 
and in mice, however, these studies mainly focussed on elucidating the tissue 
tropism231,291-293. In chapter 2.1 these results were confirmed in the mouse model. In 
addition, the cellular tropism of MVA in ferrets – the animal model most commonly 
used for influenza virus replication, pathogenesis and transmission studies – and 
in macaques, representative for humans, was described. The most common route 
of administration of rMVA in pre-clinical studies and clinical trials is IM injection, 
however, respiratory vaccination is under consideration for the optimal induction of 
local tissue resident immune responses against respiratory pathogens. Therefore, 
tropism of MVA in vivo after IM injection was compared to that after administration 
to the respiratory tract. Using rMVA expressing a fluorescent reporter protein (rMVA-
GFP), low-frequency MVA-infected cells could be sensitively detected.
In mice, ferrets and macaques, local myocytes or epithelial cells at the site of 
inoculation (the hind leg muscle or respiratory tract, respectively) were infected 
by MVA. However, the contribution of these cell types to the total MVA-infected 
population was limited. In mice and macaques, MVA was predominantly detected in 
macrophages and DCs, regardless of the administration route used. Myeloid cells 
were also infected by MVA in ferrets, however, further phenotyping of the MVA-
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infected cells was difficult due to the lack of ferret-specific antibodies. In all tested 
animal models, MVA-positive cells were detected in the LN draining the inoculation 
site as soon as 6 hours after administration, which suggests direct infection of APC 
rather than uptake of remains of MVA-infected apoptotic cells. This indicates that 
MVA-infected cells are directly involved in the shaping of the immune response, 
which can be regarded as a beneficial feature for a vaccine vector. 
Only slight differences in MVA tropism were detected between the different animal 
models. After respiratory tract administration of rMVA-GFP in mice, alveolar 
macrophages were the dominant MVA-positive cell type opposed to DCs in 
macaques. Of note, alveolar macrophages are considered to be inefficient antigen 
presenting cells compared to DCs306,307. Nonetheless, rMVA-based vaccines have 
been shown to efficiently induce antigen-specific immune responses in all tested 
animal models209. 
Since similar cell types were infected by MVA in the various animal models, it can 
reasonably be assumed that myeloid cells are also targeted by MVA in humans. 
Indeed, using human PBMC in vitro, MVA was shown to predominantly infect DCs, 
monocytes and B cells291 (chapter 2.1). Even though it seems beneficial to infect 
DCs, since these cells are directly involved in the shaping of the immune response, 
direct infection does not necessarily lead to improved vaccine immunogenicity, which 
was previously shown for an adenovirus vector in mice and non-human primates300. 
Nevertheless, the data obtained in this study potentially explain the excellent 
immunogenicity of MVA-based vaccines.
The effect of pre-existing vaccine vector-specific immunity on rMVA-based 
vaccination
Another key question that remained unanswered in current MVA literature was 
the effect of pre-existing orthopoxvirus-specific immunity on immunogenicity and 
efficacy of rMVA-based vaccines. There is concern that immunity against MVA, 
induced either during historic smallpox vaccination campaigns or by multiple rMVA-
based vaccinations, may have negative effects on the performance of rMVA-based 
vaccines. In order to address this issue, the effect of presence of pre-existing 
immunity to MVA, VACV or influenza virus on immunogenicity and efficacy of 
rMVA-based influenza vaccines was assessed (chapter 2.2). In mice, pre-existing 
MVA-specific immune responses negatively affected the antigen-specific antibody 
response induced by rMVA-based vaccination, but only under suboptimal conditions, 
e.g. when a lower vaccine dose was used. Furthermore, induction of an antigen-
specific T cell response was severely hampered by the presence of orthopoxvirus-
specific immunity induced by either MVA or VACV. Importantly, mice vaccinated with 
an rMVA-based vaccine expressing HA homologous to the A(H5N1) influenza virus 
used for challenge infection were completely protected from disease, regardless of 
the presence of pre-existing vector-specific immunity. In contrast, mice previously 
exposed to MVA or VACV and subsequently vaccinated with rMVA-based vaccines 
expressing the heterologous HA gene from A(H1N1) or A(H3N2) lost more body 
weight and showed higher viral loads in the lungs after the challenge infection 
compared to mice without pre-existing vector-specific immunity. This corresponds 
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to the prevention of induction of HA-specific cross-reactive immune responses by 
the respective MVA-based vaccines in the presence of pre-existing vector-specific 
immunity. Collectively, the results showed that under specific conditions pre-existing 
orthopoxvirus-specific immunity could negatively influence rMVA-based vaccine 
immunogenicity in mice, but the protective efficacy of an rMVA-HA-based vaccine 
against a homologous influenza virus remained unaffected.
Strikingly, negative effects on rMVA-induced antigen-specific cellular and humoral 
immune responses were detected in the presence of pre-existing immunity induced 
by MVA, whereas pre-exposure to VACV only influenced subsequent induction 
of antigen-specific T cell responses. At least two exposures to MVA and/or VACV 
were required to induce MVA-specific neutralizing antibodies, which could indicate 
why interference with induction of antigen-specific antibody responses was only 
observed in mice previously exposed to MVA (primed twice) but not VACV (primed 
only once). The detrimental effect of pre-existing orthopoxvirus-specific immunity 
on the induction of antigen-specific T cell responses is therefore likely caused by 
non-neutralizing immune responses, since this was also observed in mice primed 
with a single VACV exposure. Further studies, e.g. adoptive transfer studies, are 
required to obtain a thorough understanding of the mechanisms underlying the 
interference of pre-existing orthopoxvirus-specific immunity on rMVA-based vaccine 
immunogenicity.
It is important to note that in this mouse study a ‘worst-case scenario’ was investigated 
as the interval between induction of pre-existing immunity and vaccination was only 
four weeks. Obviously, this deviates from the human situation were the last VACV 
vaccinations were administered over 40 years ago and antibody responses are 
likely to have waned over time. However, VACV-specific antibody responses could 
still be detected in serum of VACV vaccinated individuals born in 1970 and 1971, 
shortly before the smallpox vaccination campaigns were discontinued. Importantly, 
these antibody responses cross-reacted with MVA only to a limited extent and were 
not able to neutralize MVA in vitro in a plaque reduction assay. Indeed, an rMVA-
based vaccine inducing antigen-specific T cell responses was still immunogenic in 
people born before 1962, which is before smallpox vaccination campaigns were 
discontinued271. Of note, in this study the number of study subjects was limited, the 
immune status against MVA or VACV was not validated and no proper control group 
was included. Nonetheless, these results indicate that pre-existing orthopoxvirus-
specific immunity induced by historic smallpox vaccination campaigns does not 
substantially interfere with rMVA-based vaccination in humans. 
The interference of pre-existing orthopoxvirus-specific immunity is likely to be more 
relevant in the context of repeated rMVA-based vaccination, in which a four-week 
interval between vaccinations is frequently used234,260,335. Human study subjects that 
were exposed to rMVA repeatedly (up to 3x) in clinical trials showed a boost of 
MVA-specific immunity induced by every vaccination234,260,327 (chapter 2.2). However, 
the rMVA-based vaccine still remained immunogenic, even after a third vaccination 
administered one year after the initial rMVA-based vaccination260.
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Taken together, the results from the study described in chapter 2.2 suggest that the 
concern of pre-existing immunity affecting rMVA-based vaccine immunogenicity is 
valid, but only under specific circumstances. Further studies are warranted to address 
if the specific conditions described in this study in which pre-existing orthopoxvirus-
specific immunity can interfere with subsequent rMVA-based vaccination are similar 
between mice and humans. To circumvent or overcome potential negative effects of 
pre-existing vaccine vector-specific immunity, several strategies could be adopted. 
First, a booster vaccination with a high dose of an rMVA-based vaccine was shown 
to overcome observed negative effects on the antibody response after a single 
vaccination268 (chapter 2.2). Second, administration of the rMVA-based vaccine to 
different sites, e.g. IM injection followed by respiratory tract administration, could 
circumvent local vector-specific immunity333. It was shown in non-human primates 
that rMVA can be nebulized and administered to the respiratory tract (chapter 2.1) to 
induce local immunity against respiratory pathogens, thereby preventing the use of 
needles305. Third, rMVA-based vaccines could be used in heterologous prime-boost 
regimens, for example in combination with DNA or recombinant adenovirus-based 
vaccines325, thereby preventing a boost of the vector-specific immune responses. 
Finally, in order to assure optimal induction of antigen-specific immune responses 
using rMVA-based vaccines, it seems important to take into account the immune 
status of a vaccine recipient, the vaccine dose used and the main correlate of 
protection to be induced by rMVA-based vaccination. 
Immunogenicity of protein- and rMVA-based influenza vaccines
For decades, inactivated protein-based influenza vaccines have been used to reduce 
influenza virus-related morbidity and mortality through the induction of HA-specific 
neutralizing antibodies131. In chapter 3, the immunogenicity of protein- and rMVA-
based influenza vaccines was compared in mice using NP (target of virus-specific T 
cells, chapter 3.2) or HA (major target of virus neutralizing antibodies, chapter 3.3) 
as vaccine antigens. In both studies, unadjuvanted protein-based vaccines were 
poorly immunogenic, but the addition of Matrix-M™ adjuvant potentiated the immune 
response substantially and allowed significant antigen dose sparing. Compared to the 
protein-based vaccines, rMVA-based influenza vaccines were more immunogenic 
as they induced stronger functional immune responses (NP-specific CD8+ T cells 
or HA-specific HI antibodies) than either unadjuvanted or adjuvanted protein-based 
vaccines. The enhanced immunogenicity of rMVA-based vaccines can be explained 
by de novo antigen synthesis. Subsequently, NP is endogenously processed and 
presented on MHC class I to induce CD8+ T cell responses. Furthermore, expression 
of large quantities of HA in its native conformation on the surface of rMVA-infected 
cells contributes to the induction of potent HA-specific antibody responses. In 
addition to the antigen delivery route, the lack of many immune evasion and 
suppression proteins in MVA compared to the parental VACV allows for recruitment 
and activation of (innate) immune cells by the vector backbone, which contributes 
to vaccine immunogenicity. These results underline the advantages of using MVA-
based vaccines compared to protein-based vaccines for the induction of potent 
antigen-specific humoral and cellular immune responses. 
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It is generally assumed that addition of an adjuvant to rMVA-based vaccines (or 
any vector-based vaccine) is not required because the vector backbone itself 
potently induces innate immune responses and directly infects APC involved in 
the shaping of the immune response. Indeed, the recruitment, proliferation and/
or activation of immune cells in the LN draining the site of vaccine injection was 
enhanced after vaccination with an rMVA-based influenza vaccine expressing 
HA (rMVA-HA) compared to a protein-based HA vaccine (chapter 3.3). Of special 
interest, the immunogenicity of the rMVA-HA vaccine could be improved by adding 
Matrix-M™ adjuvant to the vaccine preparation. Co-formulation with Matrix-M™ 
adjuvant resulted in enhanced total cell counts in the draining LN and monocytes, 
including the CD169+ medullary sinus macrophages, in particular. The medullary 
sinus macrophages are known to phagocytose antigens and viruses in the lymphatic 
system, and have been shown to be an important effector mechanism of saponin-
based adjuvants437,439,465. Along with the total cell count, also the number of activated 
DC, B cells, T cells, monocytes and NK cells was enhanced after injection of 
Matrix-M™ adjuvanted vaccines. Interestingly, no differences between Matrix-M™ 
adjuvanted protein- and rMVA-based vaccines were observed in the recruitment, 
proliferation and/or activation of immune cells in the draining LN. However, rMVA-
HA co-formulated with Matrix-M™ adjuvant induced stronger functional immune 
responses than HA protein with Matrix-M™. This indicates that Matrix-M™ adjuvant 
potentiated the immune response, but the quality of the response is still dependent 
on the antigen delivery system.
The results in chapter 3.3 describe the effects of adding Matrix-M™ adjuvant to 
a high dose of rMVA-HA vaccine. It was not addressed in this study if Matrix-M™ 
adjuvant allows rMVA-HA dose sparing, as was described for protein-based 
vaccines. This would be of particular interest in the context of an influenza virus 
pandemic where a large number of vaccine doses need to be available in a short 
period of time. Furthermore, in chapter 2.2 it was demonstrated in mice that a high 
dose of the rMVA-H5 vaccine is required to overcome negative effects induced by 
MVA-specific pre-existing immunity observed after the first vaccination with a low 
dose of rMVA-H5. Hypothetically, a lower dose of rMVA-HA vaccine can be used to 
overcome this pre-existing vector immunity barrier if Matrix-M™ adjuvant is added to 
the vaccine formulation. In addition to antigen dose sparing, it would be interesting 
to address if the observed increase in immunogenicity of rMVA-HA, expressing HA 
from an A(H1N1) influenza virus, co-formulated with Matrix-M™ adjuvant broadens 
the immune response induced by vaccination to protect from a lethal challenge with, 
for example, a heterologous A(H5N1) influenza virus.
Pre-clinical and clinical assessment of novel rMVA-based influenza vaccines
Different approaches are under investigation to improve currently used influenza 
vaccines. These include the use of novel vaccine platforms allowing faster production, 
novel antigen delivery systems, more conserved vaccine antigens, activation of non-
neutralizing antibodies or T cell responses to confer protective immunity or various 
combinations of these approaches. 
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Currently used inactivated influenza vaccines inefficiently induce CD8+ T cell 
responses136. However, the main targets of CD8+ T cell responses during an influenza 
virus infection, including NP and M1, are relatively conserved. Therefore, these T 
cell responses have the capacity to provide protection against different influenza 
virus subtypes. Indeed, CD8+ and CD4+ T cells have been shown to contribute 
to heterologous protection in humans during the 2009 A(H1N1) influenza virus 
pandemic82,108. It is important to note that for efficient induction of T cell responses, 
an infection needs to be established because endogenous protein synthesis is 
required. Thus, vaccines that exclusively induce cellular immunity do not afford 
sterile immunity, but their use can reduce the extent of viral shedding, severity and/
or duration of the disease. Therefore, when aiming for broadly protective immune 
responses, it is important to include a vaccine component designed for efficient 
induction of cross-reactive CD8+ T cell responses.
rMVA vector-based vaccines allow for efficient induction of antigen-specific T cells 
by driving de novo synthesis of the antigen of interest, followed by processing via 
the endogenous route of antigen presentation. One of the crucial steps in antigen 
presentation to CD8+ T cells is processing of antigens by the proteasome in order to 
release peptides from proteins, which subsequently are transported from the cytosol 
to the endoplasmic reticulum to be loaded onto MHC class I molecules. By increasing 
protein degradation, potentially more peptides are available for presentation to CD8+ 
T cells, which could lead to better T cell activation. In order to test this hypothesis, 
three different modifications were made to NP that was expressed from rMVA (chapter 
3.1 & 3.2). Two modifications (deletion of the nuclear localization signal [NLS] and 
fusion of NP to the proteasome signalling molecule ubiquitin) resulted in increased 
protein degradation and showed enhanced activation of a CD8+ T cell clone in vitro. 
Beneficial effects of enhanced protein degradation were only observed in vitro under 
suboptimal conditions, i.e. when a low avidity T cell clone was used or APC were 
infected at a low multiplicity of infection (MOI). However, vaccination with rMVA 
expressing one of the modified NP proteins did not improve the NP-specific CD8+ T 
cell response in vivo and did not result in enhanced protection from a homologous 
influenza virus challenge infection in either C57BL/6 or BALB/c mice. This suggests 
that wild-type NP is already optimally processed and presented in vivo, therefore, 
the modifications did not have any added effect. However, NP is known as a highly 
immunogenic protein. Potentially, less immunogenic proteins, such as M1 and the 
polymerase subunits, could benefit from increased protein degradation. 
Contrary to the hypothesis tested in chapter 3.1 and 3.2, it has been hypothesized 
in literature that for activation of antigen-specific CD8+ T cell responses the delivery 
of stable proteins might be more advantageous compared to antigens that were 
designed for rapid intracellular degradation363,364,466. Stable antigens would allow for 
more cross-presentation because the protein is still present by the time the infected 
and apoptotic cell is engulfed by a professional APC467. It is debatable if this would 
apply to rMVA-based vaccines because APC are directly infected (chapter 2.1), 
therefore, the contribution of cross-priming might be limited.
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In addition to evaluation of rMVA-NP vaccines in mice, the human immune response 
induced by vaccination with an rMVA-based vaccine expressing HA from influenza 
virus A/Vietnam/1194/04 (H5N1, rMVA-H5) was assessed (chapter 4). Previously, it 
was shown that HA-specific antibody responses induced by rMVA-H5 displayed HI 
and VN activity, and cross-reacted with antigenically different A(H5N1) and A(H5N8) 
influenza viruses260,261. The results in chapter 4 describe vaccine-induced antibodies 
that cross-react with all tested A(H5N1), A(H5N3), A(H5N6) and A(H5N8) influenza 
viruses in protein microarray. Functional antibodies reactive with multiple A(H5N1), 
A(H5N6) and A(H5N8) viruses were detected by HI and/or VN assay. In addition, 
efficient induction of ADCC-mediating antibodies and T cells was observed after 
rMVA-H5 vaccination. Different vaccination regimens, including a high (108 PFU) 
and low (107 PFU) dose rMVA-H5, and a single and two vaccinations at a four-
week interval were evaluated. Two vaccinations with a high dose rMVA-H5 seemed 
to most efficiently induce (broadly reactive) immune responses, although no clear 
differences between the various vaccination regimens could be detected after a 
booster vaccination after one year. Taken together, the results showed that rMVA-H5 
efficiently induces broadly reactive immune responses against antigenically distinct 
A(H5Nx) influenza viruses. 
The human immune responses induced by rMVA-H5 vaccination will most likely 
protect from disease after infection with the homologous and even a heterologous 
A(H5Nx) virus, as was demonstrated in a non-human primate model258,259. However, 
considering the large and ever-increasing diversity in HA within the H5 influenza 
virus subtype, the full extent of cross-protection against A(H5N1) influenza viruses 
is unclear. Heterologous prime-boost regimens may be required to improve the 
breadth of the virus-specific antibody response. For example, vaccination with rMVA 
expressing the HA gene from A/Vietnam/1194/04 could be followed by vaccination 
against an influenza virus from an antigenically distinct clade, which would boost 
antibody responses against conserved epitopes. Nevertheless, the results obtained 
in this study confirm that the rMVA-H5 vaccine candidate holds promise in the face of 
a potential pandemic outbreak with an H5 influenza virus or even as a pre-pandemic 
vaccine in pandemic preparedness plans.
Practical and regulatory issues regarding the use of rMVA-based influenza 
vaccines
The continuing advances in genetic engineering, process development and large-
scale manufacturing have brought rMVA-based vaccines into clinical trials at an 
increasing scale249,250,468,469. However, there are some hurdles to overcome in the 
development of novel rMVA-based influenza vaccines, particularly in the context 
of a pandemic. First, there are practical issues regarding the timely development 
of suitable animal models for newly emerging respiratory infections. Second, for 
each new vaccine antigen potency and purity assays need to be developed for 
the appropriate quality assessment of rMVA vaccine preparations. Although all the 
hands-on development work can be performed rapidly, non-clinical safety testing, 
e.g. toxicity studies and ethics approval for animal experiments and clinical trials, 
always depends on external parties, which could substantially slow down vaccine 
development.
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In addition to practical issues, there are regulatory issues that need to be addressed 
regarding the registration of an rMVA-based vaccine. Thus far, only one guideline 
for the quality and (non-)clinical aspects of live recombinant viral vectors exists470. 
However, to date no rMVA-based has been approved for human use. For novel 
influenza vaccines, special procedures are in place in the European Union to 
speed up the authorization process. First, using the ‘mock-up procedure’ a proof-of-
principle vaccine is registered using a prototype influenza virus. Once the viral strain 
that is causing a pandemic is identified, this can be included in the mock-up dossier 
and approved rapidly to develop a tailor-made vaccine. Second, the ‘emergency 
procedure’ allows for fast-track approval (within 70 days) of a vaccine during a 
pandemic. Currently, rMVA and other vector-based vaccines are not covered by these 
pandemic influenza vaccine registration procedures. This complicates approval of 
rMVA-based vaccines as each rMVA virus is regarded as a new biological entity. 
Furthermore, combination vaccination strategies, e.g. priming with an adenovirus 
vector and boosting with an rMVA-based vaccine, will lead to complicated regulatory 
procedures because two distinct biological entities need to be approved. Thus, there 
is a need for the development of ‘mock-up procedures’ for vector-based vaccines that 
allow for fast-track development and approval. Defining MVA tropism in vivo in non-
human primates, with high relevance for the use of MVA in humans (as described in 
chapter 2.1), provides essential knowledge for the eventual approval of rMVA-based 
vaccines.
Universal influenza vaccines
Considering the extensive antigenic variation of influenza viruses there clearly is the 
need for the development of a ‘universal influenza vaccine’: a single vaccine that 
protects against all influenza A virus subtypes. However, development of an influenza 
vaccine that protects against all HA group 1 or group 2 influenza viruses would 
already be a major advancement. For that matter, even broad protection within a 
single subtype, e.g. A(H1N1), induced by a single vaccine would be an improvement 
over the currently used influenza vaccines. A few promising new vaccine antigens 
and delivery systems that allow for broadly reactive immune responses are currently 
under development and have advanced to clinical trials. Thus, on a relatively short 
term, possibly within the next decade, substantial advances towards the development 
of ‘next-generation’ influenza vaccines can be made.
Induction of broadly protective immunity against antigenically distinct influenza 
viruses, whether within a subtype or across subtypes, most likely requires a 
multifaceted approach. First, a novel influenza vaccine should still contain an HA 
component that induces neutralizing antibodies, even if they only afford protection 
against a narrow antigenic range of influenza viruses. The HA component can be 
combined with an antigen that induces cross-reactive non-neutralizing antibodies 
and/or T cells, which confer protective immunity in the event of an HA antigenic 
mismatch. In this case, sterile immunity and full protection might not be conferred, 
however, disease duration and severity can be substantially reduced. At the 
population level this results in reduced spread of the virus due to reduced viral loads 
and duration of shedding.
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For the evaluation of novel influenza vaccines that induce correlates of protection 
other than virus neutralizing antibodies there are some hurdles to overcome. The 
currently used vaccines are designed to induce strain-specific antibodies against the 
head-domain of HA for which correlates of protection have been defined: an HI (a 
good proxy for VN) antibody titre of 40 or higher is considered to provide protection 
in vivo459. Even though this value may not always correlate with protection471, it 
is the best available guide to predict and compare vaccine efficacy. In contrast, 
standardized immunological assays for detection and quantification of virus-specific 
non-neutralizing antibodies and/or T cells are lacking. It is important to invest in the 
development of these assays and defining cut-off values for protection to predict the 
efficacy of novel vaccine candidates.
Concluding remarks
The variable nature of influenza A virus complicates development of effective 
influenza vaccines. MVA holds promise as a vaccine platform in the context of an 
emerging influenza virus pandemic because rMVA can be rapidly constructed and 
produced. Furthermore, the vector is of considerable interest for the development 
of broadly protective influenza vaccines since foreign antigens can be expressed 
in their native conformation and will be properly processed and presented to the 
immune system. This allows for induction of humoral and cellular responses that 
induce solid pathogen-specific immunity. The excellent immunogenicity of rMVA-
based vaccines can partially be explained by direct infection of APC and can 
further be improved by the use of an adjuvant. However, there are some hurdles 
to overcome regarding the use of rMVA-based vaccines. First, in mice, pre-existing 
immunity to the vector induced by previous exposure to MVA, and to a lesser extent 
VACV, can hamper the induction of antigen-specific immunity by rMVA vaccination 
under specific conditions. However, the impact of pre-existing immunity on the 
outcome of rMVA-based vaccination is limited compared to other vaccine vectors 
such as replication competent VACV or adenovirus212,213,322. The relevance of the in 
chapter 2.2 defined conditions where pre-existing orthopoxvirus-specific immunity 
interferes with rMVA-based vaccination needs to be addressed in humans to be 
able to predict the effectiveness of rMVA-based vaccines. Second, there are some 
practical and regulatory issues that need to be addressed to allow rapid approval 
for the use of rMVA-based vaccines, particularly if the MVA vector vaccine platform 
is to be used in the face of an emerging influenza virus pandemic outbreak. Finally, 
there are currently no standardized assays and defined cut-off values to predict if 
heterosubtypic immunity, conferred by for example cross-reactive ADCC-mediating 
antibodies or CD8+ T cells, actually protect from infection. Taken together, although 
there are issues that need to be addressed before rMVA-based vaccines can be used 
in humans, the vector platform holds considerable promise as a (pre-)pandemic or 
‘universal’ influenza vaccine.
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Griep is een luchtweginfectie die wordt veroorzaakt door het influenzavirus. 
Influenzavirussen behoren tot de familie van orthomyxovirussen en zijn verder onder 
te verdelen in influenza A-, B-, C- en D-virussen. Influenza A-virussen worden verder 
gecategoriseerd in zogenaamde subtypes op basis van twee eiwitten op het oppervlak 
van het viruspartikel: hemagglutinine (HA) en neuraminidase (NA). Momenteel zijn 
er 18 verschillende HA subtypes (H1-18) en 11 verschillende NA subtypes (N1-11) 
bekend. De naamgeving van de subtypes van influenza A-virussen is gebaseerd op 
de HA en NA types op het oppervlak van het viruspartikel, bijvoorbeeld H5N1 (ook 
wel bekend als vogelgriep). 
Influenza A- (H1N1 en H3N2 subtypes) en B-virussen zijn de veroorzakers van de 
jaarlijkse griepepidemie in de wintermaanden. De Wereldgezondheidsorganisatie 
(WHO) schat dat het influenzavirus wereldwijd jaarlijks 3-5 miljoen ernstige 
luchtweginfecties veroorzaakt, waarvan 250.000-500.000 met een dodelijke 
afloop. Naast de continu circulerende virussen die de seizoensgriep veroorzaken, 
vinden er sporadisch besmettingen plaats met voor de mens onbekende influenza 
A-virussen. Deze virussen worden vanuit het dierenrijk, voornamelijk door vogels 
en varkens, overgedragen op de mens. Als deze nieuwe influenzavirussen zich zo 
aanpassen dat ze gemakkelijk van mens-op-mens overgedragen kunnen worden, 
een eigenschap die deze virussen vaak (nog) niet bezitten, is er een kans op een 
wereldwijde uitbraak (pandemie). Een recent voorbeeld hiervan is de Mexicaanse 
grieppandemie van 2009, die veroorzaakt werd door een H1N1 influenza A-virus 
afkomstig uit varkens.
Vaccinatie tegen influenzavirussen
Kwetsbare groepen, zoals ouderen of mensen met luchtwegproblemen, komen 
in Nederland in aanmerking voor de jaarlijkse ‘griepprik’. Dit vaccin tegen de 
seizoensgriep bestaat uit verzwakte of geïnactiveerde (delen van) influenza 
A(H1N1)-, A(H3N2)- en B-virussen. Vaccinatie zorgt voornamelijk voor aanmaak 
van antilichamen die het HA-eiwit op het oppervlakte van een viruspartikel of door 
influenzavirus geïnfecteerde cellen kunnen herkennen. Wanneer de gastheer 
daarna in aanraking komt met het influenzavirus, binden deze antilichamen aan het 
HA-eiwit waardoor wordt voorkomen dat het virus aan gastheercellen kan binden 
en een infectie kan veroorzaken. Echter, er zijn twee scenario’s waarin de jaarlijkse 
influenzavaccins minder of niet werkzaam zijn. Ten eerste, door mutaties in het HA-
eiwit kan het influenzavirus ontsnappen aan herkenning door eerder aangemaakte 
antilichamen. Het huidige influenzavaccin moet hierdoor bijna jaarlijks aangepast 
worden om voor de juiste afweer te zorgen tegen de nieuwe influenzavirussen. 
Om voldoende influenzavaccins te kunnen produceren moet een half jaar voor het 
griepseizoen worden vastgesteld welke A(H1N1)-, A(H3N2)- en influenza B-virussen 
er in het vaccin worden opgenomen. Indien er niet goed voorspeld wordt welke 
virussen er de komende winter zullen circuleren, is er sprake van een mismatch 
tussen het vaccin en de circulerende influenzavirussen. Dit resulteert in verlaagde 
vaccineffectiviteit: de gevaccineerde mensen hebben grotere kans om toch ziek te 
worden. Ten tweede beschermt het jaarlijkse influenzavaccin niet tegen pandemische 
influenzavirussen. In dat geval moet er een geheel nieuw vaccin ontwikkeld worden, 
wat veel tijd in beslag neemt. Zo kwam tijdens de Mexicaanse grieppandemie het 
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vaccin in veel landen pas beschikbaar toen de piek van de pandemie al voorbij 
was. Samengevat: er is een grote behoefte aan nieuwe influenzavaccins die sneller 
geproduceerd kunnen worden en/of brede(re) bescherming kunnen bieden tegen 
verschillende subtypes van het influenzavirus.
Brede immuniteit tegen influenzavirussen
Er wordt veel onderzoek gedaan naar de ontwikkeling van nieuwe influenzavaccins 
die bescherming tegen meerdere influenzavirussen bieden, oftewel die brede 
immuniteit induceren. Om dit te bereiken wordt er onderzocht of bepaalde vaccins 
een antilichaamrespons kunnen opwekken die meerdere subtypes van het influenza 
A-virus herkent. Daarnaast wordt er onderzoek gedaan naar een efficiëntere activatie 
van influenzavirus-specifieke T-cellen, die door de huidige vaccins niet tot nauwelijks 
geactiveerd worden. Cytotoxische T-cellen hebben de capaciteit om influenzavirus-
geïnfecteerde cellen te lyseren en zo te voorkomen dat een infectie zich kan 
ontwikkelen en uitbreiden. T-cellen kunnen niet alleen de oppervlakte eiwitten van 
een virus herkennen, maar ook de eiwitten die in een viruspartikel worden omgeven 
door een membraan met daarin de oppervlakte eiwitten. In tegenstelling tot HA en 
NA, zijn deze interne eiwitten een minder variabel onderdeel van de verschillende 
influenzavirussen en kunnen daarom een sleutelfactor zijn voor het induceren van 
brede immuniteit.
Andere onderzoeken naar een verbeterde vaccin-geïnduceerde immuunrespons 
tegen het influenzavirus richten zich op het gebruik van adjuvantia: bestanddelen 
die aan een vaccin worden toegevoegd om te zorgen dat het immuunsysteem 
beter op het antigeen (viraal eiwit waartegen de immuunrespons opgewekt moet 
worden) reageert. Daarnaast worden nieuwe methodes ontwikkeld om een antigeen 
aan te bieden aan het immuunsysteem zodat zowel antilichamen als T-cellen 
geactiveerd kunnen worden. Een van die vaccinatiemethodes waar op dit moment 
zeer veel belangstelling voor bestaat is het gebruik van virale vectoren, zoals de 
vector Modified Vaccinia virus Ankara (MVA). MVA is een verzwakte variant van 
het vacciniavirus dat tot halverwege de jaren ‘70 is gebruikt om de bevolking tegen 
het inmiddels uitgeroeide pokkenvirus te beschermen. Het is relatief makkelijk 
om een recombinant (r)MVA te maken dat een antigeen tot expressie brengt van 
bijvoorbeeld het influenzavirus. In relatief korte tijd kunnen grote hoeveelheden 
van een rMVA griepvaccin geproduceerd worden. Bij vaccinatie met rMVA worden 
gastheercellen geïnfecteerd en vindt er expressie van virale eiwitten, inclusief het 
influenzavirus antigeen van interesse, plaats. Er is echter geen sprake van actieve 
virusreplicatie in zoogdiercellen, dus er worden geen nieuwe viruspartikels gevormd. 
MVA is in ruim 100.000 vrijwilligers getest en altijd veilig gebleken, zelfs bij personen 
met een gecompromitteerd immuunsysteem. In vele studies met verschillende 
diermodellen en in klinische trials is aangetoond dat op deze manier efficiënt zowel 
antilichaamresponsen als T-cellen geïnduceerd kunnen worden tegen het antigeen 
van interesse. 
Dit proefschrift beschrijft onderzoek naar de MVA-vaccinvector en de ontwikkeling 
van nieuwe influenzavaccins op basis van MVA. Tevens wordt de toevoegde waarde 
van adjuvantia bij het gebruik van MVA-vaccins onderzocht. In hoofdstuk 1 wordt 
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een algemene introductie op dit proefschrift gegeven met achtergrondinformatie 
over influenzavirussen, huidige influenzavaccins, de MVA-vaccinvector en de 
ontwikkelingen op het gebied van nieuwe influenzavaccins. 
MVA als influenzavaccinvector
Hoofdstuk 2 beschrijft twee studies die fundamentele vragen beantwoorden over het 
gebruik van de MVA-vaccinvector. In hoofdstuk 2.1 is onderzocht welke celtypes er in 
muizen, fretten en makaken geïnfecteerd worden door MVA. Dit is van belang omdat 
het antigeen waartegen een immuunrespons opgewekt moet worden door middel 
van vaccinatie met rMVA tot expressie wordt gebracht in deze cellen. Daarnaast 
werd in de verschillende diermodellen toediening van MVA door middel van injectie 
in een spier (de meest gebruikte vaccinatiemethode) vergeleken met toediening 
aan de luchtwegen. De resultaten lieten zien dat in alle diermodellen via beide 
toedieningsmethodes voornamelijk antigeen presenterende cellen (APC) zoals 
dendritische cellen (DC) geïnfecteerd werden door MVA. Dit is een zeer gunstige 
eigenschap van MVA als vaccinvector aangezien DC een belangrijke rol spelen bij 
het opwekken en reguleren van immuunresponsen. 
In hoofdstuk 2.2 is onderzocht of reeds aanwezige immuniteit tegen de MVA-
vaccinvector effect heeft op het induceren van immuunresponsen door vaccinatie 
met rMVA. Immuniteit tegen de vaccinvector kan geïnduceerd zijn door historische 
vaccinatiecampagnes tegen de pokken, waarbij gevaccineerd werd met 
vacciniavirus. Daarnaast kan vaccinvector-specifieke immuniteit opgewekt worden 
door meerdere keren achter elkaar te vaccineren met een vaccin gebaseerd op 
MVA. In theorie zou deze pokkenvirus-specifieke immuniteit de werking van rMVA 
negatief kunnen beïnvloeden. De resultaten van hoofdstuk 2.2 lieten zien dat zowel 
in muizen als mensen antilichamen tegen de vaccinvector de capaciteit hebben om 
MVA in vitro te neutraliseren. In muizen werd voornamelijk activatie van antigeen-
specifieke T-cellen negatief beïnvloed door de bestaande immuunrespons tegen de 
MVA-vaccinvector. Het effect van de MVA-specifieke immuunrespons op activatie 
van antigeen-specifieke antilichamen was minimaal en werd alleen gevonden onder 
‘suboptimale’ vaccinatie omstandigheden, zoals bij het gebruik van een lagere 
vaccindosis. Onder alle geteste omstandigheden waren muizen nog steeds volledig 
beschermd tegen infectie met het influenzavirus waartegen gevaccineerd werd. De 
precieze werking van de immuunresponsen tegen de vaccinvector op vaccinatie 
met een vaccin gebaseerd op MVA in mensen moet nog onderzocht worden. Echter, 
de studies in muizen suggereren dat het belangrijk is om de vaccindosis en de 
afweerstatus van een ontvanger van een rMVA-vaccin te beoordelen voordat het 
vaccin wordt toegediend. 
Influenzavaccinkandidaten gebaseerd op MVA
Hoofdstuk 3 richt zich op de ontwikkeling en het testen van nieuwe influenzavaccins 
gebaseerd op de MVA-vaccinvector. Om T-cellen te activeren worden virale 
eiwitten die aanwezig zijn in een cel tijdens een infectie afgebroken en de stukjes 
eiwit die overblijven, zogenaamde peptiden, worden op het oppervlak van de 
gastheercel gepresenteerd. Cytotoxische T-cellen worden door herkenning van 
deze peptiden geactiveerd, en kunnen vervolgens de geïnfecteerde cel lyseren en 
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zo de virusreplicatie reduceren. Door middel van vaccinatie kunnen cytotoxische 
T-cellen worden getraind om bepaalde virale peptiden te herkennen (immunologisch 
geheugen), zodat deze bij een daadwerkelijke infectie met het influenzavirus snel 
kunnen reageren en de geïnfecteerde cellen kunnen opruimen. Hoofdstuk 3.1 
beschrijft onderzoek naar optimalisatie van de T-cel respons tegen het interne 
influenzavirus eiwit nucleoproteïne (NP). Er zijn modificaties aangebracht in het NP-
eiwit, dat tot expressie komt door middel van MVA, die erop gericht zijn om het eiwit 
sneller af te breken. In theorie zijn er dan sneller en/of meer peptiden beschikbaar 
voor antigeenpresentatie, dus zouden meer T-cellen geactiveerd kunnen worden 
door vaccinatie. De resultaten lieten zien dat dit in vitro inderdaad het geval is, maar 
dat leidde in muizen niet tot sterkere T-cel responsen of betere bescherming tegen 
een influenzavirus infectie.
In hoofdstuk 3.2 zijn de resultaten uit hoofdstuk 3.1 bevestigd in een muismodel met 
een iets andere immuunrespons tegen het influenzavirus. Tevens werd vaccinatie 
met een op rMVA gebaseerd NP-vaccin vergeleken met NP-eiwit vaccinatie. Over 
het algemeen hebben eiwitvaccins adjuvantia nodig om een sterke immuunrespons 
te induceren. In deze studie konden NP-eiwitvaccins inderdaad een sterkere NP-
specifieke immuunrespons opwekken wanneer het adjuvans Matrix-M™, een olie-in-
water emulsie, werd toegevoegd. Echter, influenza NP-vaccins gebaseerd op MVA 
induceerden betere cytotoxische T-cel activatie dan vaccins gebaseerd op eiwit, ook 
als Matrix-M™ aan het eiwitvaccin werd toegevoegd.
Vervolgens is in hoofdstuk 3.3 de immuunrespons na vaccinatie met HA-eiwit of 
rMVA dat HA tot expressie brengt onderzocht in muizen. Dit vaccin is er voornamelijk 
op gericht om antilichaamresponsen te induceren. In deze studie wekte het 
vaccin gebaseerd op MVA een betere immuunrespons op dan het eiwitvaccin. De 
antilichaamresponsen werden vastgesteld werd door de antilichaamtiter tegen 
het receptor-bindingsdomein van HA (hemagglutination inhibition [HI] titer) te 
bepalen. Verder is onderzocht wat het effect was van het toevoegen van Matrix-M™ 
adjuvans aan eiwit of MVA-gebaseerde HA-vaccins. Net als bij NP, werd de 
immuunrespons tegen HA aanzienlijk verbeterd door het toevoegen van Matrix-M™ 
aan HA-eiwitvaccins. Over het algemeen wordt aangenomen dat het toevoegen van 
adjuvantia aan een vaccin gebaseerd op een virale vector niet nodig is, omdat de 
vaccinvector zelf al voor een verhoogde activatiestatus van het immuunsysteem 
zorgt. De resultaten lieten zien dat, alhoewel een vaccin gebaseerd op MVA inderdaad 
meer immunogeen is dan alleen eiwit, het toevoegen van Matrix-M™ adjuvans aan 
de vaccinmix ook van toegevoegde waarde is voor rMVA-vectorvaccins. De werking 
van Matrix-M™ adjuvans werd verder onderzocht en leidde zowel bij eiwitvaccins 
als op MVA gebaseerde HA-vaccins tot meer (geactiveerde) afweercellen in de 
lymfeknoop die de spier waarin gevaccineerd werd draineert.
Tot slot is in hoofdstuk 4 de immuunrespons in mensen onderzocht na vaccinatie met 
een rMVA-vectorvaccin dat HA van een H5N1 vogelgriepvirus tot expressie brengt 
(rMVA-H5). De resultaten lieten zien dat dit vaccin een zeer brede antilichaam respons 
induceert tegen antigeen verschillende influenzavirussen van het H5 subtype. Deze 
antilichamen hebben de capaciteit om H5N1 vogelgriepvirussen te neutraliseren, 
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maar hebben ook niet-neutraliserende capaciteiten zoals antibody dependent 
cellular cytotoxicity (ADCC) activiteit. ADCC is het proces waarbij antilichamen 
virale eiwitten op het oppervlak van een geïnfecteerde cel herkennen en binden, 
en vervolgens door middel van activatie van onder andere natural killer (NK) cellen 
lysis van de virus-geïnfecteerde cel induceren. Naast antilichaamresponsen werden 
er door het rMVA-H5 vaccin ook T-cel responsen geactiveerd die nodig zijn om een 
efficiënte antilichaamrespons tot stand te brengen. Samenvattend, de resultaten 
laten zien dat rMVA-H5 een zeer veelbelovende vaccin kandidaat is in het geval van 
een uitbraak met een vogelgriepvirus van het H5 subtype.
Implicaties van het beschreven onderzoek
De resultaten beschreven in dit proefschrift dragen bij aan de kennis over de werking 
van MVA als vaccinvector in het algemeen, en specifiek als influenzavaccin. Deze 
kennis is essentieel voor het verkrijgen van goedkeuring van regulatoire instanties voor 
het gebruik van vaccins gebaseerd op MVA in mensen. Daarnaast zijn preklinische en 
klinische studies uitgevoerd met op MVA gebaseerde influenzavaccinkandidaten om 
de immuunrespons tegen influenzavirussen te optimaliseren en analyseren. Deze 
studies dragen bij aan de ontwikkeling van een nieuwe generatie influenzavaccins.
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advies sta je altijd voor me klaar. Superfijn dat ook jij me als paranimf wil bijstaan bij 
mijn promotie!
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Mijn collega’s van de FluII groep: Stella, bedankt voor al je hulp op het lab! Dit 
was onmisbaar bij het groeien van alle MVA-stocks en (grote) experimenten! Mark, 
bedankt voor alle hulp met de ELISA, HI en VN assays. Het was altijd gezellig om 
samen te werken! Carolien, bedankt voor de gedetailleerde protocollen, en dat je 
een paar keer een dagje bij wou springen op het lab. Nella, de ADCC-data zijn een 
mooi onderdeel van het FLUPLAN-paper! En natuurlijk ook een speciaal bedankje 
voor Ruud, Joost & Heidi (bedankt voor alle hulp aan het begin van m’n PhD), 
Gerrie, Tiny en Lidewij.
Mijn kamergenoten van Ee-1771, bedankt voor alle gezelligheid! Never a dull 
moment op de virologie kamer met vele mooie tradities en goede verhalen. De 
kamer waar het op donderdag maandag is en soms gewoon donderdag, maar waar 
het uiteindelijk eigenlijk altijd vrijdagmiddag is. Dus naast de roomies die al eerder 
zijn genoemd, dank je wel Dennis (of Dr. de Meuldert na de mailtjes als coauteur 
J) voor al je gezelligheid en hulp bij de experimenten. Miranda, trotse winnaar van 
de eerste Viezerik-award! We hebben een heel aantal keer met tranen in de ogen 
dubbel gelegen van het lachen als er weer eens iemand in het plakband liep. Ook 
’s avonds of in het weekend was het zo dus altijd gezellig op de kamer! Sander, je 
hebt me (bijna) van de OCD afgeholpen door alle foto’s scheef op te hangen aan 
de muur J. De dansende kip en de hamer zijn zeer waardevolle toevoegingen aan 
onze kamer, en pim-pam-pet spelen kan nu echt niet meer zonder geluidseffect!
Alle andere collega’s van de afdeling Viroscience, bedankt voor jullie hulp, advies, 
gezellige borrels, labdagen en sinterkerst feesten. Debby (vR), bedankt voor al je 
advies en dat ik altijd even binnen kon lopen voor serieuze en minder serieuze 
zaken. Ron, bedankt voor je kritische blik op de manuscripten. Peter (vR), altijd 
leuk om het over wielrennen te hebben en natuurlijk super bedankt voor al je hulp 
bij maken van histologie coupes! Mathilde, thanks for your advice and help with the 
FLUPLAN-paper. You will get the hang of the Easter egg colour coding J. Theo en 
Monique, bedankt voor alle hulp en adviezen op het lab! Oanh, bedankt voor alle 
extra kippeneieren en je altijd oprechte vraag over hoe het gaat. Gijs, leuk en handig 
dat we samen konden uitvogelen hoe het afronden van een PhD nou eigenlijk werkt. 
We gaan er twee mooie feestjes van maken! Erwin en Felicity, bedankt voor de 
mooie protein array data en David (N) bedankt voor de hulp met het uitwerken 
hiervan. Werner en Rik, bedankt dat ik altijd kon aankloppen met vragen of voor 
reagentia J. Mart, als ik nog een ‘religious album cover’ nodig heb, weet ik bij wie 
ik moet zijn! Thomas, Jurre, Wesley & David (vdV), het was superleuk om samen 
de Tour de Rotterdam te rijden! Bri, take care of the old lady Canto! Laura, die reis 
naar Suriname voor viruskenner was echt heel speciaal en leuk dat je een paar 
keer wou meekijken op het lab. Chantal en Hans, bedankt voor alle bestellingen. 
Robert en Peter, bedankt voor de liters PBS, alle geautoclaveerde materialen en 
de voorraad schone bekerglazen, maatcilinders etc. die altijd klaarstond. En verder 
een speciaal bedankje voor Stefan (vN), Stefan (vdV), Lineke, Lonneke, Pascal, 
Ramona, Judy, Josanne, Petra, Eefje, Bernadette, Nele, Jasmin, Samira, Sarah 
en de mensen van het EDC waaronder Ingeborg, Eva, Vincent en Vincent.
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Maria, Loubna en Simone, bedankt voor alle secretariële ondersteuning! Martine, 
bedankt voor al je hulp rondom het FLUNIVAC-project en leuk dat we samen naar 
de meeting in Brussel konden afgelopen juni. En ook Anouk en Wim, bedankt voor 
alle ondersteuning!
Tijdens de dagelijkse bezigheden als PhD student heb ik zeer veel profijt gehad van 
mijn twee master stages. Linde, ik kijk nog steeds met veel plezier op mijn stage 
terug en vond het heel leuk dat we vorig jaar bij jullie in Amerika langs konden komen! 
Hidde, bedankt voor de uitdagende en zeer leerzame periode op het Whitehead 
Institute.
Sumana, when things in the lab aren’t going the way I want or expect to, I always have 
to think about what you told me about the Japanese chicken-gender-determining-
schools. It always brings a smile to my face and is good motivation to keep going! It 
was great that you came to visit Rotterdam a couple of times over the last few years. 
I know, my visit to Hong Kong is long overdue!
BMW chickies Franka, Tonja en Melanie, we leerden samen pipetteren (en werden 
van de gang weggestuurd tijdens de incubatietijden van een western blot omdat we 
iets te enthousiast ‘saboteur’ aan het spelen waren J). Vanuit de studietijd dat we 
elkaar dagelijks zagen, zijn we allemaal wat meer onze eigen weg gegaan. Met onze 
volle agenda’s is het niet altijd makkelijk elkaar regelmatig te zien, maar bijkletsen 
met jullie voelt altijd weer vertrouwd!
Voor de nodige ontspanning heb ik gelukkig een heel aantal mensen in mijn omgeving 
met wie ik vele intensieve, uitdagende, relaxte en inspirerende fietskilometers heb 
kunnen maken. Hélène, grappig om te merken dat we met een heel aantal zaken 
precies hetzelfde in elkaar zitten. Bedankt voor de vele gezamenlijke fietskilometers 
(al dan niet over kasseien) en alle tips/adviezen zowel qua fietsen als persoonlijk 
en over werk! Monica, ondanks dat we nu wat verder uit elkaar wonen en elkaar 
wat minder vaak zien, is het toch altijd als vanouds. Onze fietsvakantie in Frankrijk 
was echt genieten! Sheila, met jouw coaching, zowel met trainingsschema’s als op 
persoonlijk vlak, heb je me geholpen om het laatste stukje uit een diep dal te klimmen 
en weer grip te krijgen op alle (vele) dagelijkse activiteiten. Nu maar opzoek naar 
een nieuwe serie om te kijken tijdens een SciFi-avondje of op afstand op de tacx! 
Hedwich, onze vakanties de afgelopen paar jaar waren altijd super relaxt. Gewoon 
lekker fietsen, eten, boekje lezen en natuurlijk niet vergeten om van het uitzicht te 
genieten (btw WOW!). Ik ben benieuwd wie het nieuwe Rotterdamse prinsesje wordt 
bij de competitie volgend jaar J. Nelly, het aanstekelijke enthousiasme waarmee 
je al 20 jaar zo ontzettend veel organiseert voor het vrouwenwielrennen is echt een 
inspiratie! De sfeer die je creëert zowel bij de trainingsgroep in Utrecht als bij de 
landelijke activiteiten is echt heel bijzonder en zorgt ervoor dat ik inmiddels al 10 jaar 
met heel veel plezier deelneem aan alle activiteiten. Ik kijk uit naar het jubileumjaar 
2018! Alle dames van vrouwenwielrennen Rotterdam: bedankt voor jullie inzet en 
enthousiasme. Het organiseren en geven van de trainingen de afgelopen jaren gaf 
mij altijd een enorme energie boost!
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Dit proefschrift wil ik graag afsluiten met een speciaal bedankje voor mijn familie. 
Opa Hessel, bedankt dat u altijd zo meeleeft en altijd interesse heeft voor waar ik 
mee bezig ben.
Lieve Nynke, ik ben echt super trots op jou! Het is op dit moment misschien niet 
altijd even makkelijk, en daar kan ik me maar al te goed in inleven, maar je toont zo 
ontzettend veel doorzettingsvermogen! Ik vind het echt heel fijn dat we de laatste tijd 
weer wat meer contact hebben en hoop dat we dit blijven houden. Superleuk dat we 
samen de cover van dit boekje hebben kunnen uitwerken! 
Lieve Wiggert, ik ben benieuwd of ik over vier jaar het dankwoord in jouw proefschrift 
zit te lezen. Het is nu misschien spannend, maar samen met Jaimy vogel je die 
nieuwe stap wel uit. Welke richting je ook op gaat, ik vind het superleuk dat we 
eenzelfde studieachtergrond en Boston-ervaring hebben. Keep in mind: ‘Don’t panic 
and bring a towel’!
Lieve papa en mama, zonder jullie was ik nooit zo ver gekomen. Mijn schoolcarrière 
is niet altijd heel makkelijk geweest en ik ben jullie zo ontzettend dankbaar voor alle 
kansen die jullie voor me gecreëerd hebben. In alles wat ik doe ondersteunen en 
stimuleren jullie mijn ambities, groot of klein, maar zonder me te pushen. Jullie staan 
dag en nacht voor me klaar, en dat heb ik een heel aantal keer erg nodig gehad. 
Dank jullie wel voor alles. Ik hou van jullie.
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